

Integra Managed Care HMO 2020 Formulary

List of Covered Drugs

PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN

HPMS Approved Formulary File Submission ID 00020144, Version Number 13. This formulary was updated on 06/01/2020. For more recent information or other questions, please contact our Member Services number at 1.877-388-5195 (TTY users should call 711). Hours are Sunday through Saturday 8am to 8pm. NOTE: Between April 1 and September 30 Member Services hours for Saturday and Sunday will be operated by alternate technology. Or visit www.integramanagedcare.com.

When this drug list (formulary) refers to “we,” “us”, or “our,” it means Integra Managed Care. This document includes a list of the drugs (formulary) for our plan which is current as of 06/01/2020. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2021, and from time to time during the year.

Integra Managed Care is an HMO plan with a Medicare contract and a contract with the New York State Medicaid program. Enrollment in Integra Managed Care depends on contract renewal.

This document is available in other formats such as Braille and large print.

This document may be available in a non-English language. For additional information, call us at 1.877-388-5195. TTY users call 711.

Este documento puede estar disponible en un idioma que no sea Inglés. Para obtener información adicional, llámenos al 1.877-388-5195. Los usuarios de TTY deben llamar al 711.

What is the Integra Managed Care Formulary?

A formulary is a list of covered drugs selected by Integra Managed Care in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. Integra Managed Care will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at an Integra Managed Care network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

Can the Formulary (drug list) change?

Generally, if you are taking a drug on our 2020 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the contract year except when a new, less expensive generic drug becomes available, when new information about the safety or effectiveness of a drug is released, or the drug is removed from the market. (See bullets below for more information on changes that affect members currently taking the drug.) Other types of formulary changes, such as removing a drug from our formulary, will not affect members who are currently taking the drug. It will remain available at the same cost-sharing for those members taking it for the remainder of the coverage year. Below are changes to the drug list that will also affect members currently taking a drug:

- **New generic drugs.** We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
 - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on the steps you may take to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Integra Managed Care’s Formulary?”
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug’s manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to market to replace a brand name drug currently on the formulary or add new restrictions to the brand name drug. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug.

The enclosed formulary is current as of 05/01/2020. To get updated information about the drugs covered by Integra Managed Care, please contact us. Our contact information appears on the front and back cover pages. In the event of non-maintenance changes to the formulary throughout the plan year, Integra Managed Care may make changes via errata sheets mailed to you. Additionally, you may visit our website for a link to the most current formulary.

How do I use the Formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 1. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, CARDIOVASCULAR AGENTS. If you know what your drug is

used for, look for the category name in the list that begins on page number 1. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 104. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

Integra Managed Care covers both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs cost less than brand name drugs.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** Integra Managed Care requires your physician to get prior authorization for certain drugs. This means that you will need to get approval from Integra Managed Care before you fill your prescriptions. If you don't get approval, Integra Managed Care may not cover the drug.
- **Quantity Limits:** For certain drugs, when Integra Managed Care limits the amount of the drug that we will cover. For example, Integra Managed Care provides 30 units per prescription for atorvastatin. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy:** In some cases, Integra Managed Care requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 4. You can also get more information about the restrictions applied to specific covered drugs by visiting our Web site. We have posted on line documents that explain our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask Integra Managed Care to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, "How do I request an exception to the Integra Managed Care formulary?" below for information about how to request an exception.

What are over-the counter (OTC) drugs?

OTC drugs are non-prescription drugs that are not normally covered by a Medicare Prescription Drug Plan.

What if my drug is not on the Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Member Services and ask if your drug is covered. For more information, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you learn that Integra Managed Care does not cover your drug, you have two options:

- You can ask Member Services for a list of similar drugs that are covered by us. When you receive the list, show it to your doctor and ask him or her to prescribe a similar drug that is covered by Integra Managed Care.
- You can ask Integra Managed Care to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the Integra Managed Care Formulary?

You can ask us to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, Integra Managed Care limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.

Generally, Integra Managed Care will only approve your request for an exception if the alternative drugs included on the plan's formulary, or additional utilization restrictions would not be as effective in treating your condition and/or would cause you to have adverse medical effects.

You should contact us to ask us for an initial coverage decision for a formulary or utilization restriction exception. **When you request a formulary or utilization restriction exception you should submit a statement from your prescriber or physician supporting your request.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can request an expedited (fast) exception if you or your doctor believe that your health could be seriously harmed by waiting up to 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get a supporting statement from your doctor or other prescriber.

What do I do before I can talk to my doctor about changing my drugs or requesting an exception?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but your ability to get it is limited. For example, you may need a prior authorization from us before you can fill your prescription. You should talk to your doctor to decide if you should switch to an appropriate drug that we cover or request a formulary exception so that we will cover the drug you take. While you talk to your doctor to determine the right course of action for you, we may cover your drug in certain cases during the first 30 days you are a member of our plan.

For each of your drugs that is not on our formulary or if your ability to get your drugs is limited, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30 day supply of medication. After your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

For more information

For more detailed information about your Integra Managed Care prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about us, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day, 7 days a week. TTY users should call 1-877-486-2048. Alternatively, you may visit <http://www.medicare.gov>.

Integra Managed Care's Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by Integra Managed Care. If you have trouble finding your drug in the list, turn to the Index that begins on page 104. The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., <BRAND NAME EXAMPLE>) and generic drugs are listed in lower-case italics (e.g., <*generic example*>).

The information in the Requirements/Limits column tells you if we have any special requirements for coverage of your drug.

Integra D-SNP 2020 1-Tier (List of Covered Drugs)

List of Drugs by Medical Condition

| | |
|---|-----------|
| ANALGESICS | 4 |
| ANESTHETICS | 5 |
| ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS | 6 |
| ANTIBACTERIALS | 7 |
| ANTICONVULSANTS | 13 |
| ANTIDEMENTIA AGENTS | 17 |
| ANTIDEPRESSANTS | 17 |
| ANTIEMETICS | 20 |
| ANTIFUNGALS | 21 |
| ANTIGOUT AGENTS | 23 |
| ANTI-INFLAMMATORY AGENTS | 23 |
| ANTIMIGRAINE AGENTS | 24 |
| ANTIMYASTHENIC AGENTS | 25 |
| ANTIMYCOBACTERIALS | 25 |
| ANTINEOPLASTICS | 26 |
| ANTIPARASITICS | 32 |
| ANTIPARKINSON AGENTS | 33 |
| ANTIPSYCHOTICS | 34 |
| ANTIVIRALS | 38 |
| ANXIOLYTICS | 42 |
| BIPOLAR AGENTS | 43 |
| BLOOD GLUCOSE REGULATORS | 44 |
| BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS | 47 |
| CARDIOVASCULAR AGENTS | 49 |
| CENTRAL NERVOUS SYSTEM AGENTS | 57 |
| DENTAL AND ORAL AGENTS | 59 |
| DERMATOLOGICAL AGENTS | 59 |
| ELECTROLYTES/MINERALS/METALS/VITAMINS | 63 |
| GASTROINTESTINAL AGENTS | 66 |
| GENETIC OR ENZYME DISORDER: REPLACEMENT, MODIFIERS, TREATMENT | 68 |
| GENITOURINARY AGENTS | 69 |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (ADRENAL) | 70 |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS) | 71 |
| HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PITUITARY) | 77 |

| | |
|---|-----------|
| HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (THYROID) | 78 |
| HORMONAL AGENTS, SUPPRESSANT (PITUITARY) | 78 |
| HORMONAL AGENTS, SUPPRESSANT (THYROID)..... | 79 |
| IMMUNOLOGICAL AGENTS | 79 |
| INFLAMMATORY BOWEL DISEASE AGENTS..... | 84 |
| METABOLIC BONE DISEASE AGENTS | 84 |
| MISCELLANEOUS..... | 85 |
| OPHTHALMIC AGENTS | 85 |
| OTIC AGENTS | 88 |
| RESPIRATORY TRACT AGENTS | 89 |
| SKELETAL MUSCLE RELAXANTS | 93 |
| SLEEP DISORDER AGENTS..... | 93 |

Legend

1: Covered Medications

BvD: Part B vs. Part D- This prescription drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

LA: Limited Access- This prescription may be available only at certain pharmacies.

MO: Mail Order Eligible- This prescription may also be available via mail.

PA: Prior Authorization- You (or your physician) are required to get prior authorization before you fill your prescription for this drug. Without prior approval, we may not cover this drug.

PA2: Prior Authorization (New Starts Only)- You (or your physician) are required to get prior authorization before you fill your prescription for this drug unless you are a previous user of the drug. If you have a history of using this medication, you will not need prior authorization.

QL: Quantity Limit- There is a limit on the amount of this drug that is covered per prescription, or within a specific time frame.

ST: Step Therapy- In some cases, you may be required to first try certain drugs to treat your medical condition before we will cover another drug for that condition.

ST2: Step Therapy (New Starts Only)- In some cases, you may be required to first try certain drugs to treat your medical condition before we will cover another drug for that condition unless you are a previous user of the drug. If you have a history of using this medication, you will not need to try other medications first.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------|
| ANALGESICS | | |
| <i>Opioid Analgesics, Long-Acting</i> | | |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr</i> | 1 | QL (10 EA per 30 days) |
| <i>methadone hcl oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>morphine sulfate er oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg</i> | 1 | QL (90 EA per 30 days) |
| <i>oxycodone hcl er oral tablet er 12 hour abuse-deterrent 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg</i> | 1 | |
| <i>oxycodone hcl oral concentrate 100 mg/5ml</i> | 1 | QL (180 ML per 30 days) |
| XTAMPZA ER ORAL CAPSULE ER 12 HOUR ABUSE-DETERRENT 13.5 MG, 18 MG, 27 MG, 36 MG, 9 MG | 1 | |
| ZOXYDRO ER ORAL CAPSULE ER 12 HOUR ABUSE-DETERRENT 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 50 MG | 1 | |
| <i>Opioid Analgesics, Short-Acting</i> | | |
| <i>acetaminophen-codeine #3 oral tablet 300-30 mg</i> | 1 | QL (400 EA per 30 days) |
| <i>acetaminophen-codeine oral solution 120-12 mg/5ml</i> | 1 | QL (5000 ML per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-60 mg</i> | 1 | QL (400 EA per 30 days) |
| <i>butalbital-acetaminophen oral tablet 50-325 mg</i> | 1 | QL (180 EA per 30 days) |
| <i>butalbital-apap-cafeine oral capsule 50-325-40 mg</i> | 1 | QL (180 EA per 30 days) |
| <i>butalbital-apap-cafeine oral tablet 50-325-40 mg</i> | 1 | QL (180 EA per 30 days) |
| <i>butalbital-asa-caff-codeine oral capsule 50-325-40-30 mg</i> | 1 | QL (370 EA per 30 days) |
| <i>butalbital-aspirin-cafeine oral capsule 50-325-40 mg</i> | 1 | QL (180 EA per 30 days) |
| <i>codeine sulfate oral tablet 15 mg, 30 mg, 60 mg</i> | 1 | QL (360 EA per 30 days) |
| ENDOCET ORAL TABLET 10-325 MG, 5-325 MG, 7.5-325 MG | 1 | QL (370 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>fentanyl citrate buccal lozenge on a handle 1200 mcg, 1600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</i> | 1 | PA; QL (180 EA per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15ml</i> | 1 | QL (5500 ML per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i> | 1 | QL (370 EA per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg</i> | 1 | QL (150 EA per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 7.5-200 mg</i> | 1 | QL (180 EA per 30 days) |
| <i>hydromorphone hcl oral liquid 1 mg/ml</i> | 1 | QL (1920 ML per 30 days) |
| <i>hydromorphone hcl oral tablet 2 mg, 4 mg</i> | 1 | QL (360 EA per 30 days) |
| <i>hydromorphone hcl oral tablet 8 mg</i> | 1 | QL (240 EA per 30 days) |
| <i>hydromorphone hcl pf injection solution 10 mg/ml, 50 mg/5ml</i> | 1 | BvD; QL (240 ML per 30 days) |
| LORCET ORAL TABLET 5-325 MG | 1 | QL (370 EA per 30 days) |
| <i>morphine sulfate (concentrate) oral solution 100 mg/5ml</i> | 1 | QL (600 ML per 30 days) |
| <i>morphine sulfate oral solution 10 mg/5ml</i> | 1 | QL (3600 ML per 30 days) |
| <i>morphine sulfate oral solution 20 mg/5ml</i> | 1 | QL (2700 ML per 30 days) |
| <i>morphine sulfate oral tablet 15 mg, 30 mg</i> | 1 | QL (180 EA per 30 days) |
| <i>oxycodone hcl oral capsule 5 mg</i> | 1 | QL (180 EA per 30 days) |
| <i>oxycodone hcl oral solution 5 mg/5ml</i> | 1 | QL (1080 ML per 30 days) |
| <i>oxycodone hcl oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg</i> | 1 | QL (180 EA per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg</i> | 1 | QL (370 EA per 30 days) |
| <i>oxycodone-aspirin oral tablet 4.8355-325 mg</i> | 1 | QL (360 EA per 30 days) |
| <i>oxycodone-ibuprofen oral tablet 5-400 mg</i> | 1 | QL (360 EA per 30 days) |
| <i>tramadol hcl oral tablet 100 mg</i> | 1 | QL (120 EA per 30 days) |
| <i>tramadol hcl oral tablet 50 mg</i> | 1 | QL (240 EA per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> | 1 | QL (370 EA per 30 days) |

ANESTHETICS

Local Anesthetics

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| <i>lidocaine external patch 5 %</i> | 1 | PA; QL (90 EA per 30 days) |
| <i>lidocaine hcl external solution 4 %</i> | 1 | QL (50 ML per 30 days) |
| <i>lidocaine hcl urethral/mucosal external gel 2 %</i> | 1 | QL (30 ML per 30 days) |
| <i>lidocaine-prilocaine external cream 2.5-2.5 %</i> | 1 | QL (30 GM per 30 days) |
| <i>proparacaine hcl ophthalmic solution 0.5 %</i> | 1 | |
| ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS | | |
| <i>Alcohol Deterrents/Anti-Craving</i> | | |
| <i>acamprosate calcium oral tablet delayed release 333 mg</i> | 1 | MO |
| <i>disulfiram oral tablet 250 mg, 500 mg</i> | 1 | MO |
| <i>Opioid Antagonists</i> | | |
| <i>naloxone hcl injection solution 0.4 mg/ml</i> | 1 | |
| <i>naloxone hcl injection solution cartridge 0.4 mg/ml</i> | 1 | |
| <i>naloxone hcl injection solution prefilled syringe 2 mg/2ml</i> | 1 | |
| <i>naltrexone hcl oral tablet 50 mg</i> | 1 | |
| NARCAN NASAL LIQUID 4 MG/0.1ML | 1 | |
| VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED 380 MG | 1 | |
| <i>Opioid Dependence Treatments</i> | | |
| <i>buprenorphine hcl sublingual tablet sublingual 2 mg, 8 mg</i> | 1 | |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5 mg, 8-2 mg</i> | 1 | |
| SUBOXONE SUBLINGUAL FILM 12-3 MG, 2-0.5 MG, 4-1 MG, 8-2 MG | 1 | |
| <i>Smoking Cessation Agents</i> | | |
| <i>bupropion hcl er (smoking det) oral tablet extended release 12 hour 150 mg</i> | 1 | |
| CHANTIX CONTINUING MONTH PAK ORAL TABLET 1 MG | 1 | |
| CHANTIX ORAL TABLET 0.5 MG, 1 MG | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| CHANTIX STARTING MONTH PAK ORAL TABLET 0.5 MG X 11 & 1 MG X 42 | 1 | |
| NICOTROL INHALATION INHALER 10 MG | 1 | |
| ANTIBACTERIALS | | |
| <i>Aminoglycosides</i> | | |
| <i>amikacin sulfate injection solution 500 mg/2ml</i> | 1 | BvD |
| ARIKAYCE INHALATION SUSPENSION 590 MG/8.4ML | 1 | PA |
| <i>gentamicin in saline intravenous solution 0.8-0.9 mg/ml-%, 1-0.9 mg/ml-%, 1.2-0.9 mg/ml-%, 1.6- 0.9 mg/ml-%</i> | 1 | |
| <i>gentamicin sulfate injection solution 40 mg/ml</i> | 1 | BvD |
| <i>neomycin sulfate oral tablet 500 mg</i> | 1 | |
| <i>paromomycin sulfate oral capsule 250 mg</i> | 1 | |
| <i>tobramycin inhalation nebulization solution 300 mg/5ml</i> | 1 | BvD |
| <i>tobramycin sulfate injection solution 10 mg/ml, 80 mg/2ml</i> | 1 | BvD |
| <i>Antibacterials, Other</i> | | |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg</i> | 1 | |
| <i>clindamycin palmitate hcl oral solution reconstituted 75 mg/5ml</i> | 1 | |
| <i>clindamycin phosphate in d5w intravenous solution 300 mg/50ml, 600 mg/50ml, 900 mg/50ml</i> | 1 | |
| <i>clindamycin phosphate injection solution 300 mg/2ml, 600 mg/4ml, 900 mg/6ml</i> | 1 | BvD |
| <i>colistimethate sodium (cba) injection solution reconstituted 150 mg</i> | 1 | BvD |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 1 | MO |
| <i>daptomycin intravenous solution reconstituted 350 mg, 500 mg</i> | 1 | BvD |
| FIRVANQ ORAL SOLUTION RECONSTITUTED 25 MG/ML, 50 MG/ML | 1 | |
| <i>linezolid intravenous solution 600 mg/300ml</i> | 1 | PA |
| <i>linezolid oral suspension reconstituted 100 mg/5ml</i> | 1 | PA |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>linezolid oral tablet 600 mg</i> | 1 | PA |
| <i>methenamine hippurate oral tablet 1 gm</i> | 1 | |
| <i>metronidazole in nacl intravenous solution 500-0.79 mg/100ml-%</i> | 1 | BvD |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>nitrofurantoin monohyd macro oral capsule 100 mg</i> | 1 | |
| <i>nitrofurantoin oral suspension 25 mg/5ml</i> | 1 | |
| SIVEXTRO INTRAVENOUS SOLUTION RECONSTITUTED 200 MG | 1 | |
| SIVEXTRO ORAL TABLET 200 MG | 1 | |
| <i>tigecycline intravenous solution reconstituted 50 mg</i> | 1 | BvD |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>trimethoprim oral tablet 100 mg</i> | 1 | |
| <i>vancomycin hcl intravenous solution reconstituted 1 gm, 10 gm, 250 mg, 500 mg, 750 mg</i> | 1 | BvD |
| <i>vancomycin hcl oral capsule 125 mg, 250 mg</i> | 1 | |
| XIFAXAN ORAL TABLET 200 MG | 1 | |
| XIFAXAN ORAL TABLET 550 MG | 1 | MO |
| <i>Beta-Lactam, Cephalosporins</i> | | |
| <i>cefaclor er oral tablet extended release 12 hour 500 mg</i> | 1 | |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>cefaclor oral suspension reconstituted 125 mg/5ml, 250 mg/5ml, 375 mg/5ml</i> | 1 | |
| <i>cefadroxil oral capsule 500 mg</i> | 1 | |
| <i>cefadroxil oral suspension reconstituted 250 mg/5ml, 500 mg/5ml</i> | 1 | |
| <i>cefadroxil oral tablet 1 gm</i> | 1 | |
| <i>cefazolin sodium injection solution reconstituted 1 gm, 500 mg</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>cefazolin sodium injection solution reconstituted 10 gm</i> | 1 | BvD |
| <i>cefdinir oral capsule 300 mg</i> | 1 | |
| <i>cefdinir oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 1 | |
| <i>cefepime hcl injection solution reconstituted 1 gm, 2 gm</i> | 1 | BvD |
| <i>cefixime oral capsule 400 mg</i> | 1 | |
| <i>cefixime oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i> | 1 | |
| <i>cefotetan disodium injection solution reconstituted 1 gm, 2 gm</i> | 1 | |
| <i>cefoxitin sodium injection solution reconstituted 10 gm</i> | 1 | BvD |
| <i>cefoxitin sodium intravenous solution reconstituted 1 gm, 2 gm</i> | 1 | BvD |
| <i>cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml</i> | 1 | |
| <i>cefpodoxime proxetil oral tablet 100 mg, 200 mg</i> | 1 | |
| <i>cefprozil oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 1 | |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>ceftazidime injection solution reconstituted 1 gm, 2 gm, 6 gm</i> | 1 | |
| <i>ceftriaxone sodium injection solution reconstituted 1 gm, 2 gm, 250 mg, 500 mg</i> | 1 | BvD |
| <i>ceftriaxone sodium intravenous solution reconstituted 10 gm</i> | 1 | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>cefuroxime sodium injection solution reconstituted 7.5 gm, 750 mg</i> | 1 | BvD |
| <i>cefuroxime sodium intravenous solution reconstituted 1.5 gm</i> | 1 | BvD |
| <i>cephalexin oral capsule 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>cephalexin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>cephalexin oral tablet 250 mg, 500 mg</i> | 1 | |
| TEFLARO INTRAVENOUS SOLUTION RECONSTITUTED 400 MG, 600 MG | 1 | BvD |
| <i>Beta-Lactam, Other</i> | | |
| AZACTAM INJECTION SOLUTION RECONSTITUTED 2 GM | 1 | BvD |
| <i>aztreonam injection solution reconstituted 1 gm</i> | 1 | |
| CAYSTON INHALATION SOLUTION RECONSTITUTED 75 MG | 1 | PA; LA |
| <i>ertapenem sodium injection solution reconstituted 1 gm</i> | 1 | BvD |
| <i>imipenem-cilastatin intravenous solution reconstituted 250 mg, 500 mg</i> | 1 | BvD |
| <i>meropenem intravenous solution reconstituted 1 gm, 500 mg</i> | 1 | BvD |
| <i>Beta-Lactam, Penicillins</i> | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>amoxicillin oral suspension reconstituted 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml</i> | 1 | |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | |
| <i>amoxicillin oral tablet chewable 125 mg, 250 mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate er oral tablet extended release 12 hour 1000-62.5 mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral suspension reconstituted 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5ml, 600-42.9 mg/5ml</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet chewable 200-28.5 mg, 400-57 mg</i> | 1 | |
| <i>ampicillin oral capsule 500 mg</i> | 1 | |
| <i>ampicillin sodium injection solution reconstituted 1 gm, 125 mg</i> | 1 | BvD |
| <i>ampicillin sodium intravenous solution reconstituted 10 gm</i> | 1 | BvD |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm, 3 (2-1) gm</i> | 1 | BvD |
| <i>ampicillin-sulbactam sodium intravenous solution reconstituted 15 (10-5) gm</i> | 1 | BvD |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION 1200000 UNIT/2ML, 2400000 UNIT/4ML, 600000 UNIT/ML | 1 | |
| <i>dicloxacillin sodium oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>nafcillin sodium injection solution reconstituted 1 gm, 2 gm</i> | 1 | BvD |
| <i>nafcillin sodium intravenous solution reconstituted 10 gm</i> | 1 | BvD |
| <i>oxacillin sodium in dextrose intravenous solution 1 gm/50ml, 2 gm/50ml</i> | 1 | |
| <i>oxacillin sodium injection solution reconstituted 1 gm, 10 gm, 2 gm</i> | 1 | |
| <i>oxacillin sodium intravenous solution reconstituted 10 gm</i> | 1 | |
| <i>penicillin g pot in dextrose intravenous solution 40000 unit/ml, 60000 unit/ml</i> | 1 | |
| <i>penicillin g potassium injection solution reconstituted 20000000 unit</i> | 1 | BvD |
| <i>penicillin g procaine intramuscular suspension 600000 unit/ml</i> | 1 | |
| <i>penicillin g sodium injection solution reconstituted 5000000 unit</i> | 1 | BvD |
| <i>penicillin v potassium oral solution reconstituted 125 mg/5ml, 250 mg/5ml</i> | 1 | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>piperacillin sod-tazobactam so intravenous solution reconstituted 2.25 (2-0.25) gm, 3.375 (3-0.375) gm, 4.5 (4-0.5) gm, 40.5 (36-4.5) gm</i> | 1 | BvD |
| Macrolides | | |
| <i>azithromycin intravenous solution reconstituted 500 mg</i> | 1 | BvD |
| <i>azithromycin oral packet 1 gm</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>azithromycin oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i> | 1 | |
| <i>azithromycin oral tablet 250 mg, 250 mg (6 pack), 500 mg, 500 mg (3 pack), 600 mg</i> | 1 | |
| <i>clarithromycin er oral tablet extended release 24 hour 500 mg</i> | 1 | |
| <i>clarithromycin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 1 | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 1 | |
| ERY-TAB ORAL TABLET DELAYED RELEASE 250 MG, 333 MG, 500 MG | 1 | |
| ERYTHROCIN LACTOBIONATE INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | 1 | BvD |
| ERYTHROCIN STEARATE ORAL TABLET 250 MG | 1 | |
| <i>erythromycin base oral capsule delayed release particles 250 mg</i> | 1 | |
| <i>erythromycin base oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>erythromycin base oral tablet delayed release 250 mg, 333 mg, 500 mg</i> | 1 | |
| <i>erythromycin ethylsuccinate oral suspension reconstituted 200 mg/5ml, 400 mg/5ml</i> | 1 | |
| <i>erythromycin ethylsuccinate oral tablet 400 mg</i> | 1 | |
| Quinolones | | |
| <i>ciprofloxacin hcl oral tablet 100 mg, 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>ciprofloxacin in d5w intravenous solution 200 mg/100ml</i> | 1 | BvD |
| <i>levofloxacin in d5w intravenous solution 500 mg/100ml, 750 mg/150ml</i> | 1 | BvD |
| <i>levofloxacin intravenous solution 25 mg/ml</i> | 1 | BvD |
| <i>levofloxacin oral solution 25 mg/ml</i> | 1 | |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>moxifloxacin hcl in nacl intravenous solution 400 mg/250ml</i> | 1 | BvD |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| <i>moxifloxacin hcl oral tablet 400 mg</i> | 1 | |
| <i>ofloxacin oral tablet 300 mg, 400 mg</i> | 1 | |
| Sulfonamides | | |
| <i>sulfacetamide sodium (acne) external lotion 10 %</i> | 1 | |
| <i>sulfadiazine oral tablet 500 mg</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5ml</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i> | 1 | |
| Tetracyclines | | |
| DOXY 100 INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 1 | BvD |
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i> | 1 | |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i> | 1 | |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i> | 1 | |
| <i>doxycycline monohydrate oral tablet 100 mg, 50 mg</i> | 1 | |
| <i>minocycline hcl oral capsule 100 mg, 50 mg, 75 mg</i> | 1 | |
| <i>minocycline hcl oral tablet 100 mg, 50 mg, 75 mg</i> | 1 | |
| <i>tetracycline hcl oral capsule 250 mg, 500 mg</i> | 1 | |
| ANTICONVULSANTS | | |
| Anticonvulsants, Other | | |
| BRIVIACT ORAL SOLUTION 10 MG/ML | 1 | ST2; MO; QL (600 ML per 30 days) |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | 1 | ST2; MO; QL (60 EA per 30 days) |
| <i>carbamazepine er oral capsule extended release 12 hour 100 mg, 200 mg, 300 mg</i> | 1 | MO |
| <i>carbamazepine er oral tablet extended release 12 hour 100 mg, 200 mg, 400 mg</i> | 1 | MO |
| <i>carbamazepine oral suspension 100 mg/5ml</i> | 1 | MO |
| <i>carbamazepine oral tablet 200 mg</i> | 1 | MO |
| <i>carbamazepine oral tablet chewable 100 mg</i> | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 1 | ST2; MO |
| EPITOL ORAL TABLET 200 MG | 1 | MO |
| <i>felbamate oral suspension 600 mg/5ml</i> | 1 | |
| <i>felbamate oral tablet 400 mg, 600 mg</i> | 1 | MO |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML | 1 | ST2; MO |
| <i>levetiracetam er oral tablet extended release 24 hour 500 mg, 750 mg</i> | 1 | MO |
| <i>levetiracetam oral solution 100 mg/ml</i> | 1 | MO |
| <i>levetiracetam oral tablet 1000 mg, 250 mg, 500 mg, 750 mg</i> | 1 | MO |
| ROWEEPRAL ORAL TABLET 1000 MG, 500 MG, 750 MG | 1 | MO |
| ROWEEPRAL XR ORAL TABLET EXTENDED RELEASE 24 HOUR 500 MG, 750 MG | 1 | MO |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 1000 MG | 1 | ST2; MO; QL (90 EA per 30 days) |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 250 MG, 500 MG, 750 MG | 1 | ST2; MO; QL (120 EA per 30 days) |
| Barbiturates | | |
| <i>phenobarbital oral elixir 20 mg/5ml</i> | 1 | MO; QL (1500 ML per 30 days) |
| <i>phenobarbital oral tablet 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>phenobarbital oral tablet 15 mg, 60 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>phenobarbital oral tablet 30 mg</i> | 1 | MO; QL (300 EA per 30 days) |
| <i>primidone oral tablet 250 mg, 50 mg</i> | 1 | MO |
| Benzodiazepines | | |
| <i>clobazam oral suspension 2.5 mg/ml</i> | 1 | QL (480 ML per 30 days) |
| <i>clobazam oral tablet 10 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>clobazam oral tablet 20 mg</i> | 1 | QL (60 EA per 30 days) |
| DIASTAT ACUDIAL RECTAL GEL 10 MG, 20 MG | 1 | |
| DIASTAT PEDIATRIC RECTAL GEL 2.5 MG | 1 | |
| <i>diazepam rectal gel 10 mg, 2.5 mg, 20 mg</i> | 1 | |
| NAYZILAM NASAL SOLUTION 5 MG/0.1ML | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------|
| SYMPAZAN ORAL FILM 10 MG, 20 MG | 1 | ST2; QL (60 EA per 30 days) |
| SYMPAZAN ORAL FILM 5 MG | 1 | ST2; MO; QL (60 EA per 30 days) |
| VALTOCO 10 MG DOSE NASAL LIQUID 10 MG/0.1ML | 1 | |
| VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 7.5 MG/0.1ML | 1 | |
| VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 10 MG/0.1ML | 1 | |
| VALTOCO 5 MG DOSE NASAL LIQUID 5 MG/0.1ML | 1 | |
| Calcium Channel Modifying Agents | | |
| CELONTIN ORAL CAPSULE 300 MG | 1 | ST2; MO |
| <i>ethosuximide oral capsule 250 mg</i> | 1 | MO |
| <i>ethosuximide oral solution 250 mg/5ml</i> | 1 | MO |
| <i>zonisamide oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| Gamma-Aminobutyric Acid (Gaba) Augmenting Agents | | |
| <i>divalproex sodium er oral tablet extended release 24 hour 250 mg, 500 mg</i> | 1 | MO |
| <i>divalproex sodium oral capsule delayed release sprinkle 125 mg</i> | 1 | MO |
| <i>divalproex sodium oral tablet delayed release 125 mg, 250 mg, 500 mg</i> | 1 | MO |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 4 MG, 6 MG | 1 | ST2; QL (30 EA per 30 days) |
| FYCOMPA ORAL TABLET 2 MG, 8 MG | 1 | ST2; MO; QL (30 EA per 30 days) |
| <i>gabapentin oral capsule 100 mg, 300 mg, 400 mg</i> | 1 | MO; QL (270 EA per 30 days) |
| <i>gabapentin oral solution 250 mg/5ml</i> | 1 | MO |
| <i>gabapentin oral tablet 600 mg, 800 mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>pregabalin oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>pregabalin oral capsule 200 mg, 225 mg, 300 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> | 1 | MO; QL (900 ML per 30 days) |
| <i>tiagabine hcl oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 1 | MO |
| <i>valproic acid oral capsule 250 mg</i> | 1 | MO |
| <i>valproic acid oral solution 250 mg/5ml</i> | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| <i>vigabatrin oral packet 500 mg</i> | 1 | PA2; LA; QL (180 EA per 30 days) |
| <i>vigabatrin oral tablet 500 mg</i> | 1 | PA2; LA; QL (180 EA per 30 days) |
| VIGADRONE ORAL PACKET 500 MG | 1 | PA2; LA; QL (180 EA per 30 days) |
| Glutamate Reducing Agents | | |
| <i>lamotrigine er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg</i> | 1 | MO |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1 | MO |
| <i>lamotrigine oral tablet chewable 25 mg, 5 mg</i> | 1 | MO |
| <i>lamotrigine oral tablet dispersible 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>lamotrigine starter kit-blue oral kit 35 x 25 mg</i> | 1 | |
| <i>lamotrigine starter kit-green oral kit 84 x 25 mg & 14x100 mg</i> | 1 | |
| <i>lamotrigine starter kit-orange oral kit 42 x 25 mg & 7 x 100 mg</i> | 1 | |
| <i>topiramate er oral capsule er 24 hour sprinkle 100 mg, 150 mg, 200 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>topiramate oral capsule sprinkle 15 mg, 25 mg</i> | 1 | MO |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | MO |
| Sodium Channel Agents | | |
| APTOM ORAL TABLET 200 MG, 400 MG, 800 MG | 1 | ST2; QL (30 EA per 30 days) |
| APTOM ORAL TABLET 600 MG | 1 | ST2; QL (60 EA per 30 days) |
| BANZEL ORAL SUSPENSION 40 MG/ML | 1 | ST2; QL (2760 ML per 30 days) |
| BANZEL ORAL TABLET 200 MG | 1 | ST2; QL (480 EA per 30 days) |
| BANZEL ORAL TABLET 400 MG | 1 | ST2; QL (240 EA per 30 days) |
| DILANTIN ORAL CAPSULE 30 MG | 1 | MO |
| <i>oxcarbazepine oral suspension 300 mg/5ml</i> | 1 | MO |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> | 1 | MO |
| PEGANONE ORAL TABLET 250 MG | 1 | ST2; MO |
| <i>phenytoin oral suspension 125 mg/5ml</i> | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------------|
| <i>phenytoin oral tablet chewable 50 mg</i> | 1 | MO |
| <i>phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg</i> | 1 | MO |
| VIMPAT ORAL SOLUTION 10 MG/ML | 1 | ST2; MO; QL (1395 ML per 30 days) |
| VIMPAT ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 1 | ST2; MO; QL (60 EA per 30 days) |

ANTIDEMENTIA AGENTS

Cholinesterase Inhibitors

| | | |
|---|---|-----------------------------|
| <i>donepezil hcl oral tablet 10 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>donepezil hcl oral tablet 23 mg, 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>donepezil hcl oral tablet dispersible 10 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>donepezil hcl oral tablet dispersible 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>galantamine hydrobromide er oral capsule extended release 24 hour 16 mg, 24 mg, 8 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>galantamine hydrobromide oral solution 4 mg/ml</i> | 1 | MO; QL (180 ML per 30 days) |
| <i>galantamine hydrobromide oral tablet 12 mg, 4 mg, 8 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24hr, 4.6 mg/24hr, 9.5 mg/24hr</i> | 1 | MO; QL (30 EA per 30 days) |

N-Methyl-D-Aspartate (Nmda) Receptor Antagonist

| | | |
|---|---|-----------------------------|
| <i>memantine hcl er oral capsule extended release 24 hour 14 mg, 21 mg, 28 mg, 7 mg</i> | 1 | MO |
| <i>memantine hcl oral solution 2 mg/ml</i> | 1 | MO; QL (360 ML per 30 days) |
| <i>memantine hcl oral tablet 10 mg, 5 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>memantine hcl oral tablet 28 x 5 mg & 21 x 10 mg</i> | 1 | |
| NAMZARIC ORAL CAPSULE ER 24 HOUR THERAPY PACK 7 & 14 & 21 & 28 -10 MG | 1 | |
| NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG | 1 | MO |

ANTIDEPRESSANTS

Antidepressants, Other

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 150 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 200 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 150 mg, 300 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 450 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>bupropion hcl oral tablet 100 mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>bupropion hcl oral tablet 75 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>maprotiline hcl oral tablet 25 mg, 50 mg, 75 mg</i> | 1 | MO |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>mirtazapine oral tablet 7.5 mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>mirtazapine oral tablet dispersible 15 mg, 30 mg, 45 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nefazodone hcl oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | 1 | MO |
| <i>trazodone hcl oral tablet 100 mg, 150 mg, 300 mg, 50 mg</i> | 1 | MO |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 1 | ST2; MO; QL (30 EA per 30 days) |
| VIIBRYD ORAL TABLET 10 MG, 20 MG, 40 MG | 1 | ST2; MO; QL (30 EA per 30 days) |
| VIIBRYD STARTER PACK ORAL KIT 10 & 20 MG | 1 | ST2; QL (30 EA per 30 days) |
| <i>Monoamine Oxidase Inhibitors</i> | | |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24HR, 6 MG/24HR, 9 MG/24HR | 1 | ST2; QL (30 EA per 30 days) |
| MARPLAN ORAL TABLET 10 MG | 1 | ST2; MO; QL (180 EA per 30 days) |
| <i>phenelzine sulfate oral tablet 15 mg</i> | 1 | MO |
| <i>tranylcypromine sulfate oral tablet 10 mg</i> | 1 | MO |
| <i>Serotonin/Norepinephrine Reuptake Inhibitors</i> | | |
| <i>citalopram hydrobromide oral solution 10 mg/5ml</i> | 1 | MO; QL (600 ML per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| <i>citalopram hydrobromide oral tablet 10 mg, 40 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>citalopram hydrobromide oral tablet 20 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>desvenlafaxine er oral tablet extended release 24 hour 100 mg, 50 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>desvenlafaxine succinate er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| DRIZALMA SPRINKLE ORAL CAPSULE DELAYED RELEASE SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG | 1 | ST2; MO; QL (60 EA per 30 days) |
| <i>duloxetine hcl oral capsule delayed release particles 20 mg, 30 mg, 40 mg, 60 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>escitalopram oxalate oral solution 5 mg/5ml</i> | 1 | MO; QL (600 ML per 30 days) |
| <i>escitalopram oxalate oral tablet 10 mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>escitalopram oxalate oral tablet 20 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>escitalopram oxalate oral tablet 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| FETZIMA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 20 MG, 40 MG, 80 MG | 1 | ST2; MO; QL (30 EA per 30 days) |
| FETZIMA TITRATION ORAL CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG | 1 | ST2; QL (56 EA per 365 days) |
| <i>fluoxetine hcl oral capsule 10 mg, 40 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fluoxetine hcl oral capsule 20 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>fluoxetine hcl oral solution 20 mg/5ml</i> | 1 | MO; QL (600 ML per 30 days) |
| <i>fluoxetine hcl oral tablet 10 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fluoxetine hcl oral tablet 20 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>fluvoxamine maleate oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>paroxetine hcl oral tablet 30 mg, 40 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| PAXIL ORAL SUSPENSION 10 MG/5ML | 1 | MO; QL (900 ML per 30 days) |
| <i>sertraline hcl oral concentrate 20 mg/ml</i> | 1 | MO; QL (300 ML per 30 days) |
| <i>sertraline hcl oral tablet 100 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>sertraline hcl oral tablet 25 mg, 50 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 150 mg, 37.5 mg, 75 mg</i> | 1 | MO; QL (60 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>venlafaxine hcl er oral tablet extended release 24 hour 150 mg, 225 mg, 37.5 mg, 75 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>venlafaxine hcl oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| Tricyclics | | |
| <i>amitriptyline hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 1 | MO |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>clomipramine hcl oral capsule 25 mg, 50 mg, 75 mg</i> | 1 | MO |
| <i>desipramine hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 1 | MO |
| <i>doxepin hcl oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 1 | MO |
| <i>doxepin hcl oral concentrate 10 mg/ml</i> | 1 | MO |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>nortriptyline hcl oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i> | 1 | MO |
| <i>nortriptyline hcl oral solution 10 mg/5ml</i> | 1 | MO |
| <i>protriptyline hcl oral tablet 10 mg, 5 mg</i> | 1 | MO |
| <i>trimipramine maleate oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| ANTIEMETICS | | |
| Antiemetics, Other | | |
| COMPRO RECTAL SUPPOSITORY 25 MG | 1 | |
| <i>meclizine hcl oral tablet 12.5 mg, 25 mg</i> | 1 | |
| <i>prochlorperazine maleate oral tablet 5 mg</i> | 1 | BvD; MO |
| <i>prochlorperazine rectal suppository 25 mg</i> | 1 | |
| <i>promethazine hcl oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>scopolamine transdermal patch 72 hour 1 mg/3days</i> | 1 | QL (4 EA per 12 days) |
| TRANSDERM-SCOP (1.5 MG) TRANSDERMAL PATCH 72 HOUR 1 MG/3DAYS | 1 | QL (4 EA per 12 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| Emetogenic Therapy Adjuncts | | |
| <i>aprepitant oral capsule 125 mg, 40 mg, 80 mg</i> | 1 | BvD; QL (30 EA per 30 days) |
| <i>aprepitant oral capsule 80 & 125 mg</i> | 1 | BvD; QL (12 EA per 30 days) |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> | 1 | BvD; QL (60 EA per 30 days) |
| EMEND ORAL SUSPENSION RECONSTITUTED 125 MG | 1 | BvD |
| <i>granisetron hcl oral tablet 1 mg</i> | 1 | BvD; QL (60 EA per 30 days) |
| <i>ondansetron hcl oral solution 4 mg/5ml</i> | 1 | BvD |
| <i>ondansetron hcl oral tablet 24 mg, 4 mg, 8 mg</i> | 1 | BvD |
| <i>ondansetron oral tablet dispersible 4 mg, 8 mg</i> | 1 | BvD |
| SYNDROS ORAL SOLUTION 5 MG/ML | 1 | BvD; QL (120 ML per 30 days) |
| VARUBI (180 MG DOSE) ORAL TABLET THERAPY PACK 2 X 90 MG | 1 | BvD |
| VARUBI ORAL TABLET 90 MG | 1 | BvD |
| ANTIFUNGALS | | |
| Antifungals | | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | 1 | BvD |
| AMBISOME INTRAVENOUS SUSPENSION RECONSTITUTED 50 MG | 1 | BvD |
| <i>amphotericin b intravenous solution reconstituted 50 mg</i> | 1 | BvD |
| <i>caspofungin acetate intravenous solution reconstituted 50 mg, 70 mg</i> | 1 | BvD |
| <i>ciclopirox external gel 0.77 %</i> | 1 | |
| <i>ciclopirox external shampoo 1 %</i> | 1 | |
| <i>ciclopirox external solution 8 %</i> | 1 | |
| <i>ciclopirox olamine external cream 0.77 %</i> | 1 | |
| <i>ciclopirox olamine external suspension 0.77 %</i> | 1 | |
| <i>clotrimazole external cream 1 %</i> | 1 | |
| <i>clotrimazole external solution 1 %</i> | 1 | |
| <i>clotrimazole mouth/throat lozenge 10 mg</i> | 1 | |
| <i>econazole nitrate external cream 1 %</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| ERAXIS INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 50 MG | 1 | BvD |
| <i>fluconazole in sodium chloride intravenous solution 200-0.9 mg/100ml-%, 400-0.9 mg/200ml-%</i> | 1 | BvD |
| <i>fluconazole oral suspension reconstituted 10 mg/ml, 40 mg/ml</i> | 1 | |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 1 | |
| <i>flucytosine oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>griseofulvin microsize oral suspension 125 mg/5ml</i> | 1 | |
| <i>griseofulvin microsize oral tablet 500 mg</i> | 1 | |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250 mg</i> | 1 | |
| <i>itraconazole oral capsule 100 mg</i> | 1 | PA |
| JUBLIA EXTERNAL SOLUTION 10 % | 1 | |
| <i>ketconazole external cream 2 %</i> | 1 | |
| <i>ketconazole external shampoo 2 %</i> | 1 | |
| <i>ketconazole oral tablet 200 mg</i> | 1 | |
| NATACYN OPHTHALMIC SUSPENSION 5 % | 1 | |
| NOXAFIL ORAL SUSPENSION 40 MG/ML | 1 | PA; MO |
| NYAMYC EXTERNAL POWDER 100000 UNIT/GM | 1 | |
| <i>nystatin external cream 100000 unit/gm</i> | 1 | |
| <i>nystatin external ointment 100000 unit/gm</i> | 1 | |
| <i>nystatin external powder 100000 unit/gm</i> | 1 | |
| <i>nystatin mouth/throat suspension 100000 unit/ml</i> | 1 | |
| <i>nystatin oral tablet 500000 unit</i> | 1 | |
| NYSTOP EXTERNAL POWDER 100000 UNIT/GM | 1 | |
| <i>posaconazole oral tablet delayed release 100 mg</i> | 1 | PA; MO |
| <i>terbinafine hcl oral tablet 250 mg</i> | 1 | |
| <i>voriconazole intravenous solution reconstituted 200 mg</i> | 1 | BvD |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| <i>voriconazole oral suspension reconstituted 40 mg/ml</i> | 1 | PA |
| <i>voriconazole oral tablet 200 mg, 50 mg</i> | 1 | PA; QL (120 EA per 30 days) |
| ANTIGOUT AGENTS | | |
| <i>Antigout Agents</i> | | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | 1 | MO |
| <i>colchicine oral capsule 0.6 mg</i> | 1 | |
| <i>colchicine oral tablet 0.6 mg</i> | 1 | |
| <i>colchicine-probenecid oral tablet 0.5-500 mg</i> | 1 | MO |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> | 1 | PA; MO |
| MITIGARE ORAL CAPSULE 0.6 MG | 1 | |
| <i>probenecid oral tablet 500 mg</i> | 1 | MO |
| ANTI-INFLAMMATORY AGENTS | | |
| <i>Nonsteroidal Anti-Inflammatory Drugs</i> | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> | 1 | MO |
| <i>diclofenac potassium oral tablet 50 mg</i> | 1 | MO |
| <i>diclofenac sodium er oral tablet extended release 24 hour 100 mg</i> | 1 | MO |
| <i>diclofenac sodium oral tablet delayed release 25 mg, 50 mg, 75 mg</i> | 1 | MO |
| <i>diclofenac sodium transdermal gel 1 %</i> | 1 | |
| <i>diclofenac sodium transdermal gel 3 %</i> | 1 | PA |
| <i>diclofenac sodium transdermal solution 1.5 %</i> | 1 | |
| <i>diflunisal oral tablet 500 mg</i> | 1 | MO |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 1 | MO |
| <i>etodolac oral tablet 400 mg, 500 mg</i> | 1 | MO |
| <i>flurbiprofen oral tablet 100 mg</i> | 1 | MO |
| IBU ORAL TABLET 600 MG, 800 MG | 1 | MO |
| <i>ibuprofen oral suspension 100 mg/5ml</i> | 1 | |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | 1 | MO |
| <i>indomethacin oral capsule 25 mg</i> | 1 | MO |
| <i>ketoprofen oral capsule 25 mg, 50 mg, 75 mg</i> | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | 1 | MO |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | 1 | MO |
| <i>naproxen dr oral tablet delayed release 375 mg, 500 mg</i> | 1 | MO |
| <i>naproxen oral suspension 125 mg/5ml</i> | 1 | MO |
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i> | 1 | MO |
| <i>naproxen sodium er oral tablet extended release 24 hour 500 mg</i> | 1 | MO |
| <i>naproxen sodium oral tablet 275 mg, 550 mg</i> | 1 | MO |
| <i>oxaprozin oral tablet 600 mg</i> | 1 | MO |
| <i>piroxicam oral capsule 10 mg, 20 mg</i> | 1 | MO |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 1 | MO |
| <i>tolmetin sodium oral capsule 400 mg</i> | 1 | MO |
| <i>tolmetin sodium oral tablet 600 mg</i> | 1 | MO |

ANTIMIGRAINE AGENTS

Antimigraine Agents, Other

| | | |
|--|---|------------------------|
| <i>dihydroergotamine mesylate nasal solution 4 mg/ml</i> | 1 | |
| EMGALITY (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML | 1 | PA; MO |
| EMGALITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 120 MG/ML | 1 | PA; MO |
| EMGALITY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120 MG/ML | 1 | PA; MO |
| <i>ergotamine-caffeine oral tablet 1-100 mg</i> | 1 | QL (40 EA per 28 days) |
| MIGERGOT RECTAL SUPPOSITORY 2-100 MG | 1 | |

Serotonin (5-Ht) 1B/1D Receptor Agonists

| | | |
|---|---|------------------------|
| <i>naratriptan hcl oral tablet 1 mg, 2.5 mg</i> | 1 | QL (9 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet 10 mg</i> | 1 | QL (12 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet 5 mg</i> | 1 | QL (24 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet dispersible 10 mg</i> | 1 | QL (12 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet dispersible 5 mg</i> | 1 | QL (24 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>sumatriptan nasal solution 20 mg/act, 5 mg/act</i> | 1 | QL (18 EA per 30 days) |
| <i>sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | QL (9 EA per 30 days) |
| <i>sumatriptan succinate refill subcutaneous solution cartridge 4 mg/0.5ml, 6 mg/0.5ml</i> | 1 | QL (10 ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5ml</i> | 1 | QL (8 ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution auto-injector 4 mg/0.5ml</i> | 1 | QL (4.5 ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution auto-injector 6 mg/0.5ml</i> | 1 | QL (10 ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution prefilled syringe 6 mg/0.5ml</i> | 1 | QL (8 ML per 30 days) |
| <i>zolmitriptan oral tablet 2.5 mg</i> | 1 | QL (12 EA per 30 days) |
| <i>zolmitriptan oral tablet 5 mg</i> | 1 | QL (6 EA per 30 days) |
| <i>zolmitriptan oral tablet dispersible 2.5 mg</i> | 1 | QL (12 EA per 30 days) |
| <i>zolmitriptan oral tablet dispersible 5 mg</i> | 1 | QL (6 EA per 30 days) |
| ANTIMYASTHENIC AGENTS | | |
| <i>Parasympathomimetics</i> | | |
| <i>guanidine hcl oral tablet 125 mg</i> | 1 | |
| <i>pyridostigmine bromide oral solution 60 mg/5ml</i> | 1 | |
| <i>pyridostigmine bromide oral tablet 30 mg, 60 mg</i> | 1 | |
| ANTIMYCOBACTERIALS | | |
| <i>Antimycobacterials, Other</i> | | |
| <i>pyrazinamide oral tablet 500 mg</i> | 1 | |
| <i>rifabutin oral capsule 150 mg</i> | 1 | |
| <i>Antituberculars</i> | | |
| <i>ethambutol hcl oral tablet 100 mg, 400 mg</i> | 1 | |
| <i>isoniazid oral syrup 50 mg/5ml</i> | 1 | MO |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 1 | MO |
| PASER ORAL PACKET 4 GM | 1 | |
| PRIFTIN ORAL TABLET 150 MG | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------|
| <i>rifampin intravenous solution reconstituted 600 mg</i> | 1 | BvD |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 1 | |
| RIFATER ORAL TABLET 50-120-300 MG | 1 | |
| SIRTURO ORAL TABLET 100 MG | 1 | PA |
| TRECTOR ORAL TABLET 250 MG | 1 | |
| ANTINEOPLASTICS | | |
| <i>Alkylating Agents</i> | | |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i> | 1 | BvD |
| GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG | 1 | |
| LEUKERAN ORAL TABLET 2 MG | 1 | |
| <i>Antiangiogenic Agents</i> | | |
| <i>penicillamine oral tablet 250 mg</i> | 1 | |
| REVLIMID ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG | 1 | PA2; LA; QL (28 EA per 28 days) |
| THALOMID ORAL CAPSULE 100 MG, 200 MG, 50 MG | 1 | PA2; QL (30 EA per 30 days) |
| THALOMID ORAL CAPSULE 150 MG | 1 | PA2; QL (60 EA per 30 days) |
| <i>Antimetabolites</i> | | |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG | 1 | MO |
| <i>mercaptopurine oral tablet 50 mg</i> | 1 | |
| <i>methotrexate sodium (pf) injection solution 50 mg/2ml</i> | 1 | BvD |
| PURIXAN ORAL SUSPENSION 2000 MG/100ML | 1 | LA |
| TABLOID ORAL TABLET 40 MG | 1 | PA2 |
| <i>Antineoplastics</i> | | |
| <i>abiraterone acetate oral tablet 250 mg</i> | 1 | PA2; QL (120 EA per 30 days) |
| AFINITOR DISPERZ ORAL TABLET SOLUBLE 2 MG, 3 MG | 1 | PA2; QL (30 EA per 30 days) |
| AFINITOR DISPERZ ORAL TABLET SOLUBLE 5 MG | 1 | PA2; QL (60 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| AFINITOR ORAL TABLET 10 MG | 1 | PA2; QL (30 EA per 30 days) |
| ALECENSA ORAL CAPSULE 150 MG | 1 | PA2 |
| ALUNBRIG ORAL TABLET 180 MG | 1 | PA2; LA; QL (30 EA per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 1 | PA2; LA; QL (180 EA per 30 days) |
| ALUNBRIG ORAL TABLET 90 MG | 1 | PA2; LA; QL (60 EA per 30 days) |
| ALUNBRIG ORAL TABLET THERAPY PACK 90 & 180 MG | 1 | PA2; LA; QL (30 EA per 30 days) |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 300 MG | 1 | PA2; LA; QL (30 EA per 30 days) |
| BALVERSA ORAL TABLET 3 MG | 1 | PA2; LA; QL (90 EA per 30 days) |
| BALVERSA ORAL TABLET 4 MG | 1 | PA2; LA; QL (60 EA per 30 days) |
| BALVERSA ORAL TABLET 5 MG | 1 | PA2; LA; QL (30 EA per 30 days) |
| <i>bexarotene oral capsule 75 mg</i> | 1 | PA2; QL (300 EA per 30 days) |
| <i>bicalutamide oral tablet 50 mg</i> | 1 | |
| BOSULIF ORAL TABLET 100 MG | 1 | PA2; QL (120 EA per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 1 | PA2; QL (30 EA per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 1 | PA2; LA; QL (180 EA per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 1 | PA2; LA; QL (120 EA per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG | 1 | PA2; LA |
| CALQUENCE ORAL CAPSULE 100 MG | 1 | PA2; LA; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 100 MG | 1 | PA2; LA; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 300 MG | 1 | PA2; LA; QL (30 EA per 30 days) |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT 1 X 80 & 1 X 20 MG | 1 | PA2; LA; QL (56 EA per 28 days) |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 1 X 80 & 3 X 20 MG | 1 | PA2; LA; QL (112 EA per 28 days) |
| COMETRIQ (60 MG DAILY DOSE) ORAL KIT 20 MG | 1 | PA2; LA; QL (84 EA per 28 days) |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 1 | PA2; LA; QL (60 EA per 30 days) |
| COTELLIC ORAL TABLET 20 MG | 1 | PA2; LA; QL (63 EA per 28 days) |
| DAURISMO ORAL TABLET 100 MG, 25 MG | 1 | PA2 |
| ELIGARD SUBCUTANEOUS KIT 22.5 MG, 30 MG, 45 MG, 7.5 MG | 1 | PA2 |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| EMCYT ORAL CAPSULE 140 MG | 1 | |
| ERIVEDGE ORAL CAPSULE 150 MG | 1 | PA2 |
| ERLEADA ORAL TABLET 60 MG | 1 | PA2; LA; QL (120 EA per 30 days) |
| <i>erlotinib hcl oral tablet 100 mg, 150 mg</i> | 1 | PA2; QL (30 EA per 30 days) |
| <i>erlotinib hcl oral tablet 25 mg</i> | 1 | PA2; QL (90 EA per 30 days) |
| <i>everolimus oral tablet 2.5 mg, 5 mg, 7.5 mg</i> | 1 | PA2; QL (30 EA per 30 days) |
| FARYDAK ORAL CAPSULE 10 MG | 1 | PA2; QL (60 EA per 30 days) |
| FARYDAK ORAL CAPSULE 20 MG | 1 | PA2; QL (30 EA per 30 days) |
| FLUOROPLEX EXTERNAL CREAM 1 % | 1 | |
| <i>fluorouracil external cream 5 %</i> | 1 | |
| <i>fluorouracil external solution 2 %, 5 %</i> | 1 | |
| <i>flutamide oral capsule 125 mg</i> | 1 | |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 1 | PA2; LA; QL (30 EA per 30 days) |
| <i>hydroxyurea oral capsule 500 mg</i> | 1 | |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | 1 | PA2 |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 1 | PA2 |
| ICLUSIG ORAL TABLET 15 MG | 1 | PA2; LA; QL (60 EA per 30 days) |
| ICLUSIG ORAL TABLET 45 MG | 1 | PA2; LA; QL (30 EA per 30 days) |
| IDHIFA ORAL TABLET 100 MG | 1 | PA2; LA; QL (30 EA per 30 days) |
| IDHIFA ORAL TABLET 50 MG | 1 | PA2; LA; QL (60 EA per 30 days) |
| <i>imatinib mesylate oral tablet 100 mg</i> | 1 | PA2; QL (180 EA per 30 days) |
| <i>imatinib mesylate oral tablet 400 mg</i> | 1 | PA2; QL (60 EA per 30 days) |
| IMBRUVICA ORAL CAPSULE 140 MG, 70 MG | 1 | PA2; LA; QL (120 EA per 30 days) |
| IMBRUVICA ORAL TABLET 140 MG | 1 | PA2; LA; QL (120 EA per 30 days) |
| IMBRUVICA ORAL TABLET 280 MG | 1 | PA2; LA; QL (60 EA per 30 days) |
| IMBRUVICA ORAL TABLET 420 MG, 560 MG | 1 | PA2; LA; QL (30 EA per 30 days) |
| INLYTA ORAL TABLET 1 MG | 1 | PA2; QL (180 EA per 30 days) |
| INLYTA ORAL TABLET 5 MG | 1 | PA2; QL (60 EA per 30 days) |
| INREBIC ORAL CAPSULE 100 MG | 1 | PA2; QL (120 EA per 30 days) |
| IRESSA ORAL TABLET 250 MG | 1 | PA2; LA |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------|
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 1 | PA2; LA; QL (60 EA per 30 days) |
| KISQALI (200 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 1 | PA2 |
| KISQALI (400 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 1 | PA2 |
| KISQALI (600 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 1 | PA2 |
| KISQALI FEMARA (400 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 1 | PA2 |
| KISQALI FEMARA (600 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 1 | PA2 |
| KISQALI FEMARA(200 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 1 | PA2 |
| LENVIMA (10 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG | 1 | PA2 |
| LENVIMA (12 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 3 X 4 MG | 1 | PA2 |
| LENVIMA (14 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 & 4 MG | 1 | PA2 |
| LENVIMA (18 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG & 2 X 4 MG | 1 | PA2 |
| LENVIMA (20 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG | 1 | PA2 |
| LENVIMA (24 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG & 4 MG | 1 | PA2 |
| LENVIMA (4 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 4 MG | 1 | PA2 |
| LENVIMA (8 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 4 MG | 1 | PA2 |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 1 | |
| <i>leuprolide acetate injection kit 1 mg/0.2ml</i> | 1 | PA2 |
| LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG | 1 | PA2; LA |
| LORBRENA ORAL TABLET 100 MG | 1 | PA2; QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| LORBRENA ORAL TABLET 25 MG | 1 | PA2; QL (90 EA per 30 days) |
| LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 3.75 MG, 7.5 MG | 1 | PA2 |
| LUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 11.25 MG, 22.5 MG | 1 | PA2 |
| LUPRON DEPOT (4-MONTH) INTRAMUSCULAR KIT 30 MG | 1 | PA2 |
| LUPRON DEPOT (6-MONTH) INTRAMUSCULAR KIT 45 MG | 1 | PA2 |
| LYNPARZA ORAL TABLET 100 MG | 1 | PA2; LA; QL (180 EA per 30 days) |
| LYNPARZA ORAL TABLET 150 MG | 1 | PA2; LA; QL (120 EA per 30 days) |
| LYSODREN ORAL TABLET 500 MG | 1 | |
| MATULANE ORAL CAPSULE 50 MG | 1 | PA2; LA |
| MEKINIST ORAL TABLET 0.5 MG | 1 | PA2; LA; QL (120 EA per 30 days) |
| MEKINIST ORAL TABLET 2 MG | 1 | PA2; LA; QL (30 EA per 30 days) |
| MEKTOVI ORAL TABLET 15 MG | 1 | PA2; LA; QL (180 EA per 30 days) |
| MESNEX ORAL TABLET 400 MG | 1 | |
| NERLYNX ORAL TABLET 40 MG | 1 | PA2; LA; QL (180 EA per 30 days) |
| NEXAVAR ORAL TABLET 200 MG | 1 | PA2; LA; QL (120 EA per 30 days) |
| <i>nilutamide oral tablet 150 mg</i> | 1 | QL (60 EA per 30 days) |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 1 | PA2 |
| NUBEQA ORAL TABLET 300 MG | 1 | PA2; LA; QL (120 EA per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG | 1 | PA2; LA |
| PANRETIN EXTERNAL GEL 0.1 % | 1 | |
| PIQRAY (200 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 MG | 1 | PA2 |
| PIQRAY (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 & 50 MG | 1 | PA2 |
| PIQRAY (300 MG DAILY DOSE) ORAL TABLET THERAPY PACK 2 X 150 MG | 1 | PA2 |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 1 | PA2; LA; QL (21 EA per 28 days) |
| ROZLYTREK ORAL CAPSULE 100 MG | 1 | PA2; QL (150 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | 1 | PA2; QL (90 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 1 | PA2; LA |
| RYDAPT ORAL CAPSULE 25 MG | 1 | PA2; QL (240 EA per 30 days) |
| SPRYCEL ORAL TABLET 100 MG, 50 MG, 70 MG, 80 MG | 1 | PA2; QL (60 EA per 30 days) |
| SPRYCEL ORAL TABLET 140 MG | 1 | PA2; QL (30 EA per 30 days) |
| SPRYCEL ORAL TABLET 20 MG | 1 | PA2; QL (90 EA per 30 days) |
| STIVARGA ORAL TABLET 40 MG | 1 | PA2; LA; QL (84 EA per 28 days) |
| SUTENT ORAL CAPSULE 12.5 MG, 25 MG, 37.5 MG, 50 MG | 1 | PA2; QL (28 EA per 28 days) |
| SYNRIBO SUBCUTANEOUS SOLUTION RECONSTITUTED 3.5 MG | 1 | PA2 |
| TAFINLAR ORAL CAPSULE 50 MG | 1 | PA2; LA; QL (180 EA per 30 days) |
| TAFINLAR ORAL CAPSULE 75 MG | 1 | PA2; LA; QL (120 EA per 30 days) |
| TAGRISSO ORAL TABLET 40 MG, 80 MG | 1 | PA2; LA |
| TALZENNA ORAL CAPSULE 0.25 MG | 1 | PA2; LA; QL (90 EA per 30 days) |
| TALZENNA ORAL CAPSULE 1 MG | 1 | PA2; LA; QL (30 EA per 30 days) |
| <i>tamoxifen citrate oral tablet 10 mg, 20 mg</i> | 1 | MO |
| TARGRETIN EXTERNAL GEL 1 % | 1 | PA2 |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG | 1 | PA2; QL (120 EA per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 1 | PA2; QL (240 EA per 30 days) |
| TIBSOVO ORAL TABLET 250 MG | 1 | PA2; LA; QL (60 EA per 30 days) |
| TOLAK EXTERNAL CREAM 4 % | 1 | |
| <i>toremifene citrate oral tablet 60 mg</i> | 1 | PA2; QL (30 EA per 30 days) |
| <i>tretinoin oral capsule 10 mg</i> | 1 | |
| TURALIO ORAL CAPSULE 200 MG | 1 | PA2; LA; QL (120 EA per 30 days) |
| TYKERB ORAL TABLET 250 MG | 1 | PA2; QL (180 EA per 30 days) |
| VALCHLOR EXTERNAL GEL 0.016 % | 1 | PA2; QL (60 GM per 14 days) |
| VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG | 1 | PA2; LA |
| VENCLEXTA STARTING PACK ORAL TABLET THERAPY PACK 10 & 50 & 100 MG | 1 | PA2; LA |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 1 | PA2; LA |
| VITRAKVI ORAL CAPSULE 100 MG | 1 | PA2; QL (60 EA per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG | 1 | PA2; QL (180 EA per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML | 1 | PA2 |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 1 | PA2; QL (30 EA per 30 days) |
| VOTRIENT ORAL TABLET 200 MG | 1 | PA2; QL (120 EA per 30 days) |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 1 | PA2; QL (60 EA per 30 days) |
| XOSPATA ORAL TABLET 40 MG | 1 | PA2; LA |
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 1 | PA2; LA |
| XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 1 | PA2; LA |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 1 | PA2; LA |
| XPOVIO (80 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 1 | PA2; LA |
| XTANDI ORAL CAPSULE 40 MG | 1 | PA2; LA; QL (120 EA per 30 days) |
| YONSA ORAL TABLET 125 MG | 1 | PA2; QL (120 EA per 30 days) |
| ZEJULA ORAL CAPSULE 100 MG | 1 | PA2; LA; QL (90 EA per 30 days) |
| ZELBORAF ORAL TABLET 240 MG | 1 | PA2; QL (240 EA per 30 days) |
| ZOLINZA ORAL CAPSULE 100 MG | 1 | PA2; QL (120 EA per 30 days) |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 1 | PA2; LA; QL (60 EA per 30 days) |
| ZYKADIA ORAL TABLET 150 MG | 1 | PA2; QL (150 EA per 30 days) |
| ZYTIGA ORAL TABLET 500 MG | 1 | PA2; QL (120 EA per 30 days) |
| <i>Aromatase Inhibitors, 3Rd Generation</i> | | |
| <i>anastrozole oral tablet 1 mg</i> | 1 | MO |
| <i>exemestane oral tablet 25 mg</i> | 1 | MO |
| <i>letrozole oral tablet 2.5 mg</i> | 1 | MO |
| ANTIPARASITICS | | |
| <i>Anthelmintics</i> | | |
| <i>albendazole oral tablet 200 mg</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------|
| EMVERM ORAL TABLET CHEWABLE 100 MG | 1 | |
| <i>ivermectin oral tablet 3 mg</i> | 1 | |
| Antiprotozoals | | |
| ALINIA ORAL SUSPENSION RECONSTITUTED 100 MG/5ML | 1 | QL (150 ML per 30 days) |
| ALINIA ORAL TABLET 500 MG | 1 | QL (40 EA per 30 days) |
| <i>atovaquone oral suspension 750 mg/5ml</i> | 1 | |
| <i>atovaquone-proguanil hcl oral tablet 250-100 mg, 62.5-25 mg</i> | 1 | |
| <i>benznidazole oral tablet 100 mg, 12.5 mg</i> | 1 | |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 1 | MO |
| COARTEM ORAL TABLET 20-120 MG | 1 | |
| DARAPRIM ORAL TABLET 25 MG | 1 | |
| <i>mefloquine hcl oral tablet 250 mg</i> | 1 | MO |
| <i>pentamidine isethionate inhalation solution reconstituted 300 mg</i> | 1 | BvD; MO |
| <i>pentamidine isethionate injection solution reconstituted 300 mg</i> | 1 | BvD; MO |
| <i>primaquine phosphate oral tablet 26.3 mg</i> | 1 | |
| <i>quinine sulfate oral capsule 324 mg</i> | 1 | PA |
| Pediculicides/Scabicides | | |
| <i>malathion external lotion 0.5 %</i> | 1 | |
| <i>permethrin external cream 5 %</i> | 1 | |
| ANTIPARKINSON AGENTS | | |
| Anticholinergics | | |
| <i>benztropine mesylate oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | MO |
| <i>trihexyphenidyl hcl oral solution 0.4 mg/ml</i> | 1 | MO |
| <i>trihexyphenidyl hcl oral tablet 2 mg, 5 mg</i> | 1 | MO |
| Antiparkinson Agents, Other | | |
| <i>amantadine hcl oral capsule 100 mg</i> | 1 | MO |
| <i>amantadine hcl oral syrup 50 mg/5ml</i> | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>amantadine hcl oral tablet 100 mg</i> | 1 | MO |
| <i>carbidopa-levodopa er oral tablet extended release 25-100 mg, 50-200 mg</i> | 1 | MO |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i> | 1 | MO |
| <i>carbidopa-levodopa oral tablet dispersible 10-100 mg, 25-100 mg, 25-250 mg</i> | 1 | MO |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 1 | MO |
| <i>entacapone oral tablet 200 mg</i> | 1 | MO |
| GOCOVRI ORAL CAPSULE EXTENDED RELEASE 24 HOUR 137 MG, 68.5 MG | 1 | PA; LA |
| RYTARY ORAL CAPSULE EXTENDED RELEASE 23.75-95 MG, 36.25-145 MG, 48.75-195 MG, 61.25-245 MG | 1 | ST; MO |
| <i>Dopamine Agonists</i> | | |
| APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE 30 MG/3ML | 1 | PA; LA; QL (60 ML per 28 days) |
| <i>bromocriptine mesylate oral capsule 5 mg</i> | 1 | MO |
| <i>bromocriptine mesylate oral tablet 2.5 mg</i> | 1 | MO |
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24HR, 2 MG/24HR, 3 MG/24HR, 4 MG/24HR, 6 MG/24HR, 8 MG/24HR | 1 | MO |
| <i>pramipexole dihydrochloride er oral tablet extended release 24 hour 3.75 mg</i> | 1 | MO |
| <i>pramipexole dihydrochloride oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 1 | MO |
| <i>ropinirole hcl oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 1 | MO |
| <i>Monoamine Oxidase B (Mao-B) Inhibitors</i> | | |
| <i>rasagiline mesylate oral tablet 0.5 mg, 1 mg</i> | 1 | MO |
| <i>selegiline hcl oral capsule 5 mg</i> | 1 | MO |
| <i>selegiline hcl oral tablet 5 mg</i> | 1 | MO |

ANTIPSYCHOTICS

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| 1St Generation/Typical | | |
| <i>chlorpromazine hcl oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | BvD; MO |
| <i>clozapine oral tablet 100 mg, 200 mg</i> | 1 | ST2; QL (120 EA per 30 days) |
| <i>clozapine oral tablet 25 mg, 50 mg</i> | 1 | QL (120 EA per 30 days) |
| <i>clozapine oral tablet dispersible 100 mg, 12.5 mg, 150 mg, 200 mg, 25 mg</i> | 1 | ST2; QL (120 EA per 30 days) |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 1 | |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 1 | |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 1 | MO |
| <i>fluphenazine hcl oral elixir 2.5 mg/5ml</i> | 1 | MO |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 100 mg/ml 1 ml, 50 mg/ml</i> | 1 | |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 1 | |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 1 | MO |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 1 | MO |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 1 | MO |
| <i>molindone hcl oral tablet 10 mg, 25 mg, 5 mg</i> | 1 | MO |
| <i>perphenazine oral tablet 16 mg, 2 mg</i> | 1 | MO |
| <i>perphenazine oral tablet 4 mg, 8 mg</i> | 1 | BvD; MO |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 1 | MO |
| <i>prochlorperazine maleate oral tablet 10 mg</i> | 1 | BvD; MO |
| <i>thioridazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | MO |
| <i>trifluoperazine hcl oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | MO |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 1 | ST2; QL (540 ML per 30 days) |
| 2Nd Generation/Atypical | | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------|
| ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE 300 MG, 400 MG | 1 | ST2 |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 300 MG, 400 MG | 1 | ST2 |
| ABILIFY MYCITE ORAL TABLET 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG | 1 | ST2; QL (30 EA per 30 days) |
| <i>aripiprazole oral solution 1 mg/ml</i> | 1 | MO; QL (750 ML per 30 days) |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>aripiprazole oral tablet dispersible 10 mg</i> | 1 | QL (90 EA per 30 days) |
| <i>aripiprazole oral tablet dispersible 15 mg</i> | 1 | QL (60 EA per 30 days) |
| CAPLYTA ORAL CAPSULE 42 MG | 1 | ST2; QL (30 EA per 30 days) |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 1 | ST2; QL (60 EA per 30 days) |
| FANAPT TITRATION PACK ORAL TABLET 1 & 2 & 4 & 6 MG | 1 | ST2; QL (60 EA per 30 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML, 156 MG/ML, 234 MG/1.5ML, 39 MG/0.25ML, 78 MG/0.5ML | 1 | ST2 |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.875ML, 410 MG/1.315ML, 546 MG/1.75ML, 819 MG/2.625ML | 1 | ST2 |
| LATUDA ORAL TABLET 120 MG | 1 | ST2; MO; QL (30 EA per 30 days) |
| LATUDA ORAL TABLET 20 MG, 40 MG, 60 MG, 80 MG | 1 | ST2; MO; QL (60 EA per 30 days) |
| NUPLAZID ORAL CAPSULE 34 MG | 1 | PA2; LA |
| NUPLAZID ORAL TABLET 10 MG | 1 | PA2; LA |
| <i>olanzapine intramuscular solution reconstituted 10 mg</i> | 1 | QL (60 EA per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 5 mg, 7.5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olanzapine oral tablet 20 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>olanzapine oral tablet dispersible 10 mg, 5 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>olanzapine oral tablet dispersible 15 mg, 20 mg</i> | 1 | MO; QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| <i>paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>paliperidone er oral tablet extended release 24 hour 6 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>paliperidone er oral tablet extended release 24 hour 9 mg</i> | 1 | QL (30 EA per 30 days) |
| PERSERIS SUBCUTANEOUS PREFILLED SYRINGE 120 MG, 90 MG | 1 | MO; QL (1 EA per 30 days) |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg, 300 mg, 400 mg, 50 mg</i> | 1 | MO |
| <i>quetiapine fumarate oral tablet 100 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>quetiapine fumarate oral tablet 200 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG | 1 | ST2; QL (30 EA per 30 days) |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 12.5 MG, 25 MG, 37.5 MG, 50 MG | 1 | ST2 |
| <i>risperidone oral solution 1 mg/ml</i> | 1 | MO; QL (480 ML per 30 days) |
| <i>risperidone oral tablet 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>risperidone oral tablet 0.5 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>risperidone oral tablet dispersible 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>risperidone oral tablet dispersible 0.5 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| SAPHRIS SUBLINGUAL TABLET SUBLINGUAL 10 MG, 2.5 MG, 5 MG | 1 | ST2; MO; QL (60 EA per 30 days) |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24HR, 5.7 MG/24HR, 7.6 MG/24HR | 1 | ST2 |
| VRAYLAR ORAL CAPSULE 1.5 MG | 1 | ST2; QL (60 EA per 30 days) |
| VRAYLAR ORAL CAPSULE 3 MG, 4.5 MG, 6 MG | 1 | ST2; QL (30 EA per 30 days) |
| VRAYLAR ORAL CAPSULE THERAPY PACK 1.5 & 3 MG | 1 | ST2; QL (14 EA per 365 days) |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> | 1 | MO; QL (60 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------------|
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 210 MG | 1 | ST2 |
| ANTIVIRALS | | |
| <i>Anti-Cytomegalovirus (Cmv) Agents</i> | | |
| <i>valganciclovir hcl oral solution reconstituted 50 mg/ml</i> | 1 | MO |
| <i>valganciclovir hcl oral tablet 450 mg</i> | 1 | |
| ZIRGAN OPHTHALMIC GEL 0.15 % | 1 | |
| <i>Antih hepatitis Agents</i> | | |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> | 1 | PA; MO; QL (30 EA per 30 days) |
| EPIVIR HBV ORAL SOLUTION 5 MG/ML | 1 | MO |
| <i>lamivudine oral tablet 100 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| VEMLIDY ORAL TABLET 25 MG | 1 | PA; QL (30 EA per 30 days) |
| <i>Anti-Hepatitis B (Hbv) Agents</i> | | |
| <i>adefovir dipivoxil oral tablet 10 mg</i> | 1 | PA; MO; QL (30 EA per 30 days) |
| BARACLUDE ORAL SOLUTION 0.05 MG/ML | 1 | PA; QL (600 ML per 30 days) |
| INTRON A INJECTION SOLUTION 10000000 UNIT/ML, 6000000 UNIT/ML | 1 | PA2 |
| INTRON A INJECTION SOLUTION RECONSTITUTED 10000000 UNIT, 18000000 UNIT, 50000000 UNIT | 1 | PA2 |
| <i>Anti-Hepatitis C (Hcv) Agents, Direct Acting</i> | | |
| <i>sofosbuvir-velpatasvir oral tablet 400-100 mg</i> | 1 | PA |
| VOSEVI ORAL TABLET 400-100-100 MG | 1 | PA |
| <i>Anti-Hepatitis C (Hcv) Agents, Other</i> | | |
| PEGASYS PROCLICK SUBCUTANEOUS SOLUTION 180 MCG/0.5ML | 1 | PA |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/0.5ML, 180 MCG/ML | 1 | PA |
| <i>ribavirin oral capsule 200 mg</i> | 1 | |
| <i>ribavirin oral tablet 200 mg</i> | 1 | |
| SYLATRON SUBCUTANEOUS KIT 200 MCG, 300 MCG | 1 | PA2; QL (4 EA per 28 days) |
| <i>Antih erpetic Agents</i> | | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| <i>acyclovir oral capsule 200 mg</i> | 1 | |
| <i>acyclovir oral suspension 200 mg/5ml</i> | 1 | |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 1 | |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 1 | BvD |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 1 | |
| <i>valacyclovir hcl oral tablet 1 gm, 500 mg</i> | 1 | |
| Anti-Hiv Agents, Non-Nucleoside Reverse Transcriptase Inhibitors | | |
| ATRIPLA ORAL TABLET 600-200-300 MG | 1 | QL (30 EA per 30 days) |
| COMPLERA ORAL TABLET 200-25-300 MG | 1 | QL (30 EA per 30 days) |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 1 | QL (30 EA per 30 days) |
| EDURANT ORAL TABLET 25 MG | 1 | QL (30 EA per 30 days) |
| <i>efavirenz oral capsule 200 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>efavirenz oral capsule 50 mg</i> | 1 | MO; QL (480 EA per 30 days) |
| <i>efavirenz oral tablet 600 mg</i> | 1 | QL (30 EA per 30 days) |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 1 | QL (30 EA per 30 days) |
| INTELENCE ORAL TABLET 100 MG | 1 | QL (120 EA per 30 days) |
| INTELENCE ORAL TABLET 200 MG | 1 | QL (60 EA per 30 days) |
| INTELENCE ORAL TABLET 25 MG | 1 | MO; QL (120 EA per 30 days) |
| <i>nevirapine er oral tablet extended release 24 hour 100 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>nevirapine er oral tablet extended release 24 hour 400 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nevirapine oral suspension 50 mg/5ml</i> | 1 | MO; QL (1200 ML per 30 days) |
| <i>nevirapine oral tablet 200 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| PIFELTRO ORAL TABLET 100 MG | 1 | QL (30 EA per 30 days) |
| SYMFI LO ORAL TABLET 400-300-300 MG | 1 | QL (30 EA per 30 days) |
| SYMFI ORAL TABLET 600-300-300 MG | 1 | QL (30 EA per 30 days) |
| SYMTUZA ORAL TABLET 800-150-200-10 MG | 1 | QL (30 EA per 30 days) |
| VIRAMUNE ORAL SUSPENSION 50 MG/5ML | 1 | MO; QL (1200 ML per 30 days) |
| Anti-Hiv Agents, Nucleoside And Nucleotide Reverse Transcriptase Inhibitors | | |
| <i>abacavir sulfate oral solution 20 mg/ml</i> | 1 | MO; QL (960 ML per 30 days) |
| <i>abacavir sulfate oral tablet 300 mg</i> | 1 | MO; QL (60 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>abacavir sulfate-lamivudine oral tablet 600-300 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>abacavir-lamivudine-zidovudine oral tablet 300-150-300 mg</i> | 1 | QL (60 EA per 30 days) |
| CIMDUO ORAL TABLET 300-300 MG | 1 | QL (30 EA per 30 days) |
| DESCOVY ORAL TABLET 200-25 MG | 1 | QL (30 EA per 30 days) |
| <i>didanosine oral capsule delayed release 200 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>didanosine oral capsule delayed release 250 mg, 400 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| EMTRIVA ORAL CAPSULE 200 MG | 1 | MO; QL (30 EA per 30 days) |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 1 | MO; QL (680 ML per 28 days) |
| JULUCA ORAL TABLET 50-25 MG | 1 | QL (30 EA per 30 days) |
| <i>lamivudine oral solution 10 mg/ml</i> | 1 | MO; QL (900 ML per 30 days) |
| <i>lamivudine oral tablet 150 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>lamivudine oral tablet 300 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>stavudine oral capsule 15 mg, 20 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>stavudine oral capsule 30 mg, 40 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| STRIBILD ORAL TABLET 150-150-200-300 MG | 1 | QL (30 EA per 30 days) |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 1 | QL (30 EA per 30 days) |
| TRUVADA ORAL TABLET 100-150 MG, 133-200 MG, 167-250 MG, 200-300 MG | 1 | QL (30 EA per 30 days) |
| VIDEX EC ORAL CAPSULE DELAYED RELEASE 125 MG | 1 | MO; QL (90 EA per 30 days) |
| VIDEX ORAL SOLUTION RECONSTITUTED 2 GM, 4 GM | 1 | MO; QL (1200 ML per 30 days) |
| VIREAD ORAL POWDER 40 MG/GM | 1 | QL (240 GM per 30 days) |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | 1 | QL (30 EA per 30 days) |
| <i>zidovudine oral capsule 100 mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>zidovudine oral syrup 50 mg/5ml</i> | 1 | MO; QL (1680 ML per 28 days) |
| <i>zidovudine oral tablet 300 mg</i> | 1 | MO; QL (60 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| <i>Anti-Hiv Agents, Other</i> | | |
| BIKTARVY ORAL TABLET 50-200-25 MG | 1 | QL (30 EA per 30 days) |
| DOVATO ORAL TABLET 50-300 MG | 1 | QL (30 EA per 30 days) |
| FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED 90 MG | 1 | QL (60 EA per 30 days) |
| ISENTRESS HD ORAL TABLET 600 MG | 1 | QL (60 EA per 30 days) |
| ISENTRESS ORAL PACKET 100 MG | 1 | MO; QL (60 EA per 30 days) |
| ISENTRESS ORAL TABLET 400 MG | 1 | QL (120 EA per 30 days) |
| ISENTRESS ORAL TABLET CHEWABLE 100 MG, 25 MG | 1 | MO; QL (180 EA per 30 days) |
| ODEFSEY ORAL TABLET 200-25-25 MG | 1 | QL (30 EA per 30 days) |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 1 | QL (360 ML per 30 days) |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 1 | MO; QL (1800 ML per 30 days) |
| SELZENTRY ORAL TABLET 150 MG | 1 | MO; QL (240 EA per 30 days) |
| SELZENTRY ORAL TABLET 25 MG, 300 MG | 1 | MO; QL (120 EA per 30 days) |
| SELZENTRY ORAL TABLET 75 MG | 1 | MO; QL (60 EA per 30 days) |
| TIVICAY ORAL TABLET 10 MG | 1 | MO; QL (60 EA per 30 days) |
| TIVICAY ORAL TABLET 25 MG | 1 | QL (45 EA per 30 days) |
| TIVICAY ORAL TABLET 50 MG | 1 | QL (60 EA per 30 days) |
| TYBOST ORAL TABLET 150 MG | 1 | MO; QL (30 EA per 30 days) |
| <i>Anti-Hiv Agents, Protease Inhibitors</i> | | |
| APTIVUS ORAL CAPSULE 250 MG | 1 | MO; QL (120 EA per 30 days) |
| APTIVUS ORAL SOLUTION 100 MG/ML | 1 | MO; QL (285 ML per 28 days) |
| <i>atazanavir sulfate oral capsule 150 mg, 200 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>atazanavir sulfate oral capsule 300 mg</i> | 1 | QL (60 EA per 30 days) |
| CRIXIVAN ORAL CAPSULE 200 MG | 1 | MO; QL (450 EA per 30 days) |
| CRIXIVAN ORAL CAPSULE 400 MG | 1 | MO; QL (270 EA per 30 days) |
| EVOTAZ ORAL TABLET 300-150 MG | 1 | QL (30 EA per 30 days) |
| <i>fosamprenavir calcium oral tablet 700 mg</i> | 1 | QL (120 EA per 30 days) |
| INVIRASE ORAL TABLET 500 MG | 1 | QL (120 EA per 30 days) |
| KALETRA ORAL TABLET 100-25 MG | 1 | MO; QL (300 EA per 30 days) |
| KALETRA ORAL TABLET 200-50 MG | 1 | QL (150 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| LEXIVA ORAL SUSPENSION 50 MG/ML | 1 | MO; QL (1575 ML per 28 days) |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5ml</i> | 1 | MO; QL (400 ML per 30 days) |
| NORVIR ORAL PACKET 100 MG | 1 | MO; QL (360 EA per 30 days) |
| NORVIR ORAL SOLUTION 80 MG/ML | 1 | MO; QL (480 ML per 30 days) |
| PREZCOBIX ORAL TABLET 800-150 MG | 1 | QL (30 EA per 30 days) |
| PREZISTA ORAL TABLET 150 MG | 1 | MO; QL (240 EA per 30 days) |
| PREZISTA ORAL TABLET 600 MG | 1 | QL (60 EA per 30 days) |
| PREZISTA ORAL TABLET 75 MG | 1 | MO; QL (480 EA per 30 days) |
| PREZISTA ORAL TABLET 800 MG | 1 | QL (30 EA per 30 days) |
| REYATAZ ORAL PACKET 50 MG | 1 | MO; QL (180 EA per 30 days) |
| <i>ritonavir oral tablet 100 mg</i> | 1 | MO; QL (360 EA per 30 days) |
| VIRACEPT ORAL TABLET 250 MG | 1 | MO; QL (300 EA per 30 days) |
| VIRACEPT ORAL TABLET 625 MG | 1 | QL (120 EA per 30 days) |
| Anti-Influenza Agents | | |
| <i>oseltamivir phosphate oral capsule 30 mg, 45 mg, 75 mg</i> | 1 | |
| <i>oseltamivir phosphate oral suspension reconstituted 6 mg/ml</i> | 1 | |
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5 MG/BLISTER | 1 | |
| <i>rimantadine hcl oral tablet 100 mg</i> | 1 | |
| XOFLUZA (40 MG DOSE) ORAL TABLET THERAPY PACK 2 X 20 MG | 1 | |
| XOFLUZA (80 MG DOSE) ORAL TABLET THERAPY PACK 2 X 40 MG | 1 | |
| ANXIOLYTICS | | |
| Anxiolytics, Other | | |
| <i>buspirone hcl oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 1 | |
| <i>hydroxyzine hcl oral syrup 10 mg/5ml</i> | 1 | |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 1 | |
| <i>hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| Benzodiazepines | | |
| ALPRAZOLAM INTENSOL ORAL CONCENTRATE 1 MG/ML | 1 | QL (300 ML per 30 days) |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg</i> | 1 | QL (120 EA per 30 days) |
| <i>alprazolam oral tablet 1 mg</i> | 1 | QL (240 EA per 30 days) |
| <i>alprazolam oral tablet 2 mg</i> | 1 | QL (150 EA per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | 1 | QL (120 EA per 30 days) |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> | 1 | MO; QL (300 EA per 30 days) |
| <i>clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>clonazepam oral tablet dispersible 2 mg</i> | 1 | MO; QL (300 EA per 30 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | 1 | QL (180 EA per 30 days) |
| <i>diazepam oral concentrate 5 mg/ml</i> | 1 | QL (240 ML per 30 days) |
| <i>diazepam oral solution 5 mg/5ml</i> | 1 | QL (1200 ML per 30 days) |
| <i>diazepam oral tablet 10 mg</i> | 1 | QL (120 EA per 30 days) |
| <i>diazepam oral tablet 2 mg</i> | 1 | QL (600 EA per 30 days) |
| <i>diazepam oral tablet 5 mg</i> | 1 | QL (240 EA per 30 days) |
| <i>lorazepam oral concentrate 2 mg/ml</i> | 1 | QL (240 ML per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | QL (150 EA per 30 days) |
| BIPOLAR AGENTS | | |
| Mood Stabilizers | | |
| GEODON INTRAMUSCULAR SOLUTION RECONSTITUTED 20 MG | 1 | ST2 |
| <i>lithium carbonate er oral tablet extended release 300 mg, 450 mg</i> | 1 | MO |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 1 | MO |
| <i>lithium carbonate oral tablet 300 mg</i> | 1 | MO |
| <i>lithium oral solution 8 meq/5ml</i> | 1 | MO |
| <i>olanzapine-fluoxetine hcl oral capsule 12-25 mg, 12-50 mg, 6-50 mg</i> | 1 | MO; QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| <i>olanzapine-fluoxetine hcl oral capsule 3-25 mg, 6-25 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| BLOOD GLUCOSE REGULATORS | | |
| <i>Antidiabetic Agents, Supply</i> | | |
| ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML | 1 | |
| COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML | 1 | |
| EXEL COMFORT POINT PEN NEEDLE 29G X 12MM | 1 | |
| <i>global alcohol prep ease pad 70 %</i> | 1 | |
| <i>preferred plus insulin syringe 28g x 1/2" 0.5 ml</i> | 1 | |
| RELI-ON INSULIN SYRINGE 29G 0.3 ML | 1 | |
| <i>Antidiabetic Agents</i> | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>glimepiride oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | MO |
| <i>glipizide er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| <i>glipizide oral tablet 10 mg, 5 mg</i> | 1 | MO |
| <i>glipizide-metformin hcl oral tablet 2.5-250 mg, 2.5-500 mg, 5-500 mg</i> | 1 | MO |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg</i> | 1 | MO |
| INVOKAMET ORAL TABLET 150-1000 MG, 150-500 MG, 50-1000 MG, 50-500 MG | 1 | MO |
| INVOKAMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 150-1000 MG, 150-500 MG, 50-1000 MG, 50-500 MG | 1 | MO |
| INVOKANA ORAL TABLET 100 MG, 300 MG | 1 | MO |
| JANUMET ORAL TABLET 50-1000 MG, 50-500 MG | 1 | MO |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG, 50-1000 MG, 50-500 MG | 1 | MO |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 1 | MO |
| <i>metformin hcl er oral tablet extended release 24 hour 500 mg, 750 mg</i> | 1 | MO |
| <i>metformin hcl oral tablet 1000 mg, 500 mg, 850 mg</i> | 1 | MO |
| <i>miglitol oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 1 | MO |
| OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML | 1 | MO |
| OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML | 1 | MO |
| <i>pioglitazone hcl oral tablet 15 mg, 30 mg, 45 mg</i> | 1 | MO |
| <i>pioglitazone hcl-glimepiride oral tablet 30-2 mg, 30-4 mg</i> | 1 | MO |
| <i>pioglitazone hcl-metformin hcl oral tablet 15-500 mg, 15-850 mg</i> | 1 | MO |
| <i>repaglinide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | MO |
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG | 1 | MO |
| SOLIQUA SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-33 UNT-MCG/ML | 1 | MO |
| SYNJARDY ORAL TABLET 12.5-1000 MG, 12.5-500 MG, 5-1000 MG, 5-500 MG | 1 | MO |
| SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 12.5-1000 MG, 25-1000 MG, 5-1000 MG | 1 | MO |
| TRULICITY SUBCUTANEOUS SOLUTION PEN-INJECTOR 0.75 MG/0.5ML, 1.5 MG/0.5ML | 1 | MO |
| VICTOZA SUBCUTANEOUS SOLUTION PEN-INJECTOR 18 MG/3ML | 1 | MO |
| XULTOPHY SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-3.6 UNIT-MG/ML | 1 | MO |
| Glycemic Agents | | |
| GLUCAGEN HYPOKIT INJECTION SOLUTION RECONSTITUTED 1 MG | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| GLUCAGON EMERGENCY INJECTION KIT 1 MG | 1 | |
| PROGLYCEM ORAL SUSPENSION 50 MG/ML | 1 | |
| Insulins | | |
| FIASP FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 1 | MO |
| FIASP PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML | 1 | MO |
| FIASP SUBCUTANEOUS SOLUTION 100 UNIT/ML | 1 | MO |
| LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 1 | MO |
| LANTUS SUBCUTANEOUS SOLUTION 100 UNIT/ML | 1 | MO |
| LEVEMIR FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 1 | MO |
| LEVEMIR SUBCUTANEOUS SOLUTION 100 UNIT/ML | 1 | MO |
| NOVOLIN 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 1 | MO |
| NOVOLIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 1 | MO |
| NOVOLIN N FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML | 1 | MO |
| NOVOLIN N SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 1 | MO |
| NOVOLIN R FLEXPEN INJECTION SOLUTION PEN-INJECTOR 100 UNIT/ML | 1 | MO |
| NOVOLIN R INJECTION SOLUTION 100 UNIT/ML | 1 | MO |
| NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 1 | MO |
| NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 1 | MO |
| NOVOLOG MIX 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------|
| NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML | 1 | MO |
| NOVOLOG SUBCUTANEOUS SOLUTION 100 UNIT/ML | 1 | MO |
| TOUJEO MAX SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML | 1 | MO |
| TOUJEO SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML | 1 | MO |
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML, 200 UNIT/ML | 1 | MO |
| TRESIBA SUBCUTANEOUS SOLUTION 100 UNIT/ML | 1 | MO |
| BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS | | |
| Anticoagulants | | |
| ELIQUIS DVT/PE STARTER PACK ORAL TABLET 5 MG | 1 | MO |
| ELIQUIS ORAL TABLET 2.5 MG, 5 MG | 1 | MO |
| <i>enoxaparin sodium subcutaneous solution 100 mg/ml, 150 mg/ml</i> | 1 | QL (30 ML per 30 days) |
| <i>enoxaparin sodium subcutaneous solution 120 mg/0.8ml, 80 mg/0.8ml</i> | 1 | QL (24 ML per 30 days) |
| <i>enoxaparin sodium subcutaneous solution 30 mg/0.3ml</i> | 1 | QL (9 ML per 30 days) |
| <i>enoxaparin sodium subcutaneous solution 40 mg/0.4ml</i> | 1 | QL (12 ML per 30 days) |
| <i>enoxaparin sodium subcutaneous solution 60 mg/0.6ml</i> | 1 | QL (18 ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 10 mg/0.8ml</i> | 1 | QL (11.2 ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 2.5 mg/0.5ml</i> | 1 | QL (7 ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 5 mg/0.4ml</i> | 1 | QL (5.6 ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 7.5 mg/0.6ml</i> | 1 | QL (8.4 ML per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| <i>heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 20000 unit/ml, 5000 unit/ml</i> | 1 | BvD |
| JANTOVEN ORAL TABLET 1 MG, 10 MG, 2 MG, 2.5 MG, 3 MG, 4 MG, 5 MG, 6 MG, 7.5 MG | 1 | MO |
| <i>warfarin sodium oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 1 | MO |
| XARELTO ORAL TABLET 10 MG, 15 MG, 2.5 MG, 20 MG | 1 | MO |
| XARELTO STARTER PACK ORAL TABLET THERAPY PACK 15 & 20 MG | 1 | |
| Blood Formation Modifiers | | |
| LEUKINE INJECTION SOLUTION RECONSTITUTED 250 MCG | 1 | PA |
| <i>pentoxifylline er oral tablet extended release 400 mg</i> | 1 | MO |
| PROMACTA ORAL PACKET 12.5 MG | 1 | PA; QL (360 EA per 30 days) |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG | 1 | PA; QL (60 EA per 30 days) |
| PROMACTA ORAL TABLET 50 MG, 75 MG | 1 | PA; QL (30 EA per 30 days) |
| RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML | 1 | PA; QL (12 ML per 28 days) |
| RETACRIT INJECTION SOLUTION 2000 UNIT/ML | 1 | PA; QL (23 ML per 30 days) |
| RETACRIT INJECTION SOLUTION 3000 UNIT/ML | 1 | PA; QL (16 ML per 30 days) |
| <i>tranexamic acid oral tablet 650 mg</i> | 1 | |
| ZARXIO INJECTION SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML, 480 MCG/0.8ML | 1 | PA |
| Platelet Modifying Agents | | |
| <i>anagrelide hcl oral capsule 0.5 mg, 1 mg</i> | 1 | MO |
| <i>aspirin-dipyridamole er oral capsule extended release 12 hour 25-200 mg</i> | 1 | MO |
| BRILINTA ORAL TABLET 60 MG, 90 MG | 1 | MO |
| CABLIVI INJECTION KIT 11 MG | 1 | PA; LA |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 1 | MO |
| <i>clopidogrel bisulfate oral tablet 75 mg</i> | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| <i>prasugrel hcl oral tablet 10 mg, 5 mg</i> | 1 | MO |
| CARDIOVASCULAR AGENTS | | |
| Alpha-Adrenergic Agonists | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | 1 | MO |
| <i>clonidine transdermal patch weekly 0.1 mg/24hr, 0.2 mg/24hr, 0.3 mg/24hr</i> | 1 | MO |
| <i>guanfacine hcl oral tablet 1 mg, 2 mg</i> | 1 | MO |
| <i>methyldopa oral tablet 250 mg, 500 mg</i> | 1 | MO |
| <i>midodrine hcl oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| Alpha-Adrenergic Blocking Agents | | |
| <i>doxazosin mesylate oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>doxazosin mesylate oral tablet 8 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>prazosin hcl oral capsule 1 mg, 2 mg, 5 mg</i> | 1 | MO |
| <i>terazosin hcl oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | MO |
| Angiotensin II Receptor Antagonists | | |
| <i>candesartan cilexetil oral tablet 16 mg, 4 mg, 8 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>candesartan cilexetil oral tablet 32 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>losartan potassium oral tablet 100 mg, 25 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>losartan potassium oral tablet 50 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>olmesartan medoxomil oral tablet 20 mg, 40 mg, 5 mg</i> | 1 | MO |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>valsartan oral tablet 160 mg, 320 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>valsartan oral tablet 40 mg, 80 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| Angiotensin-Converting Enzyme (Ace) Inhibitors | | |
| <i>benazepril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | MO |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 1 | MO |
| <i>fosinopril sodium oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | 1 | MO |
| <i>moexipril hcl oral tablet 15 mg, 7.5 mg</i> | 1 | MO |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 1 | MO |
| <i>quinapril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | MO |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | MO |
| Antiarrhythmics | | |
| <i>amiodarone hcl oral tablet 100 mg, 200 mg, 400 mg</i> | 1 | MO |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> | 1 | MO |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> | 1 | MO |
| <i>flecainide acetate oral tablet 100 mg, 150 mg, 50 mg</i> | 1 | MO |
| <i>mexiletine hcl oral capsule 150 mg, 200 mg, 250 mg</i> | 1 | MO |
| MULTAQ ORAL TABLET 400 MG | 1 | MO |
| PACERONE ORAL TABLET 100 MG, 200 MG, 400 MG | 1 | MO |
| <i>propafenone hcl er oral capsule extended release 12 hour 225 mg, 325 mg, 425 mg</i> | 1 | MO |
| <i>propafenone hcl oral tablet 150 mg, 225 mg, 300 mg</i> | 1 | MO |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | 1 | MO |
| Antihypertensive Combinations | | |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 1 | MO |
| <i>amlodipine besy-benazepril hcl oral capsule 10-20 mg, 10-40 mg, 5-40 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>amlodipine besy-benazepril hcl oral capsule 2.5-10 mg, 5-10 mg, 5-20 mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>amlodipine besylate-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | 1 | MO; QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>amlodipine-valsartan-hctz oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | 1 | MO |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | 1 | MO |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | 1 | MO |
| <i>candesartan cilexetil-hctz oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>captopril-hydrochlorothiazide oral tablet 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg</i> | 1 | MO |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | 1 | MO |
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG | 1 | PA; MO |
| <i>fosinopril sodium-hctz oral tablet 10-12.5 mg, 20-12.5 mg</i> | 1 | MO |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 1 | MO |
| <i>losartan potassium-hctz oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>metoprolol-hydrochlorothiazide oral tablet 100-25 mg, 100-50 mg, 50-25 mg</i> | 1 | MO |
| <i>olmesartan medoxomil-hctz oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olmesartan-amlodipine-hctz oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>propranolol-hctz oral tablet 40-25 mg, 80-25 mg</i> | 1 | MO |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 1 | MO |
| <i>spironolactone-hctz oral tablet 25-25 mg</i> | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| TEKTURNA HCT ORAL TABLET 150-12.5 MG, 150-25 MG, 300-12.5 MG, 300-25 MG | 1 | MO; QL (30 EA per 30 days) |
| <i>telmisartan-hctz oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>triamterene-hctz oral capsule 37.5-25 mg</i> | 1 | MO |
| <i>triamterene-hctz oral tablet 37.5-25 mg, 75-50 mg</i> | 1 | MO |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| Beta-Adrenergic Blocking Agents | | |
| <i>acebutolol hcl oral capsule 200 mg, 400 mg</i> | 1 | MO |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>betaxolol hcl oral tablet 10 mg, 20 mg</i> | 1 | MO |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | 1 | MO |
| BYSTOLIC ORAL TABLET 10 MG, 2.5 MG, 20 MG, 5 MG | 1 | MO |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | 1 | MO |
| <i>labetalol hcl oral tablet 100 mg, 200 mg, 300 mg</i> | 1 | MO |
| <i>metoprolol succinate er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 1 | MO |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | MO |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | 1 | MO |
| <i>propranolol hcl er oral capsule extended release 24 hour 120 mg, 160 mg, 60 mg, 80 mg</i> | 1 | MO |
| <i>propranolol hcl oral solution 20 mg/5ml, 40 mg/5ml</i> | 1 | MO |
| <i>propranolol hcl oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 1 | MO |
| SORINE ORAL TABLET 120 MG, 160 MG, 240 MG, 80 MG | 1 | MO |
| <i>sotalol hcl (af) oral tablet 120 mg, 160 mg, 80 mg</i> | 1 | MO |
| <i>sotalol hcl oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | MO |
| Calcium Channel Blocking Agents | | |
| <i>amlodipine besylate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG | 1 | MO; QL (60 EA per 30 days) |
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 300 MG | 1 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er beads oral capsule extended release 24 hour 360 mg, 420 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>diltiazem hcl er coated beads oral capsule extended release 24 hour 300 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er oral capsule extended release 12 hour 120 mg, 60 mg, 90 mg</i> | 1 | MO |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | 1 | MO |
| <i>dilt-xr oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>felodipine er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>isradipine oral capsule 2.5 mg, 5 mg</i> | 1 | MO |
| KATERZIA ORAL SUSPENSION 1 MG/ML | 1 | MO |
| <i>nicardipine hcl oral capsule 20 mg, 30 mg</i> | 1 | MO |
| <i>nifedipine er oral tablet extended release 24 hour 30 mg, 60 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>nifedipine er oral tablet extended release 24 hour 90 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nifedipine er osmotic release oral tablet extended release 24 hour 30 mg, 60 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>nifedipine er osmotic release oral tablet extended release 24 hour 90 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG | 1 | MO; QL (60 EA per 30 days) |
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 300 MG, 360 MG | 1 | MO; QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------|
| TIADYL [®] ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG | 1 | MO; QL (60 EA per 30 days) |
| TIADYL [®] ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 300 MG, 360 MG, 420 MG | 1 | MO; QL (30 EA per 30 days) |
| <i>verapamil hcl er oral capsule extended release 24 hour 100 mg, 300 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>verapamil hcl er oral capsule extended release 24 hour 120 mg, 180 mg, 200 mg, 240 mg, 360 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>verapamil hcl er oral tablet extended release 120 mg, 180 mg, 240 mg</i> | 1 | MO |
| <i>verapamil hcl oral tablet 120 mg, 40 mg, 80 mg</i> | 1 | MO |
| Cardiovascular Agents, Other | | |
| <i>aliskiren fumarate oral tablet 150 mg, 300 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> | 1 | MO |
| CINRYZE INTRAVENOUS SOLUTION RECONSTITUTED 500 UNIT | 1 | PA; LA |
| CORLANOR ORAL SOLUTION 5 MG/5ML | 1 | PA; MO |
| CORLANOR ORAL TABLET 5 MG, 7.5 MG | 1 | PA; MO |
| DIGITEK ORAL TABLET 125 MCG, 250 MCG | 1 | MO; QL (30 EA per 30 days) |
| DIGOX ORAL TABLET 125 MCG, 250 MCG | 1 | MO; QL (30 EA per 30 days) |
| <i>digoxin oral solution 0.05 mg/ml</i> | 1 | MO; QL (255 ML per 30 days) |
| <i>digoxin oral tablet 125 mcg, 250 mcg</i> | 1 | MO; QL (30 EA per 30 days) |
| NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG | 1 | PA; LA; QL (180 EA per 30 days) |
| <i>ranolazine er oral tablet extended release 12 hour 1000 mg, 500 mg</i> | 1 | MO |
| RUCONEST INTRAVENOUS SOLUTION RECONSTITUTED 2100 UNIT | 1 | PA |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2ML | 1 | PA; LA; QL (4 ML per 28 days) |
| VYNDAMAX ORAL CAPSULE 61 MG | 1 | PA; LA; QL (30 EA per 30 days) |
| Diuretics, Carbonic Anhydrase Inhibitors | | |
| <i>acetazolamide er oral capsule extended release 12 hour 500 mg</i> | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 1 | MO |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 1 | MO |
| Diuretics, Loop | | |
| <i>bumetanide injection solution 0.25 mg/ml</i> | 1 | |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | MO |
| <i>furosemide injection solution 10 mg/ml, 10 mg/ml (4ml syringe)</i> | 1 | BvD |
| <i>furosemide oral solution 10 mg/ml, 8 mg/ml</i> | 1 | MO |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | MO |
| <i>torseamide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 1 | MO |
| Diuretics, Potassium-Sparing | | |
| <i>amiloride hcl oral tablet 5 mg</i> | 1 | MO |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> | 1 | MO |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| Diuretics, Thiazide | | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 1 | MO |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | MO |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | MO |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| Dyslipidemics, Fibric Acid Derivatives | | |
| <i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 67 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>fenofibrate micronized oral capsule 43 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fenofibrate oral capsule 150 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>fenofibrate oral capsule 50 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fenofibrate oral tablet 145 mg, 160 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>fenofibrate oral tablet 40 mg, 48 mg, 54 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>gemfibrozil oral tablet 600 mg</i> | 1 | MO |
| Dyslipidemics, Hmg Coa Reductase Inhibitors | | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>atorvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| LIVALO ORAL TABLET 1 MG, 2 MG, 4 MG | 1 | MO |
| <i>lovastatin oral tablet 10 mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>lovastatin oral tablet 20 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>lovastatin oral tablet 40 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>pravastatin sodium oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>rosuvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | MO |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg, 80 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>Dyslipidemics, Other</i> | | |
| <i>cholestyramine light oral powder 4 gm/dose</i> | 1 | MO |
| <i>cholestyramine oral packet 4 gm</i> | 1 | MO |
| <i>colesevelam hcl oral packet 3.75 gm</i> | 1 | MO |
| <i>colesevelam hcl oral tablet 625 mg</i> | 1 | MO |
| <i>colestipol hcl oral packet 5 gm</i> | 1 | MO |
| <i>colestipol hcl oral tablet 1 gm</i> | 1 | MO |
| <i>ezetimibe oral tablet 10 mg</i> | 1 | MO |
| JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 40 MG, 5 MG, 60 MG | 1 | PA |
| <i>niacin er (antihyperlipidemic) oral tablet extended release 1000 mg, 500 mg, 750 mg</i> | 1 | MO |
| <i>omega-3-acid ethyl esters oral capsule 1 gm</i> | 1 | MO |
| PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML, 75 MG/ML | 1 | PA; MO |
| PRALUENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 150 MG/ML, 75 MG/ML | 1 | PA; MO |
| PREVALITE ORAL PACKET 4 GM | 1 | MO |
| REPATHA PUSHTRONEX SYSTEM SUBCUTANEOUS SOLUTION CARTRIDGE 420 MG/3.5ML | 1 | PA; MO |
| REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140 MG/ML | 1 | PA; MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| REPATHA SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML | 1 | PA; MO |
| VASCEPA ORAL CAPSULE 0.5 GM, 1 GM | 1 | MO |
| Vasodilators, Direct-Acting Arterial/Venous | | |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg</i> | 1 | MO |
| <i>isosorbide mononitrate er oral tablet extended release 24 hour 120 mg, 30 mg, 60 mg</i> | 1 | MO |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 1 | MO |
| NITRO-DUR TRANSDERMAL PATCH 24 HOUR 0.3 MG/HR, 0.8 MG/HR | 1 | MO |
| <i>nitroglycerin sublingual tablet sublingual 0.3 mg, 0.4 mg, 0.6 mg</i> | 1 | MO |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nitroglycerin translingual solution 0.4 mg/spray</i> | 1 | MO |
| Vasodilators, Direct-Acting Arterial | | |
| <i>hydralazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 1 | MO |
| CENTRAL NERVOUS SYSTEM AGENTS | | |
| Attention Deficit Hyperactivity Disorder Agents, Amphetamines | | |
| <i>amphetamine-dextroamphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>amphetamine-dextroamphetamine oral tablet 30 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 10 mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 15 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 5 mg</i> | 1 | MO; QL (360 EA per 30 days) |
| <i>dextroamphetamine sulfate oral solution 5 mg/5ml</i> | 1 | MO; QL (1800 ML per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 10 mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 5 mg</i> | 1 | MO; QL (150 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------|
| Attention Deficit Hyperactivity Disorder Agents, Non-Amphetamines | | |
| <i>atomoxetine hcl oral capsule 10 mg, 100 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg</i> | 1 | ST; MO; QL (30 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 10 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 2.5 mg</i> | 1 | MO; QL (240 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 5 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>guanfacine hcl er oral tablet extended release 24 hour 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | MO |
| METADATE ER ORAL TABLET EXTENDED RELEASE 20 MG | 1 | MO; QL (90 EA per 30 days) |
| <i>methylphenidate hcl er oral tablet extended release 10 mg, 20 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>methylphenidate hcl oral solution 10 mg/5ml</i> | 1 | MO; QL (900 ML per 30 days) |
| <i>methylphenidate hcl oral solution 5 mg/5ml</i> | 1 | MO; QL (1800 ML per 30 days) |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| Central Nervous System, Other | | |
| AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG | 1 | PA; LA; QL (120 EA per 30 days) |
| NUEDEXTA ORAL CAPSULE 20-10 MG | 1 | PA; MO |
| <i>riluzole oral tablet 50 mg</i> | 1 | MO |
| TEGSEDI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 284 MG/1.5ML | 1 | PA; LA |
| <i>tetrabenazine oral tablet 12.5 mg</i> | 1 | PA; QL (240 EA per 30 days) |
| <i>tetrabenazine oral tablet 25 mg</i> | 1 | PA; QL (120 EA per 30 days) |
| TIGLUTIK ORAL SUSPENSION 50 MG/10ML | 1 | |
| Fibromyalgia Agents | | |
| <i>pregabalin oral capsule 150 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>pregabalin oral capsule 75 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG | 1 | MO; QL (60 EA per 30 days) |
| SAVELLA TITRATION PACK ORAL 12.5 & 25 & 50 MG | 1 | QL (110 EA per 365 days) |
| Multiple Sclerosis Agents | | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 30 MCG/0.5ML | 1 | PA |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 30 MCG/0.5ML | 1 | PA |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 1 | PA |
| COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML, 40 MG/ML | 1 | PA |
| <i>dalfampridine er oral tablet extended release 12 hour 10 mg</i> | 1 | PA; QL (60 EA per 30 days) |
| GILENYA ORAL CAPSULE 0.5 MG | 1 | PA |
| <i>glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml</i> | 1 | PA |
| MAYZENT ORAL TABLET 0.25 MG | 1 | PA; QL (210 EA per 30 days) |
| MAYZENT ORAL TABLET 2 MG | 1 | PA; QL (30 EA per 30 days) |
| TECFIDERA ORAL 120 & 240 MG | 1 | PA |
| TECFIDERA ORAL CAPSULE DELAYED RELEASE 120 MG, 240 MG | 1 | PA |
| DENTAL AND ORAL AGENTS | | |
| <i>Dental And Oral Agents</i> | | |
| <i>chlorhexidine gluconate mouth/throat solution 0.12 %</i> | 1 | |
| <i>lidocaine viscous hcl mouth/throat solution 2 %</i> | 1 | |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i> | 1 | MO |
| <i>triamcinolone acetonide mouth/throat paste 0.1 %</i> | 1 | |
| DERMATOLOGICAL AGENTS | | |
| <i>Dermatological Agents</i> | | |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i> | 1 | PA |
| <i>alclometasone dipropionate external cream 0.05 %</i> | 1 | |
| <i>alclometasone dipropionate external ointment 0.05 %</i> | 1 | |
| <i>amcinonide external cream 0.1 %</i> | 1 | |
| <i>amcinonide external ointment 0.1 %</i> | 1 | |
| <i>ammonium lactate external cream 12 %</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>ammonium lactate external lotion 12 %</i> | 1 | |
| AMNESTEEM ORAL CAPSULE 10 MG, 20 MG, 40 MG | 1 | |
| <i>benzoyl peroxide-erythromycin external gel 5-3 %</i> | 1 | |
| <i>betamethasone dipropionate aug external cream 0.05 %</i> | 1 | |
| <i>betamethasone dipropionate aug external lotion 0.05 %</i> | 1 | |
| <i>betamethasone dipropionate aug external ointment 0.05 %</i> | 1 | |
| <i>betamethasone dipropionate external cream 0.05 %</i> | 1 | |
| <i>betamethasone dipropionate external lotion 0.05 %</i> | 1 | |
| <i>betamethasone dipropionate external ointment 0.05 %</i> | 1 | |
| <i>betamethasone valerate external cream 0.1 %</i> | 1 | |
| <i>betamethasone valerate external lotion 0.1 %</i> | 1 | |
| <i>betamethasone valerate external ointment 0.1 %</i> | 1 | |
| <i>calcipotriene external solution 0.005 %</i> | 1 | |
| CLARAVIS ORAL CAPSULE 20 MG, 30 MG, 40 MG | 1 | |
| <i>clindamycin phos-benzoyl perox external gel 1-5 %</i> | 1 | |
| <i>clindamycin phosphate external gel 1 %</i> | 1 | |
| <i>clindamycin phosphate external lotion 1 %</i> | 1 | |
| <i>clindamycin phosphate external solution 1 %</i> | 1 | |
| <i>clobetasol propionate e external cream 0.05 %</i> | 1 | |
| <i>clobetasol propionate external cream 0.05 %</i> | 1 | |
| <i>clobetasol propionate external gel 0.05 %</i> | 1 | |
| <i>clobetasol propionate external ointment 0.05 %</i> | 1 | |
| <i>clobetasol propionate external solution 0.05 %</i> | 1 | |
| <i>clotrimazole-betamethasone external cream 1-0.05 %</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>clotrimazole-betamethasone external lotion 1-0.05 %</i> | 1 | |
| <i>desonide external cream 0.05 %</i> | 1 | |
| <i>desonide external lotion 0.05 %</i> | 1 | |
| <i>desonide external ointment 0.05 %</i> | 1 | |
| <i>desoximetasone external cream 0.05 %, 0.25 %</i> | 1 | |
| <i>desoximetasone external gel 0.05 %</i> | 1 | |
| <i>desoximetasone external ointment 0.25 %</i> | 1 | |
| <i>diflorasone diacetate external cream 0.05 %</i> | 1 | |
| <i>ery external pad 2 %</i> | 1 | |
| <i>erythromycin external gel 2 %</i> | 1 | |
| <i>erythromycin external solution 2 %</i> | 1 | |
| EUCRISA EXTERNAL OINTMENT 2 % | 1 | |
| <i>fluocinolone acetonide external cream 0.01 %, 0.025 %</i> | 1 | |
| <i>fluocinolone acetonide external ointment 0.025 %</i> | 1 | |
| <i>fluocinolone acetonide external solution 0.01 %</i> | 1 | |
| <i>fluocinonide emulsified base external cream 0.05 %</i> | 1 | |
| <i>fluocinonide external gel 0.05 %</i> | 1 | |
| <i>fluocinonide external ointment 0.05 %</i> | 1 | |
| <i>fluocinonide external solution 0.05 %</i> | 1 | |
| <i>fluticasone propionate external cream 0.05 %</i> | 1 | |
| <i>fluticasone propionate external ointment 0.005 %</i> | 1 | |
| <i>gentamicin sulfate external cream 0.1 %</i> | 1 | |
| <i>gentamicin sulfate external ointment 0.1 %</i> | 1 | |
| <i>halobetasol propionate external cream 0.05 %</i> | 1 | |
| <i>halobetasol propionate external ointment 0.05 %</i> | 1 | |
| <i>hydrocortisone ace-pramoxine external cream 1-1 %</i> | 1 | |
| <i>hydrocortisone ace-pramoxine rectal cream 1-1 %</i> | 1 | |
| <i>hydrocortisone external cream 1 %, 2.5 %</i> | 1 | |
| <i>hydrocortisone external lotion 2.5 %</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>hydrocortisone external ointment 1 %, 2.5 %</i> | 1 | |
| <i>hydrocortisone rectal enema 100 mg/60ml</i> | 1 | |
| <i>hydrocortisone valerate external cream 0.2 %</i> | 1 | |
| <i>hydrocortisone valerate external ointment 0.2 %</i> | 1 | |
| <i>imiquimod external cream 5 %</i> | 1 | |
| <i>isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 1 | |
| <i>metronidazole external cream 0.75 %</i> | 1 | |
| <i>metronidazole external gel 0.75 %, 1 %</i> | 1 | |
| <i>metronidazole external lotion 0.75 %</i> | 1 | |
| <i>mometasone furoate external cream 0.1 %</i> | 1 | |
| <i>mometasone furoate external ointment 0.1 %</i> | 1 | |
| <i>mometasone furoate external solution 0.1 %</i> | 1 | |
| <i>mupirocin external ointment 2 %</i> | 1 | |
| MYORISAN ORAL CAPSULE 30 MG | 1 | |
| <i>nystatin-triamcinolone external cream 100000-0.1 unit/gm-%</i> | 1 | |
| <i>nystatin-triamcinolone external ointment 100000-0.1 unit/gm-%</i> | 1 | |
| PICATO EXTERNAL GEL 0.015 %, 0.05 % | 1 | |
| <i>pimecrolimus external cream 1 %</i> | 1 | |
| <i>podofilox external solution 0.5 %</i> | 1 | |
| <i>prednicarbate external cream 0.1 %</i> | 1 | |
| <i>prednicarbate external ointment 0.1 %</i> | 1 | |
| PROCTO-MED HC EXTERNAL CREAM 2.5 % | 1 | |
| PROCTO-MED HC RECTAL CREAM 2.5 % | 1 | |
| PROCTO-PAK EXTERNAL CREAM 1 % | 1 | |
| PROCTO-PAK RECTAL CREAM 1 % | 1 | |
| PROCTOSOL HC EXTERNAL CREAM 2.5 % | 1 | |
| PROCTOSOL HC RECTAL CREAM 2.5 % | 1 | |
| PROCTOZONE-HC EXTERNAL CREAM 2.5 % | 1 | |
| PROCTOZONE-HC RECTAL CREAM 2.5 % | 1 | |
| RECTIV RECTAL OINTMENT 0.4 % | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| REGRANEX EXTERNAL GEL 0.01 % | 1 | PA |
| SANTYL EXTERNAL OINTMENT 250 UNIT/GM | 1 | |
| <i>selenium sulfide external lotion 2.5 %</i> | 1 | |
| <i>silver sulfadiazine external cream 1 %</i> | 1 | |
| SSD EXTERNAL CREAM 1 % | 1 | |
| <i>tacrolimus external ointment 0.03 %, 0.1 %</i> | 1 | |
| <i>tazarotene external cream 0.1 %</i> | 1 | |
| TAZORAC EXTERNAL CREAM 0.05 % | 1 | |
| TAZORAC EXTERNAL GEL 0.05 %, 0.1 % | 1 | |
| <i>tretinoin external cream 0.025 %, 0.05 %, 0.1 %</i> | 1 | |
| <i>tretinoin external gel 0.01 %, 0.025 %, 0.05 %</i> | 1 | |
| <i>triamcinolone acetonide external cream 0.025 %, 0.1 %, 0.5 %</i> | 1 | |
| <i>triamcinolone acetonide external lotion 0.025 %, 0.1 %</i> | 1 | |
| <i>triamcinolone acetonide external ointment 0.025 %, 0.1 %, 0.5 %</i> | 1 | |
| TRIDERM EXTERNAL CREAM 0.1 % | 1 | |
| UCERIS RECTAL FOAM 2 MG/ACT | 1 | |
| ELECTROLYTES/MINERALS/METALS/VITAMINS | | |
| <i>Electrolyte/Mineral Replacement</i> | | |
| <i>dextrose-nacl intravenous solution 10-0.2 %, 10-0.45 %, 2.5-0.45 %, 5-0.2 %, 5-0.225 %, 5-0.45 %, 5-0.9 %</i> | 1 | BvD |
| <i>kcl in dextrose-nacl intravenous solution 10-5-0.45 meq/l-%-%, 20-5-0.2 meq/l-%-%, 20-5-0.45 meq/l-%-%, 20-5-0.9 meq/l-%-%, 30-5-0.45 meq/l-%-%, 40-5-0.45 meq/l-%-%, 40-5-0.9 meq/l-%-%</i> | 1 | BvD |
| <i>kcl-lactated ringers-d5w intravenous solution 20 meq/l</i> | 1 | BvD |
| KLOR-CON 10 ORAL TABLET EXTENDED RELEASE 10 MEQ | 1 | MO |
| KLOR-CON M10 ORAL TABLET EXTENDED RELEASE 10 MEQ | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| KLOR-CON M15 ORAL TABLET EXTENDED RELEASE 15 MEQ | 1 | MO |
| KLOR-CON M20 ORAL TABLET EXTENDED RELEASE 20 MEQ | 1 | MO |
| KLOR-CON ORAL PACKET 20 MEQ | 1 | MO |
| KLOR-CON ORAL TABLET EXTENDED RELEASE 8 MEQ | 1 | MO |
| <i>magnesium sulfate injection solution 50 %, 50 % (10ml syringe)</i> | 1 | BvD |
| <i>potassium chloride crys er oral tablet extended release 10 meq, 20 meq</i> | 1 | MO |
| <i>potassium chloride er oral capsule extended release 10 meq, 8 meq</i> | 1 | MO |
| <i>potassium chloride er oral tablet extended release 10 meq, 20 meq, 8 meq</i> | 1 | MO |
| <i>potassium chloride in dextrose intravenous solution 20-5 meq/l-%, 40-5 meq/l-%</i> | 1 | BvD |
| <i>potassium chloride in nacl intravenous solution 20-0.45 meq/l-%, 20-0.9 meq/l-%, 40-0.9 meq/l-%</i> | 1 | BvD |
| <i>potassium chloride intravenous solution 2 meq/ml, 2 meq/ml (20 ml), 20 meq/100ml</i> | 1 | BvD |
| <i>potassium chloride oral packet 20 meq</i> | 1 | MO |
| <i>potassium chloride oral solution 20 meq/15ml (10%), 40 meq/15ml (20%)</i> | 1 | MO |
| <i>potassium citrate er oral tablet extended release 10 meq (1080 mg), 15 meq (1620 mg), 5 meq (540 mg)</i> | 1 | |
| <i>sodium chloride intravenous solution 0.45 %, 0.9 %, 3 %, 5 %</i> | 1 | BvD |
| <i>Electrolyte/Mineral/Metal Modifiers</i> | | |
| CHEMET ORAL CAPSULE 100 MG | 1 | |
| CLOVIQUE ORAL CAPSULE 250 MG | 1 | PA |
| <i>deferasirox oral tablet soluble 125 mg, 250 mg, 500 mg</i> | 1 | PA |
| FERRIPROX ORAL SOLUTION 100 MG/ML | 1 | PA; LA |
| FERRIPROX ORAL TABLET 1000 MG, 500 MG | 1 | PA; LA |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------|
| ISOLYTE-P IN D5W INTRAVENOUS SOLUTION | 1 | |
| KIONEX ORAL SUSPENSION 15 GM/60ML | 1 | |
| LOKELMA ORAL PACKET 10 GM, 5 GM | 1 | MO |
| NORMOSOL-M IN D5W INTRAVENOUS SOLUTION | 1 | BvD |
| NORMOSOL-R IN D5W INTRAVENOUS SOLUTION | 1 | BvD |
| SAMSCA ORAL TABLET 15 MG, 30 MG | 1 | QL (60 EA per 30 days) |
| <i>sodium chloride irrigation solution 0.9 %</i> | 1 | |
| <i>sodium polystyrene sulfonate oral powder</i> | 1 | |
| SPS ORAL SUSPENSION 15 GM/60ML | 1 | |
| <i>trientine hcl oral capsule 250 mg</i> | 1 | PA |
| Nutrients | | |
| AMINOSYN II INTRAVENOUS SOLUTION 10 % | 1 | BvD |
| AMINOSYN-PF INTRAVENOUS SOLUTION 10 %, 7 % | 1 | BvD |
| CLINIMIX E/DEXTROSE (2.75/5) INTRAVENOUS SOLUTION 2.75 % | 1 | BvD |
| CLINIMIX E/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25 % | 1 | BvD |
| CLINIMIX E/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25 % | 1 | BvD |
| CLINIMIX E/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5 % | 1 | BvD |
| CLINIMIX E/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5 % | 1 | BvD |
| CLINIMIX/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25 % | 1 | BvD |
| CLINIMIX/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25 % | 1 | BvD |
| CLINIMIX/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5 % | 1 | BvD |
| CLINIMIX/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5 % | 1 | BvD |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>dextrose intravenous solution 10 %, 5 %</i> | 1 | BvD |
| FREAMINE HBC INTRAVENOUS SOLUTION 6.9 % | 1 | BvD |
| HEPATAMINE INTRAVENOUS SOLUTION 8 % | 1 | BvD |
| INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % | 1 | BvD |
| ISOLYTE-S INTRAVENOUS SOLUTION | 1 | BvD |
| NEPHRAMINE INTRAVENOUS SOLUTION 5.4 % | 1 | BvD |
| NORMOSOL-R PH 7.4 INTRAVENOUS SOLUTION | 1 | BvD |
| <i>nutrilipid intravenous emulsion 20 %</i> | 1 | BvD |
| PLASMA-LYTE 148 INTRAVENOUS SOLUTION | 1 | BvD |
| PLASMA-LYTE A INTRAVENOUS SOLUTION | 1 | BvD |
| PREMASOL INTRAVENOUS SOLUTION 10 % | 1 | BvD |
| PROCALAMINE INTRAVENOUS SOLUTION 3 % | 1 | BvD |
| PROSOL INTRAVENOUS SOLUTION 20 % | 1 | BvD |
| TPN ELECTROLYTES INTRAVENOUS CONCENTRATE | 1 | BvD |
| TPN ELECTROLYTES INTRAVENOUS SOLUTION | 1 | BvD |
| TRAVASOL INTRAVENOUS SOLUTION 10 % | 1 | BvD |
| TROPHAMINE INTRAVENOUS SOLUTION 10 % | 1 | BvD |
| GASTROINTESTINAL AGENTS | | |
| <i>Antispasmodics, Gastrointestinal</i> | | |
| <i>dicyclomine hcl oral capsule 10 mg</i> | 1 | |
| <i>dicyclomine hcl oral solution 10 mg/5ml</i> | 1 | |
| <i>dicyclomine hcl oral tablet 20 mg</i> | 1 | |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | 1 | |
| <i>Gastrointestinal Agents, Other</i> | | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| CREON ORAL CAPSULE DELAYED RELEASE PARTICLES 12000 UNIT, 24000-76000 UNIT, 3000-9500 UNIT, 36000 UNIT, 6000 UNIT | 1 | MO |
| <i>cromolyn sodium oral concentrate 100 mg/5ml</i> | 1 | MO |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5ml</i> | 1 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | 1 | |
| GATTEX SUBCUTANEOUS KIT 5 MG | 1 | PA; LA |
| <i>loperamide hcl oral capsule 2 mg</i> | 1 | |
| <i>metoclopramide hcl oral solution 5 mg/5ml</i> | 1 | |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> | 1 | MO |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | 1 | QL (30 EA per 30 days) |
| MYTESI ORAL TABLET DELAYED RELEASE 125 MG | 1 | PA; MO |
| <i>ursodiol oral capsule 300 mg</i> | 1 | MO |
| <i>ursodiol oral tablet 250 mg, 500 mg</i> | 1 | MO |
| ZENPEP ORAL CAPSULE DELAYED RELEASE PARTICLES 10000-32000 UNIT, 15000-47000 UNIT, 20000-63000 UNIT, 25000-79000 UNIT, 3000-14000 UNIT, 40000-126000 UNIT, 5000-24000 UNIT | 1 | MO |
| <i>Histamine2 (H2) Receptor Antagonists</i> | | |
| <i>cimetidine hcl oral solution 300 mg/5ml</i> | 1 | MO |
| <i>cimetidine oral tablet 400 mg</i> | 1 | MO |
| <i>famotidine oral suspension reconstituted 40 mg/5ml</i> | 1 | MO |
| <i>famotidine oral tablet 20 mg, 40 mg</i> | 1 | MO |
| <i>Irritable Bowel Syndrome Agents</i> | | |
| <i>alosetron hcl oral tablet 0.5 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>alosetron hcl oral tablet 1 mg</i> | 1 | QL (60 EA per 30 days) |
| AMITIZA ORAL CAPSULE 24 MCG, 8 MCG | 1 | MO; QL (60 EA per 30 days) |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG | 1 | MO; QL (30 EA per 30 days) |
| <i>Laxatives</i> | | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| CLENPIQ ORAL SOLUTION 10-3.5-12 MG-GM -GM/160ML | 1 | |
| <i>constulose oral solution 10 gm/15ml</i> | 1 | MO |
| <i>enulose oral solution 10 gm/15ml</i> | 1 | MO |
| GAVILYTE-C ORAL SOLUTION RECONSTITUTED 240 GM | 1 | |
| GAVILYTE-N WITH FLAVOR PACK ORAL SOLUTION RECONSTITUTED 420 GM | 1 | |
| <i>generlac oral solution 10 gm/15ml</i> | 1 | MO |
| <i>lactulose oral solution 10 gm/15ml</i> | 1 | MO |
| <i>peg 3350-kcl-na bicarb-nacl oral solution reconstituted 420 gm</i> | 1 | |
| <i>peg-3350/electrolytes oral solution reconstituted 236 gm</i> | 1 | |
| SUPREP BOWEL PREP KIT ORAL SOLUTION 17.5-3.13-1.6 GM/177ML | 1 | |
| TRILYTE ORAL SOLUTION RECONSTITUTED 420 GM | 1 | |
| Protectants | | |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> | 1 | MO |
| <i>sucralfate oral suspension 1 gm/10ml</i> | 1 | MO |
| <i>sucralfate oral tablet 1 gm</i> | 1 | MO |
| Proton Pump Inhibitors | | |
| DEXILANT ORAL CAPSULE DELAYED RELEASE 30 MG, 60 MG | 1 | ST; MO |
| <i>esomeprazole magnesium oral capsule delayed release 40 mg</i> | 1 | MO |
| <i>omeprazole oral capsule delayed release 10 mg, 20 mg, 40 mg</i> | 1 | MO |
| <i>pantoprazole sodium oral tablet delayed release 20 mg, 40 mg</i> | 1 | MO |
| GENETIC OR ENZYME DISORDER: REPLACEMENT, MODIFIERS, TREATMENT | | |
| Enzyme Replacement/Modifiers | | |
| CARBAGLU ORAL TABLET 200 MG | 1 | PA; LA |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------------|
| CYSTADANE ORAL POWDER | 1 | |
| ENDARI ORAL PACKET 5 GM | 1 | LA |
| GALAFOLD ORAL CAPSULE 123 MG | 1 | PA; LA; QL (14 EA per 28 days) |
| KUVAN ORAL PACKET 100 MG, 500 MG | 1 | PA; LA |
| KUVAN ORAL TABLET SOLUBLE 100 MG | 1 | PA; LA |
| <i>levocarnitine oral solution 1 gm/10ml</i> | 1 | BvD; MO |
| <i>levocarnitine oral tablet 330 mg</i> | 1 | BvD; MO |
| <i>miglustat oral capsule 100 mg</i> | 1 | PA; LA |
| ORFADIN ORAL CAPSULE 10 MG, 2 MG, 20 MG, 5 MG | 1 | PA; LA |
| RAVICTI ORAL LIQUID 1.1 GM/ML | 1 | PA; LA |
| <i>sodium phenylbutyrate oral powder 3 gm/tsp</i> | 1 | PA |
| <i>sodium phenylbutyrate oral tablet 500 mg</i> | 1 | PA; MO |
| XURIDEN ORAL PACKET 2 GM | 1 | PA |

GENTOURINARY AGENTS

Antispasmodics, Urinary

| | | |
|---|---|----------------------------|
| <i>darifenacin hydrobromide er oral tablet extended release 24 hour 15 mg, 7.5 mg</i> | 1 | MO |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HOUR 25 MG, 50 MG | 1 | MO |
| <i>oxybutynin chloride er oral tablet extended release 24 hour 10 mg, 15 mg, 5 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>oxybutynin chloride oral syrup 5 mg/5ml</i> | 1 | MO |
| <i>oxybutynin chloride oral tablet 5 mg</i> | 1 | MO |
| <i>tolterodine tartrate er oral capsule extended release 24 hour 2 mg, 4 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>tolterodine tartrate oral tablet 1 mg, 2 mg</i> | 1 | MO; QL (60 EA per 30 days) |

Benign Prostatic Hypertrophy Agents

| | | |
|--|---|----------------------------|
| <i>alfuzosin hcl er oral tablet extended release 24 hour 10 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>dutasteride oral capsule 0.5 mg</i> | 1 | MO |
| <i>dutasteride-tamsulosin hcl oral capsule 0.5-0.4 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>finasteride oral tablet 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| <i>silodosin oral capsule 4 mg, 8 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>tamsulosin hcl oral capsule 0.4 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| Genitourinary Agents, Other | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 1 | |
| CYSTAGON ORAL CAPSULE 150 MG, 50 MG | 1 | PA; LA |
| ELMIRON ORAL CAPSULE 100 MG | 1 | |
| Phosphate Binders | | |
| AURYXIA ORAL TABLET 1 GM 210 MG(Fe) | 1 | PA; MO |
| <i>calcium acetate (phos binder) oral capsule 667 mg</i> | 1 | MO |
| <i>calcium acetate (phos binder) oral tablet 667 mg</i> | 1 | MO |
| <i>sevelamer carbonate oral packet 0.8 gm</i> | 1 | QL (540 EA per 30 days) |
| <i>sevelamer carbonate oral packet 2.4 gm</i> | 1 | QL (180 EA per 30 days) |
| <i>sevelamer carbonate oral tablet 800 mg</i> | 1 | MO; QL (540 EA per 30 days) |
| VELPHORO ORAL TABLET CHEWABLE 500 MG | 1 | MO |
| Vaginal Products | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> | 1 | |
| <i>estradiol vaginal cream 0.1 mg/gm</i> | 1 | MO |
| <i>estradiol vaginal tablet 10 mcg</i> | 1 | MO |
| IMVEXXY MAINTENANCE PACK VAGINAL INSERT 10 MCG, 4 MCG | 1 | |
| IMVEXXY STARTER PACK VAGINAL INSERT 10 MCG, 4 MCG | 1 | |
| INTRAROSA VAGINAL INSERT 6.5 MG | 1 | PA; MO |
| <i>metronidazole vaginal gel 0.75 %</i> | 1 | |
| OSPHENA ORAL TABLET 60 MG | 1 | PA; MO |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 1 | |
| <i>terconazole vaginal suppository 80 mg</i> | 1 | |
| VANDAZOLE VAGINAL GEL 0.75 % | 1 | |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (ADRENAL) | | |
| Glucocorticoids/Mineralocorticoids | | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>budesonide er oral tablet extended release 24 hour 9 mg</i> | 1 | |
| <i>budesonide oral capsule delayed release particles 3 mg</i> | 1 | |
| DEXAMETHASONE INTENSOL ORAL CONCENTRATE 1 MG/ML | 1 | |
| <i>dexamethasone oral elixir 0.5 mg/5ml</i> | 1 | |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i> | 1 | |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 1 | |
| <i>methylprednisolone oral tablet therapy pack 4 mg</i> | 1 | |
| <i>prednisolone oral solution 15 mg/5ml</i> | 1 | |
| <i>prednisolone sodium phosphate oral solution 10 mg/5ml, 20 mg/5ml, 25 mg/5ml, 6.7 (5 base) mg/5ml</i> | 1 | |
| <i>prednisolone sodium phosphate oral tablet dispersible 10 mg, 15 mg, 30 mg</i> | 1 | |
| PREDNISONE INTENSOL ORAL CONCENTRATE 5 MG/ML | 1 | |
| <i>prednisone oral solution 5 mg/5ml</i> | 1 | |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | |
| <i>prednisone oral tablet therapy pack 10 mg (21), 10 mg (48), 5 mg (21), 5 mg (48)</i> | 1 | |
| Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal) | | |
| <i>cortisone acetate oral tablet 25 mg</i> | 1 | |
| DEMSEER ORAL CAPSULE 250 MG | 1 | |
| <i>fludrocortisone acetate oral tablet 0.1 mg</i> | 1 | MO |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS) | | |
| Anabolic Steroids | | |
| ANADROL-50 ORAL TABLET 50 MG | 1 | |
| <i>oxandrolone oral tablet 10 mg, 2.5 mg</i> | 1 | PA |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Androgens | | |
| ANDRODERM TRANSDERMAL PATCH 24 HOUR 2 MG/24HR, 4 MG/24HR | 1 | MO |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | 1 | |
| <i>methyltestosterone oral capsule 10 mg</i> | 1 | |
| <i>testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)</i> | 1 | |
| <i>testosterone enanthate intramuscular solution 200 mg/ml</i> | 1 | PA |
| <i>testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)</i> | 1 | PA; MO |
| <i>testosterone transdermal solution 30 mg/act</i> | 1 | PA; MO |
| Contraceptives | | |
| ALTAVERA ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| <i>alyacen 1/35 oral tablet 1-35 mg-mcg</i> | 1 | MO |
| APRI ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| ARANELLE ORAL TABLET 0.5/1/0.5-35 MG-MCG | 1 | MO |
| AUBRA ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| AVIANE ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| BALZIVA ORAL TABLET 0.4-35 MG-MCG | 1 | MO |
| BLISOVI FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | MO |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i> | 1 | MO |
| CAZIAN ORAL TABLET 0.1/0.125/0.15 -0.025 MG | 1 | MO |
| CRYSELLE-28 ORAL TABLET 0.3-30 MG-MCG | 1 | MO |
| CYCLAFEM 1/35 ORAL TABLET 1-35 MG-MCG | 1 | MO |
| CYCLAFEM 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG | 1 | MO |
| CYRED ORAL TABLET 0.15-30 MG-MCG | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5), 0.15-30 mg-mcg</i> | 1 | MO |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg, 3-0.03 mg</i> | 1 | MO |
| ELURYNG VAGINAL RING 0.12-0.015 MG/24HR | 1 | MO |
| EMOQUETTE ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| ENPRESSE-28 ORAL TABLET 50-30/75-40/125-30 MCG | 1 | MO |
| ENSKYCE ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| ESTARYLLA ORAL TABLET 0.25-35 MG-MCG | 1 | MO |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg, 1-50 mg-mcg</i> | 1 | MO |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24hr</i> | 1 | MO |
| FALMINA ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| FEMYNOR ORAL TABLET 0.25-35 MG-MCG | 1 | MO |
| GIANVI ORAL TABLET 3-0.02 MG | 1 | MO |
| INTROVALE ORAL TABLET 0.15-0.03 MG | 1 | MO |
| ISIBLOOM ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| JASMIEL ORAL TABLET 3-0.02 MG | 1 | MO |
| JULEBER ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| JUNEL 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | MO |
| JUNEL 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| JUNEL FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | MO |
| JUNEL FE 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| KARIVA ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 1 | MO |
| KELNOR 1/35 ORAL TABLET 1-35 MG-MCG | 1 | MO |
| KELNOR 1/50 ORAL TABLET 1-50 MG-MCG | 1 | MO |
| KURVELO ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| LARIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| LARIN 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| LARIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | MO |
| LARIN FE 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| LARISSIA ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| LEENA ORAL TABLET 0.5/1/0.5-35 MG-MCG | 1 | MO |
| LESSINA ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| LEVONEST ORAL TABLET 50-30/75-40/ 125-30 MCG | 1 | MO |
| <i>levonorgest-eth estrad 91-day oral tablet 0.15-0.03 mg</i> | 1 | MO |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 0.15-30 mg-mcg</i> | 1 | MO |
| <i>levonorg-eth estrad triphasic oral tablet 50-30/75-40/ 125-30 mcg</i> | 1 | MO |
| LEVORA 0.15/30 (28) ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| LORYNA ORAL TABLET 3-0.02 MG | 1 | MO |
| LOW-OGESTREL ORAL TABLET 0.3-30 MG-MCG | 1 | MO |
| LUTERA ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| <i>marlissa oral tablet 0.15-30 mg-mcg</i> | 1 | MO |
| <i>medroxyprogesterone acetate intramuscular suspension 150 mg/ml</i> | 1 | |
| <i>medroxyprogesterone acetate intramuscular suspension prefilled syringe 150 mg/ml</i> | 1 | |
| MICROGESTIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | MO |
| MICROGESTIN 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| MICROGESTIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | MO |
| MICROGESTIN FE 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| MILI ORAL TABLET 0.25-35 MG-MCG | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| NECON 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG | 1 | MO |
| NIKKI ORAL TABLET 3-0.02 MG | 1 | MO |
| <i>norethindrone acet-ethinyl est oral tablet 1-20 mg-mcg</i> | 1 | MO |
| <i>norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg</i> | 1 | MO |
| <i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | 1 | MO |
| NORTREL 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG | 1 | MO |
| NORTREL 1/35 (21) ORAL TABLET 1-35 MG-MCG | 1 | MO |
| NORTREL 1/35 (28) ORAL TABLET 1-35 MG-MCG | 1 | MO |
| NORTREL 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG | 1 | MO |
| OCELLA ORAL TABLET 3-0.03 MG | 1 | MO |
| ORSYTHIA ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| PIMTREA ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 1 | MO |
| PIRMELLA 1/35 ORAL TABLET 1-35 MG-MCG | 1 | MO |
| PORTIA-28 ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| PREVIFEM ORAL TABLET 0.25-35 MG-MCG | 1 | MO |
| RECLIPSEN ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| SETLAKIN ORAL TABLET 0.15-0.03 MG | 1 | MO |
| SPRINTEC 28 ORAL TABLET 0.25-35 MG-MCG | 1 | MO |
| SRONYX ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| SYEDA ORAL TABLET 3-0.03 MG | 1 | MO |
| TARINA 24 FE ORAL TABLET 1-20 MG-MCG(24) | 1 | MO |
| TARINA FE 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| TRI-ESTARYLLA ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 1 | MO |
| TRI-LEGEST FE ORAL TABLET 1-20/1-30/1-35 MG-MCG | 1 | MO |
| TRI-MILI ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 1 | MO |
| TRI-PREVIFEM ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 1 | MO |
| TRI-SPRINTEC ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 1 | MO |
| TRIVORA (28) ORAL TABLET 50-30/75-40/125-30 MCG | 1 | MO |
| TRI-VYLIBRA ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 1 | MO |
| VELIVET ORAL TABLET 0.1/0.125/0.15 -0.025 MG | 1 | MO |
| VIENVA ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| VYFEMLA ORAL TABLET 0.4-35 MG-MCG | 1 | MO |
| VYLIBRA ORAL TABLET 0.25-35 MG-MCG | 1 | MO |
| ZOVIA 1/35E (28) ORAL TABLET 1-35 MG-MCG | 1 | MO |
| Estrogens | | |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | MO |
| <i>estradiol transdermal patch twice weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr</i> | 1 | MO |
| <i>estradiol transdermal patch weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.06 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr</i> | 1 | MO |
| MENEST ORAL TABLET 0.3 MG, 0.625 MG, 1.25 MG | 1 | MO |
| <i>norethindrone-eth estradiol oral tablet 1-5 mg-mcg</i> | 1 | MO |
| Progestins | | |
| CAMILA ORAL TABLET 0.35 MG | 1 | MO |
| DEBLITANE ORAL TABLET 0.35 MG | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| DEPO-PROVERA INTRAMUSCULAR SUSPENSION 400 MG/ML | 1 | BvD |
| ERRIN ORAL TABLET 0.35 MG | 1 | MO |
| INCASSIA ORAL TABLET 0.35 MG | 1 | MO |
| LYZA ORAL TABLET 0.35 MG | 1 | MO |
| <i>medroxyprogesterone acetate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| <i>megestrol acetate oral suspension 40 mg/ml</i> | 1 | |
| <i>megestrol acetate oral suspension 625 mg/5ml</i> | 1 | MO |
| <i>megestrol acetate oral tablet 20 mg, 40 mg</i> | 1 | |
| NORA-BE ORAL TABLET 0.35 MG | 1 | MO |
| <i>norethindrone acetate oral tablet 5 mg</i> | 1 | MO |
| <i>norethindrone oral tablet 0.35 mg</i> | 1 | MO |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG | 1 | MO |
| PREMARIN VAGINAL CREAM 0.625 MG/GM | 1 | MO |
| PREMPHASE ORAL TABLET 0.625-5 MG | 1 | MO |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 1 | MO |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i> | 1 | MO |
| SHAROBEL ORAL TABLET 0.35 MG | 1 | MO |
| Selective Estrogen Receptor Modifying Agents | | |
| <i>raloxifene hcl oral tablet 60 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| SOLTAMOX ORAL SOLUTION 10 MG/5ML | 1 | PA2; MO |
| HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PITUITARY) | | |
| Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary) | | |
| <i>cabergoline oral tablet 0.5 mg</i> | 1 | |
| <i>desmopressin ace spray refrig nasal solution 0.01 %</i> | 1 | MO |
| <i>desmopressin acetate oral tablet 0.1 mg, 0.2 mg</i> | 1 | MO |
| INCRELEX SUBCUTANEOUS SOLUTION 40 MG/4ML | 1 | PA; LA |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| NOC DURNA SUBLINGUAL TABLET SUBLINGUAL 27.7 MCG, 55.3 MCG | 1 | MO |
| OMNITROPE SUBCUTANEOUS SOLUTION 10 MG/1.5ML, 5 MG/1.5ML | 1 | PA |
| OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED 5.8 MG | 1 | PA |
| ORILISSA ORAL TABLET 150 MG, 200 MG | 1 | PA |

HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (THYROID)

Hormonal Agents, Stimulant/Replacement/Modifying (Thyroid)

| | | |
|--|---|----|
| EUTHYROX ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 1 | MO |
| LEVO-T ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 1 | MO |
| <i>levothyroxine sodium oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | MO |
| LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 1 | MO |
| <i>liothyronine sodium oral tablet 25 mcg, 5 mcg, 50 mcg</i> | 1 | MO |
| SYNTHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 1 | MO |
| UNITHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 1 | MO |

HORMONAL AGENTS, SUPPRESSANT (PITUITARY)

Hormonal Agents, Suppressant (Pituitary)

| | | |
|---------------------------|---|---------|
| KORLYM ORAL TABLET 300 MG | 1 | PA2; LA |
|---------------------------|---|---------|

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------------|
| <i>octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml</i> | 1 | PA; MO |
| <i>octreotide acetate injection solution 500 mcg/ml</i> | 1 | PA |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML, 0.6 MG/ML, 0.9 MG/ML | 1 | PA; LA; QL (60 ML per 30 days) |
| SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 120 MG/0.5ML, 60 MG/0.2ML, 90 MG/0.3ML | 1 | PA2; QL (1 ML per 28 days) |
| SOMAVERT SUBCUTANEOUS SOLUTION RECONSTITUTED 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 1 | PA; LA; QL (60 EA per 30 days) |
| SYNAREL NASAL SOLUTION 2 MG/ML | 1 | PA |
| TRELSTAR MIXJECT INTRAMUSCULAR SUSPENSION RECONSTITUTED 11.25 MG, 22.5 MG, 3.75 MG | 1 | PA2 |

HORMONAL AGENTS, SUPPRESSANT (THYROID)

Antithyroid Agents

| | | |
|--|---|----|
| <i>methimazole oral tablet 10 mg, 5 mg</i> | 1 | MO |
| <i>propylthiouracil oral tablet 50 mg</i> | 1 | MO |

IMMUNOLOGICAL AGENTS

Immune Suppressants

| | | |
|---|---|---------------------------------|
| AZASAN ORAL TABLET 100 MG, 75 MG | 1 | BvD; MO |
| <i>azathioprine oral tablet 50 mg</i> | 1 | BvD; MO |
| BENLYSTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/ML | 1 | PA |
| BENLYSTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/ML | 1 | PA |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | BvD; MO |
| <i>cyclosporine modified oral solution 100 mg/ml</i> | 1 | BvD; MO |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | 1 | BvD; MO |
| ENVARUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.75 MG, 1 MG, 4 MG | 1 | BvD; MO |
| <i>everolimus oral tablet 0.25 mg</i> | 1 | PA2; MO; QL (60 EA per 30 days) |
| <i>everolimus oral tablet 0.5 mg</i> | 1 | PA2; QL (120 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------|
| <i>everolimus oral tablet 0.75 mg</i> | 1 | PA2; QL (60 EA per 30 days) |
| GENGRAF ORAL CAPSULE 100 MG, 25 MG | 1 | BvD; MO |
| GENGRAF ORAL SOLUTION 100 MG/ML | 1 | BvD; MO |
| <i>methotrexate oral tablet 2.5 mg</i> | 1 | BvD |
| <i>methotrexate sodium injection solution 50 mg/2ml</i> | 1 | BvD |
| <i>mycophenolate mofetil oral capsule 250 mg</i> | 1 | BvD; MO |
| <i>mycophenolate mofetil oral suspension reconstituted 200 mg/ml</i> | 1 | BvD |
| <i>mycophenolate mofetil oral tablet 500 mg</i> | 1 | BvD; MO |
| <i>mycophenolate sodium oral tablet delayed release 180 mg, 360 mg</i> | 1 | BvD; MO |
| PROGRAF ORAL PACKET 0.2 MG, 1 MG | 1 | BvD; MO |
| SANDIMMUNE ORAL CAPSULE 100 MG, 25 MG | 1 | BvD; MO |
| SANDIMMUNE ORAL SOLUTION 100 MG/ML | 1 | BvD; MO |
| <i>sirolimus oral solution 1 mg/ml</i> | 1 | BvD |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | BvD; MO |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> | 1 | BvD; MO |
| TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG | 1 | BvD |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 1 | BvD |
| ZORTRESS ORAL TABLET 0.25 MG | 1 | PA2; MO; QL (60 EA per 30 days) |
| ZORTRESS ORAL TABLET 0.5 MG | 1 | PA2; QL (120 EA per 30 days) |
| ZORTRESS ORAL TABLET 0.75 MG, 1 MG | 1 | PA2; QL (60 EA per 30 days) |
| Immunomodulators | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 2000000 UNIT/0.5ML | 1 | PA2; LA |
| ARCALYST SUBCUTANEOUS SOLUTION RECONSTITUTED 220 MG | 1 | PA; LA |
| COSENTYX (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML | 1 | PA |
| COSENTYX SENSOREADY (300 MG) SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML | 1 | PA |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| ENBREL MINI SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML | 1 | PA |
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML, 50 MG/ML | 1 | PA |
| ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED 25 MG | 1 | PA |
| ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML | 1 | PA |
| HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML | 1 | PA |
| HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.4ML, 40 MG/0.8ML | 1 | PA |
| HUMIRA PEN-CD/UC/HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML, 80 MG/0.8ML | 1 | PA |
| HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML | 1 | PA |
| HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 10 MG/0.2ML, 20 MG/0.2ML, 20 MG/0.4ML, 40 MG/0.4ML, 40 MG/0.8ML | 1 | PA |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> | 1 | MO |
| OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML | 1 | BvD |
| PANZYGA INTRAVENOUS SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML | 1 | BvD |
| PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML | 1 | BvD |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 15 MG | 1 | PA |
| SKYRIZI (150 MG DOSE) SUBCUTANEOUS PREFILLED SYRINGE KIT 75 MG/0.83ML | 1 | PA |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML | 1 | PA |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML | 1 | PA |
| XELJANZ ORAL TABLET 10 MG, 5 MG | 1 | PA |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HOUR 11 MG, 22 MG | 1 | PA |
| Vaccines | | |
| ACTHIB INTRAMUSCULAR SOLUTION RECONSTITUTED | 1 | |
| ADACEL INTRAMUSCULAR SUSPENSION 5- 2-15.5 (PREFILLED SYRINGE), 5-2-15.5 LF- MCG/0.5 | 1 | |
| <i>bcg vaccine injection injectable</i> | 1 | |
| BEXSERO INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| BOOSTRIX INTRAMUSCULAR SUSPENSION 5-2.5-18.5 , 5-2.5-18.5 (0.5ML SYRINGE) | 1 | |
| DAPTACEL INTRAMUSCULAR SUSPENSION 23-15-5 | 1 | |
| <i>diphtheria-tetanus toxoids dt intramuscular suspension 25-5 lfu/0.5ml</i> | 1 | BvD |
| ENGRIX-B INJECTION SUSPENSION 10 MCG/0.5ML, 20 MCG/ML | 1 | BvD |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION | 1 | |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| HAVRIX INTRAMUSCULAR SUSPENSION 1440 EL U/ML, 1440 EL U/ML 1 ML, 720 EL U/0.5ML, 720 EL U/0.5ML 0.5 ML | 1 | |
| HIBERIX INJECTION SOLUTION RECONSTITUTED 10 MCG | 1 | |
| IMOVAX RABIES INTRAMUSCULAR INJECTABLE 2.5 UNIT/ML | 1 | BvD |
| INFANRIX INTRAMUSCULAR SUSPENSION 25-58-10 | 1 | |
| IPOLE INJECTION INJECTABLE | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| IXIARO INTRAMUSCULAR SUSPENSION | 1 | |
| KINRIX INTRAMUSCULAR SUSPENSION , INJECTION 0.5 ML | 1 | |
| MENACTRA INTRAMUSCULAR INJECTABLE | 1 | |
| MENVEO INTRAMUSCULAR SOLUTION RECONSTITUTED | 1 | |
| M-M-R II INJECTION SOLUTION RECONSTITUTED | 1 | |
| PEDIARIX INTRAMUSCULAR SUSPENSION | 1 | |
| PEDVAX HIB INTRAMUSCULAR SUSPENSION 7.5 MCG/0.5ML | 1 | |
| PROQUAD SUBCUTANEOUS SUSPENSION RECONSTITUTED | 1 | |
| QUADRACEL INTRAMUSCULAR SUSPENSION | 1 | |
| RABAERT INTRAMUSCULAR SUSPENSION RECONSTITUTED | 1 | BvD |
| RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 10 MCG/ML (1ML SYRINGE), 40 MCG/ML, 5 MCG/0.5ML | 1 | BvD |
| ROTARIX ORAL SUSPENSION RECONSTITUTED | 1 | |
| ROTATEQ ORAL SOLUTION | 1 | |
| SHINGRIX INTRAMUSCULAR SUSPENSION RECONSTITUTED 50 MCG/0.5ML | 1 | |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML | 1 | BvD |
| TENIVAC INTRAMUSCULAR INJECTABLE 5-2 LFU | 1 | BvD |
| TRUMENBA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| TWINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 720-20 ELU-MCG/ML | 1 | |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5ML, 25 MCG/0.5ML (0.5ML SYRINGE) | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| VAQTA INTRAMUSCULAR SUSPENSION 25 UNIT/0.5ML, 25 UNIT/0.5ML 0.5 ML, 50 UNIT/ML, 50 UNIT/ML 1 ML | 1 | |
| VARIVAX SUBCUTANEOUS INJECTABLE 1350 PFU/0.5ML | 1 | |
| VARIZIG INTRAMUSCULAR SOLUTION 125 UNIT/1.2ML | 1 | |
| YF-VAX SUBCUTANEOUS INJECTABLE | 1 | |
| ZOSTAVAX SUBCUTANEOUS SUSPENSION RECONSTITUTED 19400 UNT/0.65ML | 1 | |

INFLAMMATORY BOWEL DISEASE AGENTS

Aminosalicylates

| | | |
|---|---|----|
| APRISO ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.375 GM | 1 | MO |
| <i>balsalazide disodium oral capsule 750 mg</i> | 1 | |
| LIALDA ORAL TABLET DELAYED RELEASE 1.2 GM | 1 | MO |
| <i>mesalamine rectal enema 4 gm</i> | 1 | |
| <i>sulfasalazine oral tablet 500 mg</i> | 1 | MO |
| <i>sulfasalazine oral tablet delayed release 500 mg</i> | 1 | MO |

METABOLIC BONE DISEASE AGENTS

Metabolic Bone Disease Agents

| | | |
|---|---|---------------------------------|
| <i>alendronate sodium oral tablet 10 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>alendronate sodium oral tablet 35 mg, 70 mg</i> | 1 | MO; QL (4 EA per 28 days) |
| <i>calcitonin (salmon) nasal solution 200 unit/act</i> | 1 | BvD; MO |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | 1 | BvD; MO |
| <i>calcitriol oral solution 1 mcg/ml</i> | 1 | BvD; MO |
| <i>cinacalcet hcl oral tablet 30 mg</i> | 1 | BvD; MO; QL (60 EA per 30 days) |
| <i>cinacalcet hcl oral tablet 60 mg</i> | 1 | BvD; QL (60 EA per 30 days) |
| <i>cinacalcet hcl oral tablet 90 mg</i> | 1 | BvD; QL (120 EA per 30 days) |
| <i>doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg</i> | 1 | BvD; MO |
| FORTEO SUBCUTANEOUS SOLUTION 600 MCG/2.4ML | 1 | PA; QL (2.4 ML per 28 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| FORTEO SUBCUTANEOUS SOLUTION PEN-INJECTOR 600 MCG/2.4ML | 1 | PA; QL (2.4 ML per 28 days) |
| <i>ibandronate sodium oral tablet 150 mg</i> | 1 | MO; QL (1 EA per 30 days) |
| NATPARA SUBCUTANEOUS CARTRIDGE 100 MCG, 25 MCG, 50 MCG, 75 MCG | 1 | LA |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg</i> | 1 | BvD; MO |
| PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 60 MG/ML | 1 | ST; QL (1 ML per 180 days) |
| <i>risedronate sodium oral tablet 150 mg</i> | 1 | MO; QL (1 EA per 28 days) |
| <i>risedronate sodium oral tablet 30 mg</i> | 1 | QL (30 EA per 30 days) |
| <i>risedronate sodium oral tablet 35 mg, 35 mg (12 pack), 35 mg (4 pack)</i> | 1 | MO; QL (4 EA per 28 days) |
| <i>risedronate sodium oral tablet 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| TYMLOS SUBCUTANEOUS SOLUTION PEN-INJECTOR 3120 MCG/1.56ML | 1 | PA |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7ML | 1 | PA; QL (2 ML per 28 days) |
| MISCELLANEOUS | | |
| <i>Miscellaneous</i> | | |
| <i>cvs gauze sterile pad 2"x2"</i> | 1 | |
| <i>hydroxychloroquine sulfate oral tablet 200 mg</i> | 1 | MO |
| PLAQUENIL ORAL TABLET 200 MG | 1 | MO |
| OPHTHALMIC AGENTS | | |
| <i>Ophthalmic Agents, Other</i> | | |
| <i>atropine sulfate ophthalmic solution 1 %</i> | 1 | MO |
| CYSTARAN OPHTHALMIC SOLUTION 0.44 % | 1 | PA |
| RESTASIS OPHTHALMIC EMULSION 0.05 % | 1 | MO; QL (60 EA per 30 days) |
| <i>Ophthalmic Anti-Allergy Agents</i> | | |
| <i>azelastine hcl ophthalmic solution 0.05 %</i> | 1 | |
| BEPREVE OPHTHALMIC SOLUTION 1.5 % | 1 | |
| <i>cromolyn sodium ophthalmic solution 4 %</i> | 1 | |
| <i>olopatadine hcl ophthalmic solution 0.1 %, 0.2 %</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| PAZEO OPHTHALMIC SOLUTION 0.7 % | 1 | |
| Ophthalmic Antiglaucoma Agents | | |
| ALPHAGAN P OPHTHALMIC SOLUTION 0.1 % | 1 | MO |
| <i>apraclonidine hcl ophthalmic solution 0.5 %</i> | 1 | |
| AZOPT OPHTHALMIC SUSPENSION 1 % | 1 | MO |
| <i>betaxolol hcl ophthalmic solution 0.5 %</i> | 1 | MO |
| <i>brimonidine tartrate ophthalmic solution 0.15 %, 0.2 %</i> | 1 | MO |
| <i>carteolol hcl ophthalmic solution 1 %</i> | 1 | MO |
| COMBIGAN OPHTHALMIC SOLUTION 0.2-0.5 % | 1 | MO |
| <i>dorzolamide hcl ophthalmic solution 2 %</i> | 1 | MO |
| <i>dorzolamide hcl-timolol mal ophthalmic solution 22.3-6.8 mg/ml</i> | 1 | MO |
| <i>dorzolamide hcl-timolol mal pf ophthalmic solution 2-0.5 %</i> | 1 | MO |
| <i>levobunolol hcl ophthalmic solution 0.5 %</i> | 1 | MO |
| <i>pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 %</i> | 1 | MO |
| RHOPRESSA OPHTHALMIC SOLUTION 0.02 % | 1 | MO |
| SIMBRINZA OPHTHALMIC SUSPENSION 1-0.2 % | 1 | MO |
| <i>timolol maleate ophthalmic gel forming solution 0.25 %, 0.5 %</i> | 1 | MO |
| <i>timolol maleate ophthalmic solution 0.25 %, 0.5 %, 0.5 % (daily)</i> | 1 | MO |
| Ophthalmic Anti-Infectives | | |
| AZASITE OPHTHALMIC SOLUTION 1 % | 1 | |
| <i>bacitracin ophthalmic ointment 500 unit/gm</i> | 1 | |
| <i>bacitracin-polymyxin b ophthalmic ointment 500-10000 unit/gm</i> | 1 | |
| BESIVANCE OPHTHALMIC SUSPENSION 0.6 % | 1 | |
| <i>ciprofloxacin hcl ophthalmic solution 0.3 %</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>erythromycin ophthalmic ointment 5 mg/gm</i> | 1 | |
| <i>gatifloxacin ophthalmic solution 0.5 %</i> | 1 | |
| GENTAK OPHTHALMIC OINTMENT 0.3 % | 1 | |
| <i>gentamicin sulfate ophthalmic solution 0.3 %</i> | 1 | |
| MOXEZA OPHTHALMIC SOLUTION 0.5 % | 1 | |
| <i>moxifloxacin hcl ophthalmic solution 0.5 %</i> | 1 | |
| <i>neomycin-bacitracin zn-polymyx ophthalmic ointment 5-400-10000</i> | 1 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic solution 1.75-10000-.025</i> | 1 | |
| <i>ofloxacin ophthalmic solution 0.3 %</i> | 1 | |
| <i>polymyxin b-trimethoprim ophthalmic solution 10000-0.1 unit/ml-%</i> | 1 | |
| <i>sulfacetamide sodium ophthalmic ointment 10 %</i> | 1 | |
| <i>sulfacetamide sodium ophthalmic solution 10 %</i> | 1 | |
| <i>tobramycin ophthalmic solution 0.3 %</i> | 1 | |
| <i>trifluridine ophthalmic solution 1 %</i> | 1 | |
| <i>Ophthalmic Anti-Inflammatories</i> | | |
| <i>bacitra-neomycin-polymyxin-hc ophthalmic ointment 1 %</i> | 1 | |
| BLEPHAMIDE S.O.P. OPHTHALMIC OINTMENT 10-0.2 % | 1 | |
| <i>bromfenac sodium (once-daily) ophthalmic solution 0.09 %</i> | 1 | |
| BROMSITE OPHTHALMIC SOLUTION 0.075 % | 1 | |
| <i>dexamethasone sodium phosphate ophthalmic solution 0.1 %</i> | 1 | |
| <i>diclofenac sodium ophthalmic solution 0.1 %</i> | 1 | |
| DUREZOL OPHTHALMIC EMULSION 0.05 % | 1 | |
| <i>fluorometholone ophthalmic suspension 0.1 %</i> | 1 | |
| <i>flurbiprofen sodium ophthalmic solution 0.03 %</i> | 1 | |
| ILEVRO OPHTHALMIC SUSPENSION 0.3 % | 1 | |
| <i>ketorolac tromethamine ophthalmic solution 0.4 %, 0.5 %</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| LOTEMAX OPHTHALMIC GEL 0.5 % | 1 | |
| LOTEMAX OPHTHALMIC OINTMENT 0.5 % | 1 | |
| LOTEMAX SM OPHTHALMIC GEL 0.38 % | 1 | |
| <i>loteprednol etabonate ophthalmic suspension 0.5 %</i> | 1 | |
| <i>neomycin-polymyxin-dexameth ophthalmic ointment 3.5-10000-0.1</i> | 1 | |
| <i>neomycin-polymyxin-dexameth ophthalmic suspension 3.5-10000-0.1</i> | 1 | |
| <i>neomycin-polymyxin-hc ophthalmic suspension 3.5-10000-1</i> | 1 | |
| <i>prednisolone acetate ophthalmic suspension 1 %</i> | 1 | |
| <i>prednisolone sodium phosphate ophthalmic solution 1 %</i> | 1 | |
| PROLENSA OPHTHALMIC SOLUTION 0.07 % | 1 | |
| <i>sulfacetamide-prednisolone ophthalmic solution 10-0.23 %</i> | 1 | |
| <i>tobramycin-dexamethasone ophthalmic suspension 0.3-0.1 %</i> | 1 | |
| ZYLET OPHTHALMIC SUSPENSION 0.5-0.3 % | 1 | |
| Ophthalmic Prostaglandin And Prostamide Analogs | | |
| <i>latanoprost ophthalmic solution 0.005 %</i> | 1 | MO |
| LUMIGAN OPHTHALMIC SOLUTION 0.01 % | 1 | MO |
| <i>travoprost (bak free) ophthalmic solution 0.004 %</i> | 1 | MO |
| VYZULTA OPHTHALMIC SOLUTION 0.024 % | 1 | MO |
| ZIOPTAN OPHTHALMIC SOLUTION 0.0015 % | 1 | MO |
| OTIC AGENTS | | |
| Otic Agents | | |
| <i>acetic acid otic solution 2 %</i> | 1 | |
| CIPRODEX OTIC SUSPENSION 0.3-0.1 % | 1 | |
| <i>ciprofloxacin hcl otic solution 0.2 %</i> | 1 | |
| <i>ciprofloxacin-fluocinolone pf otic solution 0.3-0.025 %</i> | 1 | |
| <i>fluocinolone acetonide otic oil 0.01 %</i> | 1 | |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| <i>neomycin-polymyxin-hc otic solution 1 %</i> | 1 | |
| <i>neomycin-polymyxin-hc otic suspension 3.5-10000-1</i> | 1 | |
| <i>ofloxacin otic solution 0.3 %</i> | 1 | |
| RESPIRATORY TRACT AGENTS | | |
| Antihistamines | | |
| <i>cetirizine hcl oral solution 1 mg/ml</i> | 1 | |
| <i>clemastine fumarate oral tablet 2.68 mg</i> | 1 | |
| <i>desloratadine oral tablet 5 mg</i> | 1 | |
| <i>levocetirizine dihydrochloride oral solution 2.5 mg/5ml</i> | 1 | |
| <i>levocetirizine dihydrochloride oral tablet 5 mg</i> | 1 | |
| Anti-Inflammatories, Inhaled Corticosteroids | | |
| ARNUITY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT | 1 | MO; QL (30 EA per 30 days) |
| ASMANEX (120 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220 MCG/INH | 1 | MO; QL (2 EA per 30 days) |
| ASMANEX (30 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 110 MCG/INH, 220 MCG/INH | 1 | MO; QL (2 EA per 30 days) |
| ASMANEX (60 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220 MCG/INH | 1 | MO; QL (2 EA per 30 days) |
| ASMANEX HFA INHALATION AEROSOL 100 MCG/ACT, 200 MCG/ACT | 1 | MO; QL (26 GM per 30 days) |
| <i>budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml</i> | 1 | BvD; MO |
| FLOVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100 MCG/BLIST, 250 MCG/BLIST, 50 MCG/BLIST | 1 | MO; QL (60 EA per 30 days) |
| FLOVENT HFA INHALATION AEROSOL 110 MCG/ACT, 220 MCG/ACT | 1 | MO; QL (24 GM per 30 days) |
| FLOVENT HFA INHALATION AEROSOL 44 MCG/ACT | 1 | MO; QL (21.2 GM per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------------|
| Antileukotrienes | | |
| <i>montelukast sodium oral packet 4 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>montelukast sodium oral tablet 10 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>montelukast sodium oral tablet chewable 4 mg, 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| Bronchodilators, Anticholinergic | | |
| <i>acetylcysteine inhalation solution 10 %, 20 %</i> | 1 | BvD |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 1 | BvD; MO |
| SPIRIVA HANDIHALER INHALATION CAPSULE 18 MCG | 1 | MO; QL (30 EA per 30 days) |
| SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25 MCG/ACT, 2.5 MCG/ACT | 1 | MO; QL (4 GM per 30 days) |
| Bronchodilators, Phosphodiesterase Inhibitors (Xanthines) | | |
| DALIRESP ORAL TABLET 250 MCG, 500 MCG | 1 | MO; QL (30 EA per 30 days) |
| <i>sildenafil citrate oral tablet 20 mg</i> | 1 | PA; MO; QL (90 EA per 30 days) |
| <i>theophylline er oral tablet extended release 12 hour 300 mg</i> | 1 | MO |
| <i>theophylline er oral tablet extended release 24 hour 400 mg, 600 mg</i> | 1 | MO |
| <i>theophylline oral solution 80 mg/15ml</i> | 1 | MO |
| Bronchodilators, Sympathomimetic | | |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act (nda020983)</i> | 1 | MO; QL (36 GM per 30 days) |
| <i>albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, (5 mg/ml) 0.5%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml</i> | 1 | BvD; MO |
| <i>albuterol sulfate oral syrup 2 mg/5ml</i> | 1 | MO |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | 1 | MO |
| COMBIVENT RESPIMAT INHALATION AEROSOL SOLUTION 20-100 MCG/ACT | 1 | MO; QL (4 GM per 20 days) |
| <i>ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml</i> | 1 | BvD; MO |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| SEREVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 50 MCG/DOSE | 1 | MO; QL (60 EA per 30 days) |
| <i>terbutaline sulfate oral tablet 2.5 mg, 5 mg</i> | 1 | MO |
| VENTOLIN HFA INHALATION AEROSOL SOLUTION 108 (90 BASE) MCG/ACT | 1 | MO; QL (36 GM per 30 days) |
| Nasal Agents | | |
| <i>azelastine hcl nasal solution 0.1 %, 0.15 %</i> | 1 | QL (30 ML per 25 days) |
| <i>flunisolide nasal solution 25 mcg/act (0.025%)</i> | 1 | QL (50 ML per 30 days) |
| <i>fluticasone propionate nasal suspension 50 mcg/act</i> | 1 | QL (16 GM per 30 days) |
| <i>ipratropium bromide nasal solution 0.03 %</i> | 1 | MO; QL (60 ML per 30 days) |
| <i>ipratropium bromide nasal solution 0.06 %</i> | 1 | MO; QL (30 ML per 30 days) |
| <i>mometasone furoate nasal suspension 50 mcg/act</i> | 1 | QL (34 GM per 30 days) |
| Pulmonary Antihypertensives | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | 1 | PA; LA; QL (90 EA per 30 days) |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> | 1 | PA; QL (30 EA per 30 days) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> | 1 | PA; LA; QL (60 EA per 30 days) |
| OPSUMIT ORAL TABLET 10 MG | 1 | PA; LA; QL (90 EA per 30 days) |
| TRACLEER ORAL TABLET SOLUBLE 32 MG | 1 | PA; LA; QL (120 EA per 30 days) |
| UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG | 1 | PA; LA; QL (60 EA per 30 days) |
| UPTRAVI ORAL TABLET THERAPY PACK 200 & 800 MCG | 1 | PA; LA; QL (400 EA per 365 days) |
| Pulmonary Fibrosis Agents | | |
| ESBRIET ORAL CAPSULE 267 MG | 1 | PA |
| ESBRIET ORAL TABLET 801 MG | 1 | PA |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 1 | PA; LA |
| Respiratory Tract Agents, Other | | |
| ADVAIR DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100-50 MCG/DOSE, 250-50 MCG/DOSE, 500-50 MCG/DOSE | 1 | MO; QL (60 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| ADVAIR HFA INHALATION AEROSOL 115-21 MCG/ACT, 230-21 MCG/ACT, 45-21 MCG/ACT | 1 | MO; QL (12 GM per 30 days) |
| ANORO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5-25 MCG/INH | 1 | MO; QL (60 EA per 30 days) |
| BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25 MCG/INH, 200-25 MCG/INH | 1 | MO; QL (60 EA per 30 days) |
| <i>cromolyn sodium inhalation nebulization solution 20 mg/2ml</i> | 1 | BvD; MO |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300 MG/2ML | 1 | PA |
| <i>epinephrine injection solution auto-injector 0.15 mg/0.3ml, 0.3 mg/0.3ml</i> | 1 | |
| FASENRA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 30 MG/ML | 1 | PA |
| FASENRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 30 MG/ML | 1 | PA |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 113-14 mcg/act, 232-14 mcg/act, 55-14 mcg/act</i> | 1 | MO; QL (1 EA per 30 days) |
| KALYDECO ORAL PACKET 25 MG, 50 MG, 75 MG | 1 | PA; LA |
| KALYDECO ORAL TABLET 150 MG | 1 | PA; LA |
| NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML | 1 | PA |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML | 1 | PA |
| NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED 100 MG | 1 | PA |
| ORKAMBI ORAL PACKET 100-125 MG, 150-188 MG | 1 | PA; LA |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 1 | PA; LA |
| PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG | 1 | PA; LA |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| PULMOZYME INHALATION SOLUTION 1 MG/ML | 1 | BvD |
| STIOLTO RESPIMAT INHALATION AEROSOL SOLUTION 2.5-2.5 MCG/ACT | 1 | MO; QL (4 GM per 30 days) |
| SYMDEKO ORAL TABLET THERAPY PACK 100-150 & 150 MG, 50-75 & 75 MG | 1 | PA; LA |
| TOBI PODHALER INHALATION CAPSULE 28 MG | 1 | PA |
| TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/INH | 1 | MO; QL (60 EA per 30 days) |
| TRIKAFTA ORAL TABLET THERAPY PACK 100-50-75 & 150 MG | 1 | PA; LA |
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 75 MG/0.5ML | 1 | PA; LA |
| XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED 150 MG | 1 | PA; LA |

SKELETAL MUSCLE RELAXANTS

Skeletal Muscle Relaxants

| | | |
|--|---|----|
| <i>baclofen oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | MO |
| <i>carisoprodol oral tablet 250 mg, 350 mg</i> | 1 | |
| <i>carisoprodol-aspirin oral tablet 200-325 mg</i> | 1 | |
| <i>chlorzoxazone oral tablet 375 mg, 500 mg, 750 mg</i> | 1 | |
| <i>cyclobenzaprine hcl oral tablet 10 mg, 5 mg, 7.5 mg</i> | 1 | |
| <i>metaxalone oral tablet 800 mg</i> | 1 | |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 1 | |
| <i>orphenadrine citrate er oral tablet extended release 12 hour 100 mg</i> | 1 | |
| <i>tizanidine hcl oral tablet 2 mg, 4 mg</i> | 1 | MO |

SLEEP DISORDER AGENTS

Benzodiazepines

| | | |
|---|---|-------------------------|
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i> | 1 | QL (120 EA per 30 days) |
| <i>temazepam oral capsule 15 mg, 22.5 mg, 30 mg</i> | 1 | QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| <i>temazepam oral capsule 7.5 mg</i> | 1 | QL (120 EA per 30 days) |
| <i>Gaba Receptor Modulators</i> | | |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 1 | QL (30 EA per 30 days) |
| <i>zolpidem tartrate oral tablet 10 mg</i> | 1 | QL (30 EA per 30 days) |
| <i>zolpidem tartrate oral tablet 5 mg</i> | 1 | QL (60 EA per 30 days) |
| <i>Sleep Disorders, Other</i> | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> | 1 | PA; MO |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 1 | QL (30 EA per 30 days) |
| HETLIOZ ORAL CAPSULE 20 MG | 1 | PA; QL (30 EA per 30 days) |
| <i>modafinil oral tablet 100 mg, 200 mg</i> | 1 | PA; MO |
| <i>ramelteon oral tablet 8 mg</i> | 1 | QL (30 EA per 30 days) |
| SILENOR ORAL TABLET 3 MG, 6 MG | 1 | QL (30 EA per 30 days) |
| XYREM ORAL SOLUTION 500 MG/ML | 1 | PA; LA; QL (540 ML per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page X of the introduction. 2020 Integra Managed Care, Formulary ID 20144, Version XX, effective 06/01/2020. Last updated XX/XX/20XX.

A

| | |
|---|--------|
| ARIKAYCE | 7 |
| aripiprazole | 36 |
| armodafinil | 94 |
| ARNUITY ELLIPTA | 89 |
| ASMANEX (120 METERED DOSES) | 89 |
| ASMANEX (30 METERED DOSES) | 89 |
| ASMANEX (60 METERED DOSES) | 89 |
| ASMANEX HFA | 89 |
| aspirin-dipyridamole er | 48 |
| ASSURE ID INSULIN SAFETY SYR | 44 |
| atazanavir sulfate | 41 |
| atenolol | 52 |
| atenolol-chlorthalidone | 51 |
| atomoxetine hcl | 58 |
| atorvastatin calcium | 56 |
| atovaquone | 33 |
| atovaquone-proguanil hcl | 33 |
| ATRIPLA | 39 |
| atropine sulfate | 85 |
| AUBRA | 72 |
| AURYXIA | 70 |
| AUSTEDO | 58 |
| AVIANE | 72 |
| AVONEX PEN | 59 |
| AVONEX PREFILLED | 59 |
| AYVAKIT | 27 |
| AZACTAM | 10 |
| AZASAN | 79 |
| AZASITE | 86 |
| azathioprine | 79 |
| azelastine hcl | 85, 91 |
| azithromycin | 11, 12 |
| AZOPT | 86 |
| aztreonam | 10 |
| B | |
| bacitracin | 86 |
| bacitracin-polymyxin b | 86 |
| bacitra-neomycin-polymyxin- hc | 87 |
| baclofen | 93 |
| balsalazide disodium | 84 |
| BALVERSA | 27 |
| BALZIVA | 72 |
| BANZEL | 16 |

| | | | | | |
|----------------------------------|--------|-----------------------------------|------|---------------------------------|------------|
| BARACLUDE | 38 | bupropion hcl er (smoking det) | 6 | cefoxitin sodium | 9 |
| bcg vaccine | 82 | bupropion hcl er (sr) | 18 | cefpodoxime proxetil | 9 |
| BELSOMRA | 94 | bupropion hcl er (xl) | 18 | cefprozil | 9 |
| benazepril hcl | 49 | buspirone hcl | 42 | ceftazidime | 9 |
| benazepril-hydrochlorothiazide | 51 | butalbital-acetaminophen | 4 | ceftriaxone sodium | 9 |
| BENLYSTA | 79 | butalbital-apap-cafeine | 4 | cefuroxime axetil | 9 |
| benznidazole | 33 | butalbital-asa-caff-codeine | 4 | cefuroxime sodium | 9 |
| benzoyl peroxide-erythromycin | 60 | butalbital-aspirin-cafeine | 4 | celecoxib | 23 |
| benztropine mesylate | 33 | BYSTOLIC | 52 | CELONTIN | 15 |
| BEPREVE | 85 | C | | cephalexin | 9, 10 |
| BESIVANCE | 86 | cabergoline | 77 | cetirizine hcl | 89 |
| betamethasone dipropionate | 60 | CABLIVI | 48 | CHANTIX | 6 |
| betamethasone dipropionate | | CABOMETYX | 27 | CHANTIX CONTINUING | |
| aug | 60 | calcipotriene | 60 | MONTH PAK | 6 |
| betamethasone valerate | 60 | calcitonin (salmon) | 84 | CHANTIX STARTING | |
| BETASERON | 59 | calcitriol | 84 | MONTH PAK | 7 |
| betaxolol hcl | 52, 86 | calcium acetate (phos binder) | 70 | CHEMET | 64 |
| bethanechol chloride | 70 | CALQUENCE | 27 | chlordiazepoxide hcl | 43 |
| bexarotene | 27 | CAMILA | 76 | chlorhexidine gluconate | 59 |
| BEXSERO | 82 | candesartan cilexetil | 49 | chloroquine phosphate | 33 |
| bicalutamide | 27 | candesartan cilexetil-hctz | 51 | chlorpromazine hcl | 35 |
| BICILLIN L-A | 11 | CAPLYTA | 36 | chlorthalidone | 55 |
| BIKTARVY | 41 | CAPRELSA | 27 | chlorzoxazone | 93 |
| bisoprolol fumarate | 52 | captopril | 49 | cholestyramine | 56 |
| bisoprolol-hydrochlorothiazide | 51 | captopril-hydrochlorothiazide | 51 | cholestyramine light | 56 |
| BLEPHAMIDE S.O.P. | 87 | CARBAGLU | 68 | ciclopirox | 21 |
| BLISOVI FE 1.5/30 | 72 | carbamazepine | 13 | ciclopirox olamine | 21 |
| BOOSTRIX | 82 | carbamazepine er | 13 | cilostazol | 48 |
| bosentan | 91 | carbidopa-levodopa | 34 | CIMDUO | 40 |
| BOSULIF | 27 | carbidopa-levodopa er | 34 | cimetidine | 67 |
| BRAFTOVI | 27 | carbidopa-levodopa- | | cimetidine hcl | 67 |
| BREO ELLIPTA | 92 | entacapone | 34 | cinacalcet hcl | 84 |
| briellyn | 72 | carisoprodol | 93 | CINRYZE | 54 |
| BRILINTA | 48 | carisoprodol-aspirin | 93 | CIPRODEX | 88 |
| brimonidine tartrate | 86 | carteolol hcl | 86 | ciprofloxacin hcl | 12, 86, 88 |
| BRIVIACT | 13 | CARTIA XT | 53 | ciprofloxacin in d5w | 12 |
| bromfenac sodium (once-daily) | 87 | carvedilol | 52 | ciprofloxacin-fluocinolone pf | 88 |
| | 87 | casprofungin acetate | 21 | | 88 |
| bromocriptine mesylate | 34 | CAYSTON | 10 | citalopram hydrobromide | 18, 19 |
| BROMSITE | 87 | CAZIENT | 72 | CLARAVIS | 60 |
| BRUKINSA | 27 | cefaclor | 8 | clarithromycin | 12 |
| budesonide | 71, 89 | cefaclor er | 8 | clarithromycin er | 12 |
| budesonide er | 71 | cefadroxil | 8 | clemastine fumarate | 89 |
| bumetanide | 55 | cefazolin sodium | 8, 9 | CLENPIQ | 68 |
| buprenorphine hcl | 6 | cefepime hcl | 9 | clindamycin hcl | 7 |
| buprenorphine hcl-naloxone | | cefepime | 9 | clindamycin palmitate hcl | 7 |
| hcl | 6 | cefexime | 9 | clindamycin phos-benzoyl | |
| bupropion hcl | 18 | cefotetan disodium | 9 | perox | 60 |
| | | | | clindamycin phosphate | 7, 60, |
| | | | | 70 | |

| | | |
|--|---|---|
| clindamycin phosphate in d5w7 | COMPLERA39 | desvenlafaxine er19 |
| CLINIMIX E/DEXTROSE (2.75/5)65 | COMPRO20 | desvenlafaxine succinate er ..19 |
| CLINIMIX E/DEXTROSE (4.25/10)65 | constulose68 | dexamethasone71 |
| CLINIMIX E/DEXTROSE (4.25/5)65 | COPAXONE59 | DEXAMETHASONE INTENSOL.....71 |
| CLINIMIX E/DEXTROSE (5/15)65 | COPIKTRA27 | dexamethasone sodium phosphate87 |
| CLINIMIX E/DEXTROSE (5/20)65 | CORLANOR54 | DEXILANT68 |
| CLINIMIX/DEXTROSE (4.25/10)65 | cortisone acetate71 | dexmethylphenidate hcl.....58 |
| CLINIMIX/DEXTROSE (4.25/5)65 | COSENTYX (300 MG DOSE)80 | dextroamphetamine sulfate...57 |
| CLINIMIX/DEXTROSE (5/15)65 | COSENTYX SENSOREADY (300 MG).....80 | dextroamphetamine sulfate er57 |
| CLINIMIX/DEXTROSE (5/20)65 | COTELLIC.....27 | dextrose.....66 |
| clobazam.....14 | CREON67 | dextrose-nacl.....63 |
| clobetasol propionate.....60 | CRIVAN41 | DIASTAT ACUDIAL14 |
| clobetasol propionate e.....60 | cromolyn sodium.....67, 85, 92 | DIASTAT PEDIATRIC14 |
| clomipramine hcl.....20 | CRYSELLE-2872 | diazepam.....14, 43 |
| clonazepam.....43 | cvs gauze sterile.....85 | diclofenac potassium23 |
| clonidine49 | CYCLAFEM 1/3572 | diclofenac sodium.....23, 87 |
| clonidine hcl49 | CYCLAFEM 7/7/772 | diclofenac sodium er.....23 |
| clopidogrel bisulfate48 | cyclobenzaprine hcl.....93 | dicloxacillin sodium11 |
| clorazepate dipotassium43 | cyclophosphamide26 | dicyclomine hcl66 |
| clotrimazole21 | cyclosporine.....79 | didanosine.....40 |
| clotrimazole-betamethasone 60, 61 | cyclosporine modified79 | diflorasone diacetate61 |
| CLOVIQUE64 | CYRED72 | diflunisal23 |
| clozapine.....35 | CYSTADANE.....69 | DIGITEK54 |
| COARTEM33 | CYSTAGON70 | DIGOX54 |
| codeine sulfate4 | CYSTARAN85 | digoxin54 |
| colchicine23 | D | dihydroergotamine mesylate 24 |
| colchicine-probenecid23 | dalfampridine er59 | DILANTIN16 |
| colesevelam hcl56 | DALIRESP90 | diltiazem hcl53 |
| colestipol hcl56 | danazol.....72 | diltiazem hcl er53 |
| colistimethate sodium (cba) ...7 | dapsone.....7 | diltiazem hcl er beads53 |
| COMBIGAN86 | DAPTACEL82 | diltiazem hcl er coated beads 53 |
| COMBIVENT RESPIMAT .90 | daptomycin7 | dilt-xr53 |
| COMETRIQ (100 MG DAILY DOSE)27 | DARAPRIM.....33 | diphenoxylate-atropine67 |
| COMETRIQ (140 MG DAILY DOSE)27 | darifenacin hydrobromide er 69 | diphtheria-tetanus toxoids dt 82 |
| COMETRIQ (60 MG DAILY DOSE)27 | DAURISMO.....27 | disopyramide phosphate50 |
| COMFORT ASSIST INSULIN SYRINGE.....44 | DEBLITANE.....76 | disulfiram.....6 |
| | deferasirox64 | divalproex sodium15 |
| | DELSTRIGO.....39 | divalproex sodium er15 |
| | DEMSE71 | dofetilide.....50 |
| | DEPO-PROVERA.....77 | donepezil hcl.....17 |
| | DESCOVY40 | dorzolamide hcl86 |
| | desipramine hcl.....20 | dorzolamide hcl-timolol mal 86 |
| | desloratadine.....89 | dorzolamide hcl-timolol mal pf86 |
| | desmopressin ace spray refig77 | DOVATO41 |
| | desmopressin acetate77 | doxazosin mesylate.....49 |
| | desogestrel-ethinyl estradiol.73 | doxepin hcl20 |
| | desonide.....61 | doxercalciferol84 |
| | desoximetasone61 | |

| | | | | | |
|--------------------------------|----|---------------------------------|------------|--------------------------------|--------|
| DOXY 100 | 13 | EPITOL | 14 | fenofibrate..... | 55 |
| doxycycline hyclate..... | 13 | EPIVIR HBV..... | 38 | fenofibrate micronized..... | 55 |
| doxycycline monohydrate ... | 13 | eplerenone | 55 | fentanyl..... | 4 |
| DRIZALMA SPRINKLE..... | 19 | ERAXIS..... | 22 | fentanyl citrate | 5 |
| dronabinol..... | 21 | ergotamine-caffeine..... | 24 | FERRIPROX | 64 |
| drospirenone-ethinyl estradiol | | ERIVEDGE..... | 28 | FETZIMA..... | 19 |
| | 73 | ERLEADA | 28 | FETZIMA TITRATION | 19 |
| DROXIA | 26 | erlotinib hcl..... | 28 | FIASP | 46 |
| duloxetine hcl | 19 | ERRIN..... | 77 | FIASP FLEXTOUCH | 46 |
| DUPIXENT | 92 | ertapenem sodium..... | 10 | FIASP PENFILL | 46 |
| DUREZOL | 87 | ery | 61 | finasteride | 69 |
| dutasteride | 69 | ERY-TAB..... | 12 | FIRVANQ | 7 |
| dutasteride-tamsulosin hcl.... | 69 | ERYTHROCIN | | flecainide acetate | 50 |
| E | | LACTOBIONATE | 12 | FLOVENT DISKUS | 89 |
| econazole nitrate..... | 21 | ERYTHROCIN STEARATE | | FLOVENT HFA | 89 |
| EDURANT..... | 39 | | 12 | fluconazole | 22 |
| efavirenz | 39 | erythromycin | 61, 87 | fluconazole in sodium chloride | |
| ELIGARD | 27 | erythromycin base | 12 | | 22 |
| ELIQUIS | 47 | erythromycin ethylsuccinate. 12 | | flucytosine | 22 |
| ELIQUIS DVT/PE STARTER | | ESBRIET..... | 91 | fludrocortisone acetate..... | 71 |
| PACK | 47 | escitalopram oxalate | 19 | flunisolide..... | 91 |
| ELMIRON..... | 70 | esomeprazole magnesium.... | 68 | fluocinolone acetonide.... | 61, 88 |
| ELURYNG..... | 73 | ESTARYLLA..... | 73 | fluocinonide | 61 |
| EMCYT..... | 28 | estradiol | 70, 76 | fluocinonide emulsified base | 61 |
| EMEND..... | 21 | ethambutol hcl | 25 | fluorometholone | 87 |
| EMGALITY | 24 | ethosuximide | 15 | FLUOROPLEX | 28 |
| EMGALITY (300 MG DOSE) | | ethynodiol diac-eth estradiol | 73 | fluorouracil | 28 |
| | 24 | etodolac | 23 | fluoxetine hcl | 19 |
| EMOQUETTE | 73 | etonogestrel-ethinyl estradiol | 73 | fluphenazine decanoate | 35 |
| EMSAM | 18 | EUCRISA..... | 61 | fluphenazine hcl..... | 35 |
| EMTRIVA..... | 40 | EUTHYROX..... | 78 | flurbiprofen..... | 23 |
| EMVERM | 33 | everolimus | 28, 79, 80 | flurbiprofen sodium | 87 |
| enalapril maleate | 49 | EVOTAZ..... | 41 | flutamide..... | 28 |
| enalapril-hydrochlorothiazide | | EXEL COMFORT POINT | | fluticasone propionate | 61, 91 |
| | 51 | PEN NEEDLE..... | 44 | fluticasone-salmeterol..... | 92 |
| ENBREL | 81 | exemestane | 32 | fluvoxamine maleate | 19 |
| ENBREL MINI | 81 | ezetimibe | 56 | fondaparinux sodium | 47 |
| ENBREL SURECLICK | 81 | F | | FORTEO..... | 84, 85 |
| ENDARI..... | 69 | FALMINA..... | 73 | fosamprenavir calcium | 41 |
| ENDOCET | 4 | famciclovir..... | 39 | fosinopril sodium..... | 49 |
| ENGERIX-B | 82 | famotidine..... | 67 | fosinopril sodium-hctz..... | 51 |
| enoxaparin sodium | 47 | FANAPT | 36 | FREAMINE HBC | 66 |
| ENPRESSE-28..... | 73 | FANAPT TITRATION PACK | | furosemide | 55 |
| ENSKYCE | 73 | | 36 | FUZEON | 41 |
| entacapone..... | 34 | FARYDAK..... | 28 | FYCOMPA..... | 14, 15 |
| entecavir | 38 | FASENRA..... | 92 | G | |
| ENTRESTO | 51 | FASENRA PEN | 92 | gabapentin..... | 15 |
| enulose..... | 68 | febuxostat | 23 | GALAFOLD..... | 69 |
| ENVARUSUS XR | 79 | felbamate | 14 | galantamine hydrobromide ... | 17 |
| EPIDIOLEX..... | 14 | felodipine er..... | 53 | galantamine hydrobromide er | |
| epinephrine | 92 | FEMYNOR | 73 | | 17 |

| | | | | | |
|--------------------------------|-----------|------------------------------|------------|--------------------------------|--------|
| GARDASIL 9..... | 82 | HUMIRA PEN-CD/UC/HS | | INVOKAMET..... | 44 |
| gatifloxacin..... | 87 | STARTER..... | 81 | INVOKAMET XR..... | 44 |
| GATTEX..... | 67 | HUMIRA PEN-PS/UV/ADOL | | INVOKANA..... | 44 |
| GAVILYTE-C..... | 68 | HS START..... | 81 | IPOL..... | 82 |
| GAVILYTE-N WITH | | hydralazine hcl..... | 57 | ipratropium bromide..... | 90, 91 |
| FLAVOR PACK..... | 68 | hydrochlorothiazide..... | 55 | ipratropium-albuterol..... | 90 |
| gemfibrozil..... | 55 | hydrocodone-acetaminophen.. | 5 | irbesartan..... | 49 |
| generlac..... | 68 | hydrocodone-ibuprofen..... | 5 | irbesartan-hydrochlorothiazide | |
| GENGRAF..... | 80 | hydrocortisone..... | 61, 62, 71 | | 51 |
| GENTAK..... | 87 | hydrocortisone ace-pramoxine | | IRESSA..... | 28 |
| gentamicin in saline..... | 7 | | 61 | ISENTRESS..... | 41 |
| gentamicin sulfate..... | 7, 61, 87 | hydrocortisone valerate..... | 62 | ISENTRESS HD..... | 41 |
| GENVOYA..... | 39 | hydromorphone hcl..... | 5 | ISIBLOOM..... | 73 |
| GEODON..... | 43 | hydromorphone hcl pf..... | 5 | ISOLYTE-P IN D5W..... | 65 |
| GIANVI..... | 73 | hydroxychloroquine sulfate.. | 85 | ISOLYTE-S..... | 66 |
| GILENYA..... | 59 | hydroxyurea..... | 28 | isoniazid..... | 25 |
| GILOTRIF..... | 28 | hydroxyzine hcl..... | 42 | isosorbide dinitrate..... | 57 |
| glatiramer acetate..... | 59 | hydroxyzine pamoate..... | 42 | isosorbide mononitrate..... | 57 |
| GLEOSTINE..... | 26 | I | | isosorbide mononitrate er..... | 57 |
| glimepiride..... | 44 | ibandronate sodium..... | 85 | isotretinoin..... | 62 |
| glipizide..... | 44 | IBRANCE..... | 28 | isradipine..... | 53 |
| glipizide er..... | 44 | IBU..... | 23 | itraconazole..... | 22 |
| glipizide-metformin hcl..... | 44 | ibuprofen..... | 23 | ivermectin..... | 33 |
| global alcohol prep ease..... | 44 | ICLUSIG..... | 28 | IXIARO..... | 83 |
| GLUCAGEN HYPOKIT..... | 45 | IDHIFA..... | 28 | J | |
| GLUCAGON EMERGENCY | | ILEVRO..... | 87 | JAKAFI..... | 29 |
| | 46 | imatinib mesylate..... | 28 | JANTOVEN..... | 48 |
| glyburide-metformin..... | 44 | IMBRUVICA..... | 28 | JANUMET..... | 44 |
| glycopyrrolate..... | 66 | imipenem-cilastatin..... | 10 | JANUMET XR..... | 44 |
| GOCOVRI..... | 34 | imipramine hcl..... | 20 | JANUVIA..... | 44 |
| granisetron hcl..... | 21 | imiquimod..... | 62 | JARDIANCE..... | 45 |
| griseofulvin microsize..... | 22 | IMOVAX RABIES..... | 82 | JASMIEL..... | 73 |
| griseofulvin ultramicrosize... | 22 | IMVEXXY MAINTENANCE | | JUBLIA..... | 22 |
| guanfacine hcl..... | 49 | PACK..... | 70 | JULEBER..... | 73 |
| guanfacine hcl er..... | 58 | IMVEXXY STARTER PACK | | JULUCA..... | 40 |
| guanidine hcl..... | 25 | | 70 | JUNEL 1.5/30..... | 73 |
| H | | INCASSIA..... | 77 | JUNEL 1/20..... | 73 |
| halobetasol propionate..... | 61 | INCRELEX..... | 77 | JUNEL FE 1.5/30..... | 73 |
| haloperidol..... | 35 | indapamide..... | 55 | JUNEL FE 1/20..... | 73 |
| haloperidol decanoate..... | 35 | indomethacin..... | 23 | JUXTAPID..... | 56 |
| haloperidol lactate..... | 35 | INFANRIX..... | 82 | K | |
| HAVRIX..... | 82 | INLYTA..... | 28 | KALETRA..... | 41 |
| heparin sodium (porcine)..... | 48 | INREBIC..... | 28 | KALYDECO..... | 92 |
| HEPATAMINE..... | 66 | INTELENCE..... | 39 | KARIVA..... | 73 |
| HETLIOZ..... | 94 | INTRALIPID..... | 66 | KATERZIA..... | 53 |
| HIBERIX..... | 82 | INTRAROSA..... | 70 | kcl in dextrose-nacl..... | 63 |
| HUMIRA..... | 81 | INTRON A..... | 38 | kcl-lactated ringers-d5w..... | 63 |
| HUMIRA PEDIATRIC | | INTROVALE..... | 73 | KELNOR 1/35..... | 73 |
| CROHNS START..... | 81 | INVEGA SUSTENNA..... | 36 | KELNOR 1/50..... | 73 |
| HUMIRA PEN..... | 81 | INVEGA TRINZA..... | 36 | ketoconazole..... | 22 |
| | | INVIRASE..... | 41 | ketoprofen..... | 23 |

| | | | | | |
|--------------------------------------|--------|--------------------------------------|------|-----------------------------------|--------|
| ketorolac tromethamine..... | 87 | LENVIMA (20 MG DAILY DOSE) | 29 | LONSURF | 29 |
| KINRIX..... | 83 | LENVIMA (24 MG DAILY DOSE) | 29 | loperamide hcl | 67 |
| KIONEX..... | 65 | LENVIMA (4 MG DAILY DOSE) | 29 | lopinavir-ritonavir..... | 42 |
| KISQALI (200 MG DOSE) . | 29 | LENVIMA (8 MG DAILY DOSE) | 29 | lorazepam | 43 |
| KISQALI (400 MG DOSE) . | 29 | LESSINA..... | 74 | LORBRENA..... | 29, 30 |
| KISQALI (600 MG DOSE) . | 29 | letrozole | 32 | LORCET..... | 5 |
| KISQALI FEMARA (400 MG DOSE) | 29 | leucovorin calcium | 29 | LORYNA | 74 |
| KISQALI FEMARA (600 MG DOSE) | 29 | LEUKERAN | 26 | losartan potassium | 49 |
| KISQALI FEMARA(200 MG DOSE) | 29 | LEUKINE..... | 48 | losartan potassium-hctz | 51 |
| KLOR-CON | 64 | leuprolide acetate..... | 29 | LOTEMAX..... | 88 |
| KLOR-CON 10 | 63 | LEVEMIR | 46 | LOTEMAX SM..... | 88 |
| KLOR-CON M10..... | 63 | LEVEMIR FLEXTOUCH ... | 46 | loteprednol etabonate..... | 88 |
| KLOR-CON M15..... | 64 | levetiracetam | 14 | lovastatin..... | 56 |
| KLOR-CON M20..... | 64 | levetiracetam er | 14 | LOW-OGESTREL | 74 |
| KORLYM..... | 78 | levobunolol hcl | 86 | loxapine succinate | 35 |
| KURVELO..... | 73 | levocarnitine | 69 | LUMIGAN | 88 |
| KUVAN | 69 | levocetirizine dihydrochloride | 89 | LUPRON DEPOT (1-MONTH) | 30 |
| L | | levofloxacin | 12 | LUPRON DEPOT (3-MONTH) | 30 |
| labetalol hcl | 52 | levofloxacin in d5w | 12 | LUPRON DEPOT (4-MONTH) | 30 |
| lactulose..... | 68 | LEVONEST | 74 | LUPRON DEPOT (6-MONTH) | 30 |
| lamivudine | 38, 40 | levonorgest-eth estrad 91-day | 74 | LUTERA | 74 |
| lamivudine-zidovudine..... | 40 | levonorgestrel-ethinyl estrad 74 | | LYNPARZA..... | 30 |
| lamotrigine | 16 | levonorg-eth estrad triphasic 74 | | LYSODREN..... | 30 |
| lamotrigine er | 16 | LEVORA 0.15/30 (28) | 74 | LYZA | 77 |
| lamotrigine starter kit-blue ... | 16 | LEVO-T..... | 78 | M | |
| lamotrigine starter kit-green . | 16 | levothyroxine sodium | 78 | magnesium sulfate | 64 |
| lamotrigine starter kit-orange | 16 | LEVOXYL | 78 | malathion | 33 |
| LANTUS | 46 | LEXIVA | 42 | maprotiline hcl | 18 |
| LANTUS SOLOSTAR | 46 | LIALDA | 84 | marlissa..... | 74 |
| LARIN 1.5/30..... | 73 | lidocaine | 6 | MARPLAN..... | 18 |
| LARIN 1/20..... | 74 | lidocaine hcl | 6 | MATULANE..... | 30 |
| LARIN FE 1.5/30..... | 74 | lidocaine hcl urethral/mucosal 6 | | MAYZENT..... | 59 |
| LARIN FE 1/20 | 74 | lidocaine viscous hcl | 59 | meclizine hcl..... | 20 |
| LARISSIA..... | 74 | lidocaine-prilocaine | 6 | medroxyprogesterone acetate | 74, 77 |
| latanoprost | 88 | linezolid..... | 7, 8 | mefloquine hcl | 33 |
| LATUDA | 36 | LINZESS | 67 | megestrol acetate | 77 |
| LEENA..... | 74 | liothyronine sodium..... | 78 | MEKINIST | 30 |
| leflunomide..... | 81 | lisinopril..... | 50 | MEKTOVI..... | 30 |
| LENVIMA (10 MG DAILY DOSE) | 29 | lisinopril-hydrochlorothiazide | 51 | meloxicam | 24 |
| LENVIMA (12 MG DAILY DOSE) | 29 | lithium | 43 | memantine hcl | 17 |
| LENVIMA (14 MG DAILY DOSE) | 29 | lithium carbonate | 43 | memantine hcl er | 17 |
| LENVIMA (18 MG DAILY DOSE) | 29 | lithium carbonate er..... | 43 | MENACTRA..... | 83 |
| | | LIVALO | 56 | MENEST | 76 |
| | | LOKELMA | 65 | MENVEO | 83 |
| | | | | mercaptopurine | 26 |
| | | | | meropenem | 10 |

| | | | | | |
|--------------------------------|-----------|--------------------------------|--------|----------------------------------|----|
| mesalamine..... | 84 | morphine sulfate er..... | 4 | NIKKI..... | 75 |
| MESNEX | 30 | MOVANTIK | 67 | nilutamide | 30 |
| METADATE ER..... | 58 | MOXEZA | 87 | NINLARO | 30 |
| metaxalone | 93 | moxifloxacin hcl..... | 13, 87 | NITRO-DUR | 57 |
| metformin hcl | 45 | moxifloxacin hcl in nacl | 12 | nitrofurantoin | 8 |
| metformin hcl er..... | 45 | MULTAQ | 50 | nitrofurantoin macrocrystal | 8 |
| methadone hcl | 4 | mupirocin..... | 62 | nitrofurantoin monohyd macro | |
| methazolamide | 55 | mycophenolate mofetil | 80 | | 8 |
| methenamine hippurate | 8 | mycophenolate sodium..... | 80 | nitroglycerin | 57 |
| methimazole | 79 | MYORISAN..... | 62 | NOC DURNA | 78 |
| methocarbamol | 93 | MYRBETRIQ | 69 | NORA-BE | 77 |
| methotrexate | 80 | MYTESI | 67 | norethindrone..... | 77 |
| methotrexate sodium | 80 | N | | norethindrone acetate..... | 77 |
| methotrexate sodium (pf) | 26 | nabumetone | 24 | norethindrone acet-ethinyl est | |
| methyl dopa..... | 49 | nadolol | 52 | | 75 |
| methylphenidate hcl | 58 | nafcillin sodium..... | 11 | norethindrone-eth estradiol... | 76 |
| methylphenidate hcl er | 58 | naloxone hcl | 6 | norgestimate-eth estradiol | 75 |
| methylprednisolone | 71 | naltrexone hcl | 6 | norgestim-eth estrad triphasic | |
| methyltestosterone..... | 72 | NAMZARIC..... | 17 | | 75 |
| metoclopramide hcl | 67 | naproxen | 24 | NORMOSOL-M IN D5W | 65 |
| metolazone | 55 | naproxen dr..... | 24 | NORMOSOL-R IN D5W | 65 |
| metoprolol succinate er | 52 | naproxen sodium | 24 | NORMOSOL-R PH 7.4..... | 66 |
| metoprolol tartrate | 52 | naproxen sodium er | 24 | NORTHERA | 54 |
| metoprolol- | | naratriptan hcl..... | 24 | NORTREL 0.5/35 (28)..... | 75 |
| hydrochlorothiazide..... | 51 | NARCAN | 6 | NORTREL 1/35 (21)..... | 75 |
| metronidazole..... | 8, 62, 70 | NATACYN | 22 | NORTREL 1/35 (28)..... | 75 |
| metronidazole in nacl | 8 | nateglinide | 45 | NORTREL 7/7/7 | 75 |
| mexiletine hcl | 50 | NATPARA | 85 | nortriptyline hcl | 20 |
| MICROGESTIN 1.5/30 | 74 | NAYZILAM..... | 14 | NORVIR..... | 42 |
| MICROGESTIN 1/20 | 74 | NECON 0.5/35 (28) | 75 | NOVOLIN 70/30..... | 46 |
| MICROGESTIN FE 1.5/30.. | 74 | nefazodone hcl..... | 18 | NOVOLIN 70/30 FLEXPEN | |
| MICROGESTIN FE 1/20..... | 74 | neomycin sulfate..... | 7 | | 46 |
| midodrine hcl..... | 49 | neomycin-bacitracin zn- | | NOVOLIN N | 46 |
| MIGERGOT..... | 24 | polymyx..... | 87 | NOVOLIN N FLEXPEN | 46 |
| miglitol | 45 | neomycin-polymyxin- | | NOVOLIN R | 46 |
| miglustat..... | 69 | dexameth | 88 | NOVOLIN R FLEXPEN..... | 46 |
| MILI | 74 | neomycin-polymyxin- | | NOVOLOG | 47 |
| minocycline hcl | 13 | gramicidin..... | 87 | NOVOLOG FLEXPEN..... | 46 |
| minoxidil | 57 | neomycin-polymyxin-hc 88, 89 | | NOVOLOG MIX 70/30 | 46 |
| mirtazapine | 18 | NEPHRAMINE..... | 66 | NOVOLOG MIX 70/30 | |
| misoprostol..... | 68 | NERLYNX..... | 30 | FLEXPEN..... | 46 |
| MITIGARE | 23 | NEUPRO..... | 34 | NOVOLOG PENFILL | 47 |
| M-M-R II..... | 83 | nevirapine | 39 | NOXAFIL..... | 22 |
| modafinil | 94 | nevirapine er | 39 | NUBEQA | 30 |
| moexipril hcl | 50 | NEXAVAR | 30 | NUCALA | 92 |
| molindone hcl..... | 35 | niacin er (antihyperlipidemic) | | NUEDEXTA | 58 |
| mometasone furoate | 62, 91 | | 56 | NUPLAZID | 36 |
| montelukast sodium..... | 90 | nicardipine hcl | 53 | nutrilipid | 66 |
| morphine sulfate..... | 5 | NICOTROL..... | 7 | NYAMYC | 22 |
| morphine sulfate (concentrate) | | nifedipine er..... | 53 | nystatin | 22 |
| | 5 | nifedipine er osmotic release | 53 | nystatin-triamcinolone | 62 |

| | | | | | |
|---------------------------------|------------|-----------------------------------|--------|--------------------------------|--------|
| NYSTOP | 22 | paromomycin sulfate | 7 | PLASMA-LYTE A | 66 |
| O | | paroxetine hcl | 19 | podofilox..... | 62 |
| OCELLA | 75 | PASER..... | 25 | polymyxin b-trimethoprim ... | 87 |
| OCTAGAM..... | 81 | PAXIL | 19 | POMALYST..... | 30 |
| octreotide acetate..... | 79 | PAZEO | 86 | PORTIA-28 | 75 |
| ODEFSEY | 41 | PEDIARIX | 83 | posaconazole..... | 22 |
| ODOMZO | 30 | PEDVAX HIB..... | 83 | potassium chloride..... | 64 |
| OFEV | 91 | peg 3350-kcl-na bicarb-nacl..... | 68 | potassium chloride crys er ... | 64 |
| ofloxacin..... | 13, 87, 89 | peg-3350/electrolytes | 68 | potassium chloride er..... | 64 |
| olanzapine..... | 36 | PEGANONE | 16 | potassium chloride in dextrose | |
| olanzapine-fluoxetine hcl..... | 43, 44 | PEGASYS | 38 | | 64 |
| olmesartan medoxomil | 49 | PEGASYS PROCLICK | 38 | potassium chloride in nacl ... | 64 |
| olmesartan medoxomil-hctz .. | 51 | penicillamine | 26 | potassium citrate er..... | 64 |
| olmesartan-amlodipine-hctz .. | 51 | penicillin g pot in dextrose ... | 11 | PRALUENT | 56 |
| olopatadine hcl | 85 | penicillin g potassium..... | 11 | pramipexole dihydrochloride | 34 |
| omega-3-acid ethyl esters..... | 56 | penicillin g procaine | 11 | pramipexole dihydrochloride er | |
| omeprazole | 68 | penicillin g sodium | 11 | | 34 |
| OMNITROPE..... | 78 | penicillin v potassium..... | 11 | prasugrel hcl | 49 |
| ondansetron | 21 | pentamidine isethionate..... | 33 | pravastatin sodium..... | 56 |
| ondansetron hcl | 21 | pentoxifylline er | 48 | prazosin hcl..... | 49 |
| OPSUMIT | 91 | perindopril erbumine | 50 | prednicarbate | 62 |
| ORFADIN | 69 | permethrin | 33 | prednisolone | 71 |
| ORILISSA | 78 | perphenazine..... | 35 | prednisolone acetate | 88 |
| ORKAMBI..... | 92 | PERSERIS..... | 37 | prednisolone sodium phosphate | |
| orphenadrine citrate er..... | 93 | phenelzine sulfate | 18 | | 71, 88 |
| ORSYTHIA..... | 75 | phenobarbital | 14 | prednisone..... | 71 |
| oseltamivir phosphate..... | 42 | phenytoin | 16, 17 | PREDNISONE INTENSOL..... | 71 |
| OSPHENA | 70 | phenytoin sodium extended.. | 17 | preferred plus insulin syringe | |
| oxacillin sodium | 11 | PICATO..... | 62 | | 44 |
| oxacillin sodium in dextrose .. | 11 | PIFELTRO | 39 | pregabalin | 15, 58 |
| oxandrolone..... | 71 | pilocarpine hcl | 59, 86 | PREMARIN | 77 |
| oxaprozin..... | 24 | pimecrolimus | 62 | PREMASOL..... | 66 |
| oxazepam..... | 93 | pimozide | 35 | PREMPHASE..... | 77 |
| oxcarbazepine..... | 16 | PIMTREA | 75 | PREMPRO | 77 |
| oxybutynin chloride..... | 69 | pindolol..... | 52 | PREVALITE | 56 |
| oxybutynin chloride er | 69 | pioglitazone hcl | 45 | PREVIFEM | 75 |
| oxycodone hcl | 4, 5 | pioglitazone hcl-glimepiride..... | 45 | PREZCOBIX..... | 42 |
| oxycodone hcl er | 4 | pioglitazone hcl-metformin hcl | | PREZISTA | 41, 42 |
| oxycodone-acetaminophen..... | 5 | | 45 | PRIFTIN | 25 |
| oxycodone-aspirin | 5 | piperacillin sod-tazobactam so | | primaquine phosphate..... | 33 |
| oxycodone-ibuprofen | 5 | | 11 | primidone..... | 14 |
| OZEMPIC (0.25 OR 0.5 | | PIQRAY (200 MG DAILY | | PRIVIGEN | 81 |
| MG/DOSE)..... | 45 | DOSE) | 30 | probenecid | 23 |
| OZEMPIC (1 MG/DOSE)..... | 45 | PIQRAY (250 MG DAILY | | PROCALAMINE | 66 |
| P | | DOSE) | 30 | prochlorperazine | 20 |
| PACERONE..... | 50 | PIQRAY (300 MG DAILY | | prochlorperazine maleate..... | 20, 35 |
| paliperidone er..... | 37 | DOSE) | 30 | PROCTO-MED HC..... | 62 |
| PANRETIN | 30 | PIRMELLA 1/35 | 75 | PROCTO-PAK | 62 |
| pantoprazole sodium | 68 | piroxicam..... | 24 | PROCTOSOL HC | 62 |
| PANZYGA..... | 81 | PLAQUENIL..... | 85 | PROCTOZONE-HC..... | 62 |
| paricalcitol..... | 85 | PLASMA-LYTE 148 | 66 | progesterone micronized | 77 |

| | | | | | |
|-------------------------------|----|-----------------------------|----|---------------------------------|--------|
| PROGLYCEM | 46 | RETACRIT | 48 | sildenafil citrate | 90 |
| PROGRAF | 80 | REVLIMID | 26 | SILENOR | 94 |
| PROLASTIN-C | 92 | REXULTI | 37 | silodosin | 70 |
| PROLENSA | 88 | REYATAZ | 42 | silver sulfadiazine | 63 |
| PROLIA | 85 | RHOPRESSA | 86 | SIMBRINZA | 86 |
| PROMACTA | 48 | ribavirin | 38 | simvastatin | 56 |
| promethazine hcl | 20 | rifabutin | 25 | sirolimus | 80 |
| propafenone hcl | 50 | rifampin | 26 | SIRTURO | 26 |
| propafenone hcl er | 50 | RIFATER | 26 | SIVEXTRO | 8 |
| proparacaine hcl | 6 | riluzole | 58 | SKYRIZI (150 MG DOSE) .. | 81 |
| propranolol hcl | 52 | rimantadine hcl | 42 | sodium chloride | 64, 65 |
| propranolol hcl er | 52 | RINVOQ | 81 | sodium phenylbutyrate | 69 |
| propranolol-hctz | 51 | risedronate sodium | 85 | sodium polystyrene sulfonate | |
| propylthiouracil | 79 | RISPERDAL CONSTA | 37 | | 65 |
| PROQUAD | 83 | risperidone | 37 | sofosbuvir-velpatasvir | 38 |
| PROSOL | 66 | ritonavir | 42 | SOLQUA | 45 |
| protriptyline hcl | 20 | rivastigmine | 17 | SOLTAMOX | 77 |
| PULMOZYME | 93 | rivastigmine tartrate | 17 | SOMATULINE DEPOT | 79 |
| PURIXAN | 26 | rizatriptan benzoate | 24 | SOMAVERT | 79 |
| pyrazinamide | 25 | ropinirole hcl | 34 | SORINE | 52 |
| pyridostigmine bromide | 25 | rosuvastatin calcium | 56 | sotalol hcl | 52 |
| Q | | ROTARIX | 83 | sotalol hcl (af) | 52 |
| QUADRACEL | 83 | ROTATEQ | 83 | SPIRIVA HANDIHALER .. | 90 |
| quetiapine fumarate | 37 | ROWEEPRA | 14 | SPIRIVA RESPIMAT | 90 |
| quetiapine fumarate er | 37 | ROWEEPRA XR | 14 | spironolactone | 55 |
| quinapril hcl | 50 | ROZLYTREK | 30 | spironolactone-hctz | 51 |
| quinapril-hydrochlorothiazide | | RUBRACA | 31 | SPRINTEC 28 | 75 |
| | 51 | RUCONEST | 54 | SPRITAM | 14 |
| quinidine sulfate | 50 | RYBELSUS | 45 | SPRYCEL | 31 |
| quinine sulfate | 33 | RYDAPT | 31 | SPS | 65 |
| R | | RYTARY | 34 | SRONYX | 75 |
| RABAVERT | 83 | S | | SSD | 63 |
| raloxifene hcl | 77 | SAMSCA | 65 | stavudine | 40 |
| ramelteon | 94 | SANDIMMUNE | 80 | STELARA | 81, 82 |
| ramipril | 50 | SANTYL | 63 | STIOLTO RESPIMAT | 93 |
| ranolazine er | 54 | SAPHRIS | 37 | STIVARGA | 31 |
| rasagiline mesylate | 34 | SAVELLA | 58 | STRIBILD | 40 |
| RAVICTI | 69 | SAVELLA TITRATION | | SUBOXONE | 6 |
| RECLIPSEN | 75 | PACK | 58 | sucralfate | 68 |
| RECOMBIVAX HB | 83 | scopolamine | 20 | sulfacetamide sodium | 87 |
| RECTIV | 62 | SECUADO | 37 | sulfacetamide sodium (acne) .. | 13 |
| REGRANEX | 63 | selegiline hcl | 34 | sulfacetamide-prednisolone .. | 88 |
| RELENZA DISKHALER | 42 | selenium sulfide | 63 | sulfadiazine | 13 |
| RELI-ON INSULIN | | SELZENTRY | 41 | sulfamethoxazole-trimethoprim | |
| SYRINGE | 44 | SEREVENT DISKUS | 91 | | 13 |
| repaglinide | 45 | sertraline hcl | 19 | sulfasalazine | 84 |
| REPATHA | 56 | SETLAKIN | 75 | sulindac | 24 |
| REPATHA PUSHTRONEX | | sevelamer carbonate | 70 | sumatriptan | 25 |
| SYSTEM | 56 | SHAROBEL | 77 | sumatriptan succinate | 25 |
| REPATHA SURECLICK | 57 | SHINGRIX | 83 | sumatriptan succinate refill .. | 25 |
| RESTASIS | 85 | SIGNIFOR | 79 | | |

| | | | | | |
|-------------------------------------|--------|-------------------------------|--------|-------------------------------------|----|
| SUPREP BOWEL PREP KIT | 68 | tetrabenazine..... | 58 | triamterene-hctz | 52 |
| SUTENT..... | 31 | tetracycline hcl | 13 | TRIDERM | 63 |
| SYEDA..... | 75 | THALOMID..... | 26 | trientine hcl..... | 65 |
| SYLATRON..... | 38 | theophylline..... | 90 | TRI-ESTARYLLA | 76 |
| SYMDEKO | 93 | theophylline er..... | 90 | trifluoperazine hcl..... | 35 |
| SYMFI..... | 39 | thioridazine hcl | 35 | trifluridine..... | 87 |
| SYMFI LO | 39 | thiothixene | 35 | trihexyphenidyl hcl..... | 33 |
| SYMPAZAN..... | 15 | TIADYLT ER..... | 54 | TRIKAFTA | 93 |
| SYMTUZA..... | 39 | tiagabine hcl | 15 | TRI-LEGEST FE..... | 76 |
| SYNAREL | 79 | TIBSOVO..... | 31 | TRILYTE | 68 |
| SYNDROS | 21 | tigecycline | 8 | trimethoprim | 8 |
| SYNJARDY | 45 | TIGLUTIK | 58 | TRI-MILI..... | 76 |
| SYNJARDY XR | 45 | timolol maleate | 53, 86 | trimipramine maleate..... | 20 |
| SYNRIBO | 31 | tinidazole | 8 | TRINTELLIX..... | 18 |
| SYNTHROID..... | 78 | TIVICAY..... | 41 | TRI-PREVIFEM..... | 76 |
| T | | tizanidine hcl | 93 | TRI-SPRINTEC | 76 |
| TABLOID | 26 | TOBI PODHALER | 93 | TRIUMEQ..... | 40 |
| tacrolimus | 63, 80 | tobramycin..... | 7, 87 | TRIVORA (28)..... | 76 |
| TAFINLAR | 31 | tobramycin sulfate | 7 | TRI-VYLIBRA..... | 76 |
| TAGRISSO | 31 | tobramycin-dexamethasone.. | 88 | TROPHAMINE | 66 |
| TAKHZYRO..... | 54 | TOLAK | 31 | TRULICITY | 45 |
| TALZENNA..... | 31 | tolmetin sodium..... | 24 | TRUMENBA..... | 83 |
| tamoxifen citrate..... | 31 | tolterodine tartrate | 69 | TRUVADA..... | 40 |
| tamsulosin hcl..... | 70 | tolterodine tartrate er | 69 | TURALIO..... | 31 |
| TARGRETIN | 31 | topiramate..... | 16 | TWINRIX..... | 83 |
| TARINA 24 FE | 75 | topiramate er..... | 16 | TYBOST..... | 41 |
| TARINA FE 1/20..... | 75 | toremifene citrate..... | 31 | TYKERB | 31 |
| TASIGNA | 31 | torsemide | 55 | TYMLOS..... | 85 |
| tazarotene | 63 | TOUJEO MAX SOLOSTAR | 47 | TYPHIM VI..... | 83 |
| TAZORAC..... | 63 | TOUJEO SOLOSTAR | 47 | U | |
| TAZTIA XT | 53 | TPN ELECTROLYTES | 66 | UCERIS | 63 |
| TAZVERIK..... | 31 | TRACLEER | 91 | UNITHROID..... | 78 |
| TDVAX..... | 83 | tramadol hcl..... | 5 | UPTRAVI..... | 91 |
| TECFIDERA..... | 59 | tramadol-acetaminophen | 5 | ursodiol | 67 |
| TEFLARO | 10 | trandolapril | 50 | V | |
| TEGSEDI | 58 | tranexamic acid..... | 48 | valacyclovir hcl | 39 |
| TEKTURNA HCT | 52 | TRANSDERM-SCOP (1.5 | | VALCHLOR | 31 |
| telmisartan | 49 | MG) | 20 | valganciclovir hcl | 38 |
| telmisartan-hctz | 52 | tranylcypromine sulfate..... | 18 | valproic acid | 15 |
| temazepam..... | 93, 94 | TRAVASOL..... | 66 | valsartan..... | 49 |
| TENIVAC | 83 | travoprost (bak free) | 88 | valsartan-hydrochlorothiazide | 52 |
| tenofovir disoproxil fumarate | 40 | trazodone hcl | 18 | VALTOCO 10 MG DOSE ... | 15 |
| terazosin hcl..... | 49 | TRECATOR..... | 26 | VALTOCO 15 MG DOSE ... | 15 |
| terbinafine hcl..... | 22 | TRELEGY ELLIPTA..... | 93 | VALTOCO 20 MG DOSE ... | 15 |
| terbutaline sulfate | 91 | TRELSTAR MIXJECT | 79 | VALTOCO 5 MG DOSE | 15 |
| terconazole | 70 | TRESIBA | 47 | vancomycin hcl..... | 8 |
| testosterone..... | 72 | TRESIBA FLEXTOUCH..... | 47 | VANDAZOLE | 70 |
| testosterone cypionate | 72 | tretinoin | 31, 63 | VAQTA | 84 |
| testosterone enanthate | 72 | TREXALL..... | 80 | VARIVAX..... | 84 |
| | | triamcinolone acetonide | 59, 63 | VARIZIG..... | 84 |

| | | | | | |
|--------------------------|--------|-------------------------|--------|-------------------------|----|
| VARUBI..... | 21 | voriconazole | 22, 23 | XTAMPZA ER..... | 4 |
| VARUBI (180 MG DOSE) .. | 21 | VOSEVI | 38 | XTANDI..... | 32 |
| VASCEPA..... | 57 | VOTRIENT | 32 | XULTOPHY | 45 |
| VELIVET | 76 | VRAYLAR..... | 37 | XURIDEN | 69 |
| VELPHORO..... | 70 | VYFEMLA..... | 76 | XYREM..... | 94 |
| VEMLIDY | 38 | VYLIBRA | 76 | Y | |
| VENCLEXTA | 31 | VYNDAMAX | 54 | YF-VAX | 84 |
| VENCLEXTA STARTING | | VYZULTA | 88 | YONSA | 32 |
| PACK | 31 | W | | Z | |
| venlafaxine hcl | 20 | warfarin sodium..... | 48 | zafirlukast | 90 |
| venlafaxine hcl er | 19, 20 | X | | zaleplon..... | 94 |
| VENTOLIN HFA..... | 91 | XALKORI | 32 | ZARXIO | 48 |
| verapamil hcl | 54 | XARELTO | 48 | ZEJULA | 32 |
| verapamil hcl er | 54 | XARELTO STARTER PACK | | ZELBORAF | 32 |
| VERSACLOZ | 35 | | 48 | ZENPEP | 67 |
| VERZENIO | 32 | XATMEP..... | 80 | zidovudine | 40 |
| VICTOZA | 45 | XELJANZ | 82 | ZIOPTAN | 88 |
| VIDEX | 40 | XELJANZ XR..... | 82 | ziprasidone hcl | 37 |
| VIDEX EC | 40 | XGEVA | 85 | ZIRGAN | 38 |
| VIENVA..... | 76 | XIFAXAN | 8 | ZOHYDRO ER | 4 |
| vigabatrin..... | 16 | XOFLUZA (40 MG DOSE) .. | 42 | ZOLINZA..... | 32 |
| VIGADRONE | 16 | XOFLUZA (80 MG DOSE) .. | 42 | zolmitriptan..... | 25 |
| VIIBRYD | 18 | XOLAIR | 93 | zolpidem tartrate | 94 |
| VIIBRYD STARTER PACK | | XOSPATA..... | 32 | zonisamide | 15 |
| | 18 | XPOVIO (100 MG ONCE | | ZORTRESS | 80 |
| VIMPAT..... | 17 | WEEKLY)..... | 32 | ZOSTAVAX..... | 84 |
| VIRACEPT | 42 | XPOVIO (60 MG ONCE | | ZOVIA 1/35E (28) | 76 |
| VIRAMUNE | 39 | WEEKLY)..... | 32 | ZYDELIG..... | 32 |
| VIREAD..... | 40 | XPOVIO (80 MG ONCE | | ZYKADIA..... | 32 |
| VITRAKVI..... | 32 | WEEKLY)..... | 32 | ZYLET | 88 |
| VIVITROL | 6 | XPOVIO (80 MG TWICE | | ZYPREXA RELPREVV | 38 |
| VIZIMPRO..... | 32 | WEEKLY)..... | 32 | ZYTIGA | 32 |

Non-Discrimination Statement

Integra Managed Care, Inc. (“Integra”) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, sex, age, or disability. Integra does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Integra Managed Care provides the following:

- Free aids and services to people with disabilities to help you communicate with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats); and
- Free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages.

If you need these services, call Integra Managed Care at 1-877-388-5195 (TTY/TDD: 711)

If you believe that Integra Managed Care has not provided you these services or treated you differently because of race, color, national origin, age, disability, or sex, you can file a grievance with Integra by:

- Mail: Appeals and Grievance Manager
Integra Managed Care, Inc.
1981 Marcus Avenue, Suite 100
Lake Success, NY 11042
- Phone: 1-877-388-5195 (TTY/TDD: 711) Monday through Friday 8:00 AM to 5:00 PM.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights by:

- Web: Office for Civil Rights Complaint Portal at available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>
- Mail: U.S. Department of Health and Human Services 200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1-800-368-1019, 1-800-537-7697 (TDD)
Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>
- Phone: 1-800-868-1019 (TTY/TDD: 1-800-537-7697)

Multi-language Interpreter Services

English: We have free interpreter services to answer any questions you may have about our health or drug plan. To get an interpreter, just call us at 1-877-388-5195. Someone who speaks English/Language can help you. This is a free service.

Spanish: Tenemos servicios de intérprete sin costo alguno para responder cualquier pregunta que pueda tener sobre nuestro plan de salud o medicamentos. Para hablar con un intérprete, por favor llame al 1-877-388-5195. Alguien que hable español le podrá ayudar. Este es un servicio gratuito.

Chinese Mandarin: 我们提供免费的翻译服务，帮助您解答关于健康或药物保险的任何疑问。如果您需要此翻译服务，请致电 1-877-388-5195。我们的中文工作人员很乐意帮助您。这是一项免费服务。

Chinese Cantonese: 您對我們的健康或藥物保險可能存有疑問，為此我們提供免費的翻譯服務。如需翻譯服務，請致電 1-877-388-5195。我們講中文的人員將樂意為您提供幫助。這是一項免費服務。

Tagalog: Mayroon kaming libreng serbisyo sa pagsasalang-wika upang masagot ang anumang mga katanungan ninyo hinggil sa aming planong pangkalusugan o panggamot. Upang makakuha ng tagasalang-wika, tawagan lamang kami sa 1-877-388-5195. Maaari kayong tulungan ng isang nakapagsalita ng Tagalog. Ito ay libreng serbisyo.

French: Nous proposons des services gratuits d'interprétation pour répondre à toutes vos questions relatives à notre régime de santé ou d'assurance-médicaments. Pour accéder au service d'interprétation, il vous suffit de nous appeler au 1-877-388-5195. Un interlocuteur parlant Français pourra vous aider. Ce service est gratuit.

Vietnamese: Chúng tôi có dịch vụ thông dịch miễn phí để trả lời các câu hỏi về chương sức khỏe và chương trình thuốc men. Nếu quý vị cần thông dịch viên xin gọi 1-877-388-5195 sẽ có nhân viên nói tiếng Việt giúp đỡ quý vị. Đây là dịch vụ miễn phí.

German: Unser kostenloser Dolmetscherservice beantwortet Ihren Fragen zu unserem Gesundheits- und Arzneimittelplan. Unsere Dolmetscher erreichen Sie unter 1-877-388-5195. Man wird Ihnen dort auf Deutsch weiterhelfen. Dieser Service ist kostenlos.

Korean: 당사는 의료 보험 또는 약품 보험에 관한 질문에 대해 드리고자 무료 통역 서비스를 제공하고 있습니다. 통역 서비스를 이용하려면 전화 1-877-388-5195번으로 문의해 주십시오. 한국어를 하는 담당자가 도와 드릴 것입니다. 이 서비스는 무료로 운영됩니다.

Russian: Если у вас возникнут вопросы относительно страхового или медикаментного плана, вы можете воспользоваться нашими бесплатными услугами переводчиков. Чтобы воспользоваться услугами переводчика, позвоните нам по телефону 1-877-388-5195. Вам окажет помощь сотрудник, который говорит по-русски. Данная услуга бесплатная.

Arabic: اننا نقدم خدمات المترجم الفوري للإجابة عن أي أسئلة تتعلق بخطةنا للصحة أو جدول الأدوية لدينا للحصول على مترجم فوري؛ ليس عليك سوى الاتصال على الرقم التالي 1-877-388-5195. سيقوم شخص ما يتحدث اللغة الانجليزية بمساعدتك. هذه خدمة مجانية

Italian: È disponibile un servizio di interpretariato gratuito per rispondere a eventuali domande sul nostro piano sanitario e farmaceutico. Per un interprete, contattare il numero 1-877-388-5195. Un nostro incaricato che parla Italiano vi fornirà l'assistenza necessaria. È un servizio gratuito.

Português: Dispomos de serviços de interpretação gratuitos para responder a qualquer questão que tenha acerca do nosso plano de saúde ou de medicação. Para obter um intérprete, contacte-nos através do número 1-877-388-5195. Irá encontrar alguém que fale o idioma Português para o ajudar. Este serviço é gratuito.

French Creole: Nou genyen sèvis entèprèt gratis pou reponn tout kesyon ou ta genyen konsènan plan medikal oswa dwòg nou an. Pou jwenn yon entèprèt, jis rele nou nan 1-877-388-5195. Yon moun ki pale Kreyòl kapab ede w. Sa a se yon sèvis ki gratis.

Polish: Umożliwiamy bezpłatne skorzystanie z usług tłumacza ustnego, który pomoże w uzyskaniu odpowiedzi na temat planu zdrowotnego lub dawkowania leków. Aby skorzystać z pomocy tłumacza znającego język polski, należy zadzwonić pod numer 1-877-388-5195. Ta usługa jest bezpłatna.

Hindi: हमारे स्वास्थ्य या दवा की योजना के बारे में आपके किसी भी प्रश्न के जवाब देने के लिए हमारे पास मुफ्त दुभाषिया सेवाएँ उपलब्ध हैं. एक दुभाषिया प्राप्त करने के लिए, बस हमें 1-877-388-5195 फोन करें. कोई व्यक्ति जो हिन्दी बोलता है आपकी मदद कर सकता है. यह एक मुफ्त सेवा है.

Japanese: 当社の健康 健康保険と薬品 処方薬プランに関するご質問にお答えする ために、無料の通訳サービスがあります。通訳をご用命になるには、 1-877-388-5195 にお電話ください。日本語を話す人 者 が支援いたします。これは 無料のサービスです。